Syneron Medical (ELOS) 20-F 19 Mar 14 2013 FY Annual report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2013
Document and Entity Information [Abstract]	'
Document Type	'20-F
Amendment Flag	'false
Document Period End Date	31-Dec-13
Entity Registrant Name	'Syneron Medical Ltd.
Entity Central Index Key	'0001291361
Current Fiscal Year End Date	'--12-31
Document Fiscal Period Focus	'FY
Document Fiscal Year Focus	'2013
Entity Filer Category	'Accelerated Filer
Entity Common Stock, Shares Outstanding	0
Entity Current Reporting Status	'Yes
Entity Well-known Seasoned Issuer	'No

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'
Lasers and other products	$187,848	$192,199	$160,220
Product-related services	69,067	71,423	68,101
Total revenues	256,915	263,622	228,321
Cost of revenues:	'	'	'
Lasers and other products	89,653	91,045	76,003
Product-related services	37,185	36,137	37,469
Total cost of revenues	126,838	127,182	113,472
Gross profit	130,077	136,440	114,849
Operating expenses, net:	'	'	'
Research and development	29,996	29,936	28,334
Selling and marketing	82,445	77,795	69,433
General and administrative	28,378	34,188	33,730
Other expenses (income), net	-4,623	2,289	32,208
Total operating expenses, net	136,196	144,208	163,705
Operating loss	-6,119	-7,768	-48,856
Financial income, net	26	925	1,015
Other income	'	'	35
Loss before taxes on income (tax benefit)	-6,093	-6,843	-47,806
Taxes on income (tax benefit)	-7,640	-4,502	3,944
Consolidated net income (loss)	1,547	-2,341	-51,750
Net loss attributable to non-controlling interests	100	998	955
Net income (loss) attributable to Syneron Medical Ltd.'s shareholders	$1,647	($1,343)	($50,795)
Net income (loss) per share:	'	'	'
Basic and diluted net income (loss) per share attributable to Syneron Medical Ltd.'s shareholders	$0.04	($0.04)	($1.44)
Weighted average number of shares used in per share calculations (in thousands):	'	'	'
Basic	35,921,848	35,474,693	35,158,191
Diluted	36,203,848	35,474,693	35,158,191

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]	'	'	'
Net income (loss)	$1,547	($2,341)	($51,750)
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustments	-1,844	-1,039	476
Available-for-sale securities:	'	'	'
Changes in unrealized gains (losses)	32	46	72
Reclassification adjustments for (gains) losses included in net income (loss)	-117	-2	54
Net change	-85	44	126
Cash flow hedges:	'	'	'
Unrealized gains, net	179	138	177
Reclassification adjustments for (gains) loss included in net income (loss)	-347	-61	-102
Net change	-168	77	75
Other comprehensive income (loss)	-2,097	-918	677
Comprehensive loss before non-controlling interest	-550	-3,259	-51,073
Net Comprehensive loss attributable to non-controlling interest	100	998	955
Comprehensive loss attributable to Syneron shareholders	($450)	($2,261)	($50,118)

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$37,583	$66,359
Short-term bank deposits	16,453	20,520
Short-term marketable securities	28,933	41,136
Trade receivables, net of allowance of $6,497 and $6,792, respectively	54,229	50,023
Deferred tax assets	6,939	3,266
Other accounts receivable and prepaid expenses	7,323	9,297
Inventories	34,707	36,862
Total current assets	186,167	227,463
LONG-TERM ASSETS:	'	'
Severance pay fund	565	600
Long-term deposits and others	1,509	1,879
Long-term marketable securities	25,571	7,966
Investments in affiliated companies	24,720	1,000
Property and equipment, net	6,603	6,148
Intangible assets, net	21,439	30,433
Goodwill	20,976	25,219
Deferred tax assets	17,927	18,390
Total long-term assets	119,310	91,635
Total assets	305,477	319,098
CURRENT LIABILITIES:	'	'
Trade payables	17,679	19,926
Deferred revenues	13,001	11,986
Other accounts payable and accrued expenses	27,831	49,889
Total current liabilities	58,511	81,801
LONG-TERM LIABILITIES:	'	'
Deferred revenues	3,461	3,924
Warranty accruals	779	708
Contingent consideration	7,896	6,750
Accrued severance pay	611	691
Deferred tax liabilities	2,430	3,095
Total long-term liabilities	15,177	15,168
Total liabilities	73,688	96,969
COMMITMENTS AND CONTINGENCIES	'	'
Syneron Medical Ltd.'s shareholders' equity:	'	'
Ordinary shares of NIS 0.01 par value: Authorized - 100,000,000 ordinary shares; Issued -37,882,160 and 36,860,304 and Outstanding -36,630,586 and 35,608,730 shares at December 31, 2013 and 2012, respective	89	86
Additional paid-in capital	187,924	177,470
Treasury shares at cost -1,251,574 ordinary shares at December 31, 2013 and 2012	-9,587	-9,587
Accumulated other comprehensive income (loss)	-1,471	626
Retained earnings	54,834	53,187
Total Syneron Medical Ltd.'s shareholders' equity	231,789	221,782
Non-controlling interests	'	347
Total equity	231,789	222,129
Total liabilities and equity	$305,477	$319,098

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical)	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified	USD ($)	ILS	USD ($)	ILS
CONSOLIDATED BALANCE SHEETS [Abstract]	'	'	'	'
Trade receivables, allowance for doubtful accounts	$6,497	'	$6,792	'
Ordinary shares, par value per share	'	0.01	'	0.01
Ordinary shares, shares authorized	100,000,000	100,000,000	100,000,000	100,000,000
Ordinary shares, shares issued	37,882,160	37,882,160	36,860,304	36,860,304
Ordinary shares, shares outstanding	36,630,586	36,630,586	35,608,730	35,608,730
Treasury shares, shares	1,251,574	1,251,574	1,251,574	1,251,574

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Ordinary Shares [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income (loss) [Member]	Treasury Shares [Member]	Retained earnings [Member]	Non-controlling interests [Member]
In Thousands
Balance at Dec. 31, 2010	$278,536	$84	$180,410	$867	($9,587)	$105,325	$1,437
Issuance of shares upon exercise of stock-based awards	4,054	1	4,053	'	'	'	'
Equity-based compensation expenses	3,400	'	3,283	'	'	'	117
Changes in equity interest in subsidiaries (see also Note 1b3 and 1b5)	-225	'	-723	'	'	'	498
Other comprehensive income (loss)	677	'	'	677	'	'	'
Net income (loss)	-51,750	'	'	'	'	-50,795	-955
Balance at Dec. 31, 2011	234,692	85	187,023	1,544	-9,587	54,530	1,097
Issuance of shares upon exercise of stock-based awards	1,950	1	1,949	'	'	'	'
Equity-based compensation expenses	4,734	'	4,486	'	'	'	248
Changes in equity interest in subsidiaries (see also Note 1b3 and 1b5)	-15,988	'	-15,988	'	'	'	'
Other comprehensive income (loss)	-918	'	'	-918	'	'	'
Net income (loss)	-2,341	'	'	'	'	-1,343	-998
Balance at Dec. 31, 2012	222,129	86	177,470	626	-9,587	53,187	347
Issuance of shares upon exercise of stock-based awards	7,232	3	7,229	'	'	'	'
Equity-based compensation expenses	4,489	'	4,010	'	'	'	479
Changes in equity interest in subsidiaries (see also Note 1b3 and 1b5)	-667	'	-785	'	'	'	118
Other comprehensive income (loss)	-2,097	'	'	-2,097	'	'	'
Sale of subsidiary	-844	'	'	'	'	'	-844
Net income (loss)	1,547	'	'	'	'	1,647	-100
Balance at Dec. 31, 2013	$231,789	$89	$187,924	($1,471)	($9,587)	$54,834	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income (loss) before non-controlling interests	$1,547	($2,341)	($51,750)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation and amortization	10,472	10,981	10,048
Share-based compensation	4,489	4,734	3,400
Impairment of investment in affiliated company	1,000	200	9,387	[1]
Impairment of intangible assets and goodwill	323	3,820	123
Gain from loss of control (b)	-7,273	'	'
Decrease (increase) in accrued interest, amortization of premium and accretion of discount and gain from sale of marketable securities	1,074	-758	1,565
Revaluation of contingent consideration, net	1,146	-1,910	-8,830
Deferred income taxes, net	-3,386	-12,064	-179
Decrease (increase) in trade receivables, net	-9,366	-6,697	-2,833
Decrease (increase) in other accounts receivable and prepaid expenses	737	775	-984
Increase in inventories	-10,860	-7,072	-8,581
Increase (decrease) in trade payables	2,236	-2,134	4,467
Increase (decrease) in long and short-term deferred revenues	833	406	-3,852
Increase (decrease) in warranty accruals	-37	676	-299
Increase (decrease) in other accounts payable and accrued expenses	-15,142	140	3,340
Others, net	255	164	281
Net cash used in operating activities	-21,952	-11,080	-44,697
Cash flows from investing activities:	'	'	'
Investment in short-term deposits, net	4,081	3,268	-22,579
Purchase of available-for-sale marketable securities	-58,745	-33,281	-83,584
Proceeds from sale of available-for-sale marketable securities	6,844	7,740	54,417
Redemption of available-for-sale marketable securities	45,340	63,292	94,195
Investments in affiliated company	'	-1,000	'
Purchase of property and equipment	-3,661	-1,993	-2,116
Net cash paid in acquisition of subsidiaries (a)	'	-15,064	'
Deconsolidation of subsidiary (b)	-320	'	'
Others	-366	-202	326
Net cash provided by (used in) investing activities	-6,827	22,760	40,659
Cash flows from financing activities:	'	'	'
Acquisition of subsidiary shares held by non-controlling shareholders	-5,156	-7,200	-571
Exercise of stock options and RSU's	7,232	1,950	4,054
Repayment of short-term bank credit, net	'	-1,082	-1,655
Net cash provided by (used in) financing activities	2,076	-6,332	1,828
Translation adjustments on cash and cash equivalents	-2,073	-1,308	708
Increase (decrease) in cash and cash equivalents	-28,776	4,040	-1,502
Cash and cash equivalents at the beginning of the year	66,359	62,319	63,821
Cash and cash equivalents at the end of the year	37,583	66,359	62,319
Supplemental disclosure of cash flow information:	'	'	'
Cash paid during the year for income taxes, net	5,515	1,340	1,563
Supplemental disclosure of non-cash financing and investing activities:	'	'	'
Reclassification of inventory to property and equipment	1,049	2,314	'
Investment in affiliated company	24,720	'	3,200
(a) Net cash paid (received) in acquisition of subsidiaries:	'	'	'
Consideration: Cash	'	15,901	'
Total consideration	'	15,901	'
Identifiable assets acquired and liabilities assumed:	'	'	'
Cash acquired	'	837	'
Current assets	'	1,491	'
Non-current assets	'	769	'
Intangible assets	'	9,867	'
Deferred tax assets	'	'	'
Liabilities assumed	'	-3,793	'
Goodwill	'	6,730	'
Total Identifiable assets acquired and liabilities assumed:	'	15,901	'
Net cash paid in acquisitions	'	15,064	'
(b) Deconsolidation of subsidiary:	'	'	'
Consideration: Investment in Iluminage Beauty at fair value	24,720	'	'
Total consideration	24,720	'	'
Subsidiary's assets and liabilities at the date of deconsolidation:	'	'	'
Current assets	-17,150	'	'
Non-current assets	-968	'	'
Intangible assets, net	-1,642	'	'
Goodwill	-4,678	'	'
Current Liabilities	5,889	'	'
Non- Current Liabilities	578	'	'
Non-controlling interests	844	'	'
Gain from loss of control (b)	-7,273	'	'
Subsidiary's assets and liabilities, net	-24,400	'	'
Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates	($320)	'	'
[1]	On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012. The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2013
GENERAL [Abstract]	'
GENERAL	'
	NOTE 1:-	GENERAL
		a.	Syneron Medical Ltd. (the "Company") commenced its operations in July 2000. The Company and its subsidiaries (together Group) are principally engaged in manufacture, research, development, marketing and sales worldwide, directly to end-users and also to distributors of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners (the professional market).
	In addition, the Company sells, markets and distributes, aesthetic devices products, which are primarily targeted to the home-use consumers (non-professional market), both directly and through retailers in the U.S. and outside the U.S. through retailers and through a chain of distributors.
	On December 9, 2013, the Company sold 100% of Syneron Beauty Ltd's shares (until that date, a fully owned subsidiary) to Iluminage Beauty Ltd. (Iluminage Beauty) in consideration of 49% of Iluminage Beauty shares (see Note 1b1 for further details).
		b.	Business Combinations and other acquisitions/disposals during 2013, 2012 and 2011
		1.	Syneron Beauty Ltd
			On November 11, 2013, Syneron and Unilever Ventures signed a definitive agreement to form a joint venture in home beauty devices: "Iluminage Beauty". Pursuant to the agreement, which closed on December 9, 2013, Syneron sold and transferred its Syneron Beauty subsidiary and related home-use businesses to Iluminage Beauty. At the same time, Unilever Ventures, the venture capital and private equity arm of Unilever, undertook to invest up to $25 million in Iluminage Beauty, and Unilever sold and transferred its luxury beauty subsidiary Iluminage to the joint venture.  Unilever Ventures holds 51% of Iluminage Beauty shares ( representing 100% of Iluminage Beauty preferred shares), and Syneron Medical retains the remaining 49% (representing 100% of Iluminage Beauty common shares).
			On December 9, 2013, based on the fair value method, the Company recorded an investment in Iluminage Beauty of $24,720, which represented the fair value of Iluminage Beauty 's common stock  held by the Company on the deconsolidation date and recorded a gain on deconsolidation of $7,273 thousands, which is recorded in other expenses (income), net. The fair value of the investment in Iluminage Beauty as of December 31, 2013, has not changed compared to the date of deconsolidation. Refer to Note 4 for further details.
		2.	Tanda Health and Beauty, Inc. (THB, formerly known as Pharos Life Corporation and Syneron Beauty Inc.)
			On December 7, 2010, the Company acquired 100% of THB's outstanding shares in contingent consideration of $15,750 to be paid to THB's former shareholders subject to reaching certain net revenue milestones in the 12-month period ending May 31, 2013 and based on a specific mechanism agreed as part of the share purchase agreement.
	THB is a manufacturer of home-use light therapy for aesthetic procedures based in Canada.
	The fair value of the contingent consideration arrangement at the acquisition date was $2,409. As of December 31, 2013, 2012 and 2011 the contingent consideration fair value was approximately $0, $0 and $2,535, respectively. Changes to the fair value were recorded in other expenses (income), net as part of operating expenses.
	THB was deconsolidated on December 9, 2013, refer to Note 1b1
		3.	Fluorinex Active Ltd . (Fluorinex)
			Fluorinex is an Israeli based company that develops advanced fluoridation and tooth whitening devices for dentists and consumers.
			During the years 2007-2011, the Company invested an aggregated amount of $4,625 in Fluorinex in consideration of 74.96% of the issued and outstanding share capital. The Company has accounted for the control gained in accordance with ASC 805 and the increase in the interests in Fluorinex after control gained, according to the provisions of ASC 810.
			Fluorinex was deconsolidated on December 9, 2013, refer to Note 1b1
		4.	TransPharma Medical Ltd. (TransPharma)
			On March 14, 2012, the Company acquired substantially all the assets of TransPharma, including its patent portfolio, for approximately $3,651 in cash. The Company has accounted for the assets purchased in accordance with ASC 805, "Business Combinations" ("ASC 805").
			The following table summarizes the estimated fair values of the assets acquired at the acquisition date:
			Fair value
	Property and equipment			59
	Technology			2,407
	Goodwill			1,185
	Assets acquired		$	3,651
		5	Syneron China
			In November 2008, the Company entered into a joint venture (JV) agreement with Beijing Art Fact MediTech (BAFM) for the formation of Syneron China. As of December 31, 2011 the Company held 51% of the JV for a total investment of $ 510. Through this JV, Syneron sells directly to medical and aesthetic professionals in China including doctors, hospitals, medi-spas and cosmetic chains. Syneron China also provides training and after-sales service and support. The Company consolidated the JV's results and recorded the non-controlling interests in accordance with the provisions of ASC 810, "Consolidation" (ASC 810).
			In August 2012, the Company entered into a share transfer agreement with BAFM to acquire its equity interest (45%) in the JV for a total amount of $2,200. Consummation of the transaction is subject to certain closing conditions, including the approval of certain governmental authorities. At the closing, the Company deposited an amount of $1,760 in escrow. Amount deposited in escrow was recorded as part of other accounts receivable and shall be released upon all closing conditions met.  In February 2013, the Ministry of Commerce of the People's Republic of China approved this transaction. During 2013, the Company entered into agreement to acquire the remaining equity interest (4%) in the JV for a total amount of $156.
			Approvals of local authorities were received during 2013. Syneron is now the 100% shareholder of Syneron China.
		6	Ultrashape Ltd. (Ultrashape)
			On February 13, 2012, Syneron acquired 100% of the outstanding shares of Ultrashape, a sole operating entity of Ultrashape Medical Ltd., which was traded on the Tel-Aviv Stock Exchange, for $ 12,000. Ultrashape is a developer, manufacturer and marketer of non- invasive technologies for fat cell destruction and body sculpting. Ultrashape's products are approved and commercially available in Europe, Canada, Latin America and Asia.
			The Company has accounted for the control gained in accordance with ASC 805.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
			Fair value
	Cash		$	837
	Current assets			1,241
	Property and equipment			710
	Developed technology (1)			5,617
	Customer relationship (2)			1,843
	Total identifiable assets acquired			10,248
	Current liabilities			(3,767	)
	Accrued severance pay			(26	)
	Total liabilities assumed			(3,793	)
	Net identifiable assets assumed			6,455
	Goodwill			5,545
	Net assets acquired		$	12,000
		-1	The developed technology will be amortized using the straight-line method over its useful life which is estimated at six years.
		-2	The Customer relationship will be amortized using a method that will reflect the consummation of such asset which is estimated at eight years.
		7	Rakuto Bio Technologies Ltd. (RBT)
			RBT is an Israeli company engaged in the development of new skin brightening treatments. RBT products are distributed through Syneron and Syneron's subsidiaries.
			During the years 2007-2011, the Company invested an aggregate amount of $4,275 for consideration of 49.52% of RBT's fully diluted share capital.
	On May 30, 2012, the Company entered into an agreement with RBT's shareholders pursuant to which the Company acquired all the remaining shares of RBT for: (i) an initial purchase price of $5,000, (ii) an additional $5,000 to be paid on May 30, 2013, (iii) certain milestone payments in the aggregate amount equal to $15,240 ("the contingent consideration"), (iv) the repayment of certain loan amounts provided by RBT to certain of its shareholders,  and (v) the payment of 2.019% of annual net sales generated by RBT intellectual properties for an unlimited period.
	The Company records the contingent consideration at fair value. Refer to Note 2k and 4 for further details.

SIGNIFICANT_ACCOUNTING_POLICIE

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	NOTE 2:-	SIGNIFICANT ACCOUNTING POLICIES
		a.	Use of estimates:
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.
		b.	Financial statements in U.S. dollars:
	A major part of the Group's operations is carried out by the Company and its subsidiaries in the United States and Israel. The functional currency of these entities is the U.S. dollar (dollar or $) as the revenues and a substantial portion of the costs are incurred in dollars.
	Accordingly, monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with ASC 830, "Foreign Currency Matters" (ASC 830). All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.
	The functional currency of the remaining subsidiaries and associates in most instances is their relevant local currency. The financial statements of those companies are included in consolidation, based on translation into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year in accordance with ASC 830. Differences resulting from translation are presented as a separate component, under accumulated other comprehensive income (loss) in changes in equity.
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of Syneron Medical Ltd. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.
	Changes in the parent's ownership interest in a subsidiary with no change of control are treated as equity transactions, with any difference between the amount of consideration paid and the change in the carrying amount of the non-controlling interest, recognized in equity (APIC) which is based on ASC 810.
		d.	Cash and cash equivalents:
	Cash and cash equivalents are short-term highly liquid investments that are readily convertible into cash with original maturities of three months or less at the date acquired.
		e.	Short-term bank deposits:
	Short term bank deposits are deposits with original maturities of more than three months but less than one year from the balance sheet date. Deposits are presented at their cost including accrued interest. Interest on deposits is recorded as financial income. As of December 31, 2013 and 2012, the Company held short-term interest bearing deposits in the amount of $16,453 and $20,520, respectively, with a weighted average interest of 1.35% and 1.59%, respectively.
		f.	Marketable securities:
	The Company classifies all of its marketable securities as available-for-sale securities in accordance with ASC 320, "Investment in Debt and Equity Securities". Such marketable securities consist primarily of U.S. government treasury bonds, U.S. agencies and government guaranteed debts and corporate bonds which are stated at fair value. Unrealized gains and losses are comprised of the difference between fair value and amortized costs of such securities and are reflected as "accumulated other comprehensive income (loss)" in changes in equity. Realized gains and losses on marketable securities are included in earnings, under financial income, net.
	The Company applied FASB ASC 320-10 which requires the Other-Than-Temporary Impairment (OTTI) for debt securities to be separated into (a) the amount representing the credit loss and (b) the amount related to all other factors. The Company typically invests in highly-rated securities, and its policy generally limits the amount of credit exposure to any one issuer. When evaluating the investments for OTTI, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, and the Company's intent to sell, or whether it is more likely than not that it will be required to sell, the investment before recovery of the investment's amortized cost basis.
	In regard to the Company's ARS, the Company used a discounted cash flow analysis to determine the portion of the impairment that relates to the credit loss. To the extent that the net present value of the estimate of the present value of cash flows expected to be collected from the debt security discounted at the effective interest rate implicit in the security at the date of acquisition is less than the amortized cost basis of the security, the difference is considered credit loss and is recorded through earnings.
	The Company did not recognize any other-than-temporary loss on outstanding securities during the three year period ended December 31, 2013. Refer to Note 3 for further details.
		g.	Derivatives and hedging activities:
	The Company implemented the requirements of ASC No. 815, "Derivatives and Hedging" which requires companies to recognize all of their derivative instruments as either assets or liabilities in the balance sheet at fair value. The accounting for changes in fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualified as part of a hedging transaction and further, on the type of hedging transaction. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.  Due to the Company's global operations, it is exposed to foreign currency exchange rate fluctuations in the normal course of its business.
	The Company's policy allows it to offset the risks associated with the effects of certain foreign currency exposures through the purchase of foreign exchange forward or option contracts (Hedging Contracts).
	The policy prohibits the Company from speculating on such Hedging Contracts for profit. To protect against the increase in value of forecasted foreign currency cash flow resulting from salaries paid in New Israeli Shekels (NIS) during the year and for certain forecasted revenue transactions in currencies other than the U.S. dollar, the Company instituted a foreign currency cash flow hedging program. The Company hedges portions of the anticipated payroll of its Israeli employees denominated in NIS or revenues anticipated in currencies other than the U.S. dollar for a period of one to 12 months with Hedging Contracts. Accordingly, when the dollar strengthens against the NIS, the decline in present value of future foreign currency expenses is offset by losses in the fair value of the Hedging Contracts.  Conversely, when the dollar weakens, the increase in the present value of future foreign currency expenses is offset by gains in the fair value of the Hedging Contracts.  These Hedging Contracts are designated and qualify as cash flow hedges.
	For derivative instruments that are designated and qualify as a cash flow hedge (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings.  Any gain or loss on a derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item is recognized in current earnings during the period of change. As of December 31, 2013 and 2012, the Company had outstanding forward contracts with a notional amount of $4,295 and $3,419, respectively, and outstanding option contracts with a notional amount of $900 and $4,790, respectively.
	For derivative instruments that are not designated and qualify as hedging instruments (the ineffective portion), the gain or loss on those derivative instruments is recorded in to earning.
		h.	Inventories:
	Inventories are stated at the lower of cost or market value. Inventory reserve is provided for slow-moving items.
	Cost is determined as follows:
	Raw materials: based on standard cost.
	Work in process: on the basis of average costs, including materials, labor and other direct and indirect manufacturing costs.
	Finished products: based on standard cost (which approximates actual cost on a first-in, first-out basis) which includes materials, labor and manufacturing overhead. Standard costs are monitored and updated as necessary, to reflect the changes in raw material costs and labor and overhead rates.
	The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. Inventory of $34,707 and $36,862 as of December 31, 2013 and 2012, respectively, is stated net of inventory reserves of $6,033 and $5,402, respectively. If actual demand for the Company's products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required.
		i.	Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:
			%
	Computers, software, manufacturing, laboratory equipment and demonstration equipment (*)		10 - 50 (mainly 33)
	Office furniture and equipment		6- 30 (mainly 15)
	Leasehold improvements		The shorter of the term of the lease or the useful life of the asset
		(*)	Demonstration equipment consists of systems for use in marketing and selling activities. Demonstration equipment is generally not held for sale and is recorded as property and equipment. The demonstration equipment is amortized on a straight-line method over their estimated economic life not to exceed two years.
		j.	Impairment of long-lived assets:
	The Company's long-lived assets and identifiable intangibles subject to amortization are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. During 2013, 2012 and 2011 the Company recorded an impairment charge, related to intangible assets, in the amount of $323, $2,860 and $123, respectively.
		k.	Business combinations:
	The Company accounts for business combinations in accordance with ASC No. 805, "Business Combinations". ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. It also requires the fair value of acquired in-process research and development (IPR&D) to be recorded as an indefinite life intangible asset (subject to impairment) until the research and developments efforts are either completed or abandoned, and restructuring and acquisition-related costs to be expensed as incurred. Any excess of the fair value of net assets acquired over the purchase price and any subsequent changes in estimated contingencies are to be recorded in earnings. In addition, changes in valuation allowance related to acquired deferred tax assets and acquired income tax positions are to be recognized in earnings.
	Contingent considerations to former owners agreed in a business combination, e.g, in the form of milestone payments upon the achievement of certain sales target, are recognized as liabilities at fair value as of the recognition date. Any subsequent changes in amounts recorded as liability are recognized in earnings under other expenses (income), net.
		1	Investments in affiliated companies:
	Part of the Company investments in affiliates are stated at cost since the Company does not have the ability to exercise significant influence over their operating and financial policies. The Company followed ASC 323, "Investments - Equity and Joint Ventures", to determine whether it should apply the equity method of accounting to investments in other-than-common stock, with regard to certain investments in preferred shares, and determined that they are not in substance common stock. The Company's investment in the affiliated companies is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable, in accordance with ASC 325-20. During 2013 and 2012 and 2011, the Company recognized an impairment loss of $ 1,000, $ 200 and $ 9,387, respectively, relating to its investments.
	As of December 31, 2013, pursuant to the deconsolidation of Syneron Beauty and its subsidiaries from December 9, 2013, the Company elected to recognize the investments in Iluminage Beauty at fair value at each reporting date with changes in the fair value recognized in earnings under other expenses (income), net. Refer to Note 4 and 7 for further details.  .
		m.	Goodwill and intangible assets:
	Goodwill and intangible assets have been recorded as a result of acquisitions. Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired.
	The Company applies ASC 350, "Intangibles - Goodwill and Other". Under ASC 350, goodwill is not amortized but instead tested for impairment at least annually (or more frequently if impairment indicators arise). The Company determined June 30 as the date of the annual impairment test for each of its reporting units. The Company operates in two operating segments: the Professional Aesthetic Devices (PAD) segment (which is comprised of two reporting units) and the Emerging Business Units (EBU) segment (which is comprised of three reporting units).
	ASC 350, as amended by ASU 2011-08, provides companies an option to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value before performing a two-step approach to testing goodwill for impairment for each reporting unit. The Company reporting units are determined by the components of the Company operating segments that constitute a business for which both: (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component.
	The first step measures for impairment by applying fair-value-based tests at the reporting unit level. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit.
	Fair value is determined using discounted cash flows methodology. Significant estimates used in the fair value methodologies include estimates of future cash flows, future growth rates and the weighted average cost of capital of the reporting units. During 2013 and 2011 no impairment charges were recorded on Goodwill. During 2012 the Company recorded a goodwill impairment charge of $450 and impairment charge of $510 related to in-process research and development assets from the acquisition of Candela.
		n.	Revenue recognition:
	Revenues are recognized in accordance with ASC 605, "Revenue Recognition" when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred.
	The timing for revenue recognition amongst the various products and customers is dependent upon satisfaction of such criteria and generally varies from shipment to delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer. Revenues from service contracts are recognized on a straight-line basis over the life of the related service contracts.
	Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers.
	The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable, non-returnable and without any rights of price protection or stock rotation. Accordingly, the Company considers all the distributors as end-users.
	In the PAD segment, in most cases, the Company does not grant a right of return for its products. In the EBU segment, customer returns are recorded on an actual basis throughout the year and also include an estimate at the end of each reporting period for future customer returns related to sales recorded prior to the end of the period.  The Company generally estimates customer returns based upon the time lag that historically occurs between the date of the sale and the date of the return, while also factoring other business conditions that might impact the historical analysis.  The Company believes that the amount of future returns is reasonably estimated. The provision for returns is recorded through a reduction of revenue.
	In respect of sale of systems with installation, the Company considers the elements in the arrangement to be a single unit of accounting. In accordance with ASC 605, the Company has concluded that its arrangements are generally consistent with the indicators suggesting that installation is not essential to the functionality of the Company's systems. Accordingly, installation is considered inconsequential and perfunctory relative to the system, and therefore the Company recognizes revenue for the system and installation upon delivery to the customer in accordance with the agreement delivery terms once all other revenue recognition criteria have been met, and provides an accrual for installation costs as appropriate.
	Part of the Company's revenue transaction with end-users includes multiple elements within a single contract and it is determined that multiple units of accounting exist.
	According to ASC 605-25, when a sales arrangement contains multiple deliverables, such as sales of products and related services, the multiple deliverables are evaluated to determine the units of accounting, and the entire fee from the arrangement is allocated to each unit of accounting based on the relative selling price. Under this approach, the selling price of a unit of accounting is determined by using a selling price hierarchy which requires the use of vendor-specific objective evidence (VSOE)  of fair value if available, third-party evidence (TPE) if VSOE is not available, or best estimate of selling price (BESP) if neither VSOE nor TPE is available. Revenue is recognized when the revenue recognition criteria for each unit of accounting are met. Accordingly, for such products and services the Company determined the selling price by reviewing historical transactions, and considering several other external and internal factors including, but not limited to, pricing practices including discounting and margin objectives.
	In certain cases, when product arrangements are bundled with extended warranty, the separation of the extended warranty falls under the scope of ASC 605- 20-25-1 through 25-6, and the separately price of the extended warranty stated in the agreement is deferred and recognized ratably over the extended warranty period.
Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues.
	o.	Research and development costs:
		Research and development costs are expensed when incurred.
	p.	Share-based compensation:
The Company measures and recognizes the compensation expense for all equity-based payments to employees and directors based on their estimated fair values in accordance with ASC 718, "Compensation-Stock Compensation". The Company estimates the fair value of employee stock options at the date of grant using a binomial valuation model and values restricted stock units based on the market value of the underlying shares at the date of grant.
The Company recognizes compensation expenses for the value of its awards based on the straight line method over the requisite service period of each of the awards, net of estimated forfeitures. Estimated forfeitures are based on actual historical pre-vesting forfeitures.
	q.	Basic and diluted net income (loss) per share:
Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each year. Basic net income (loss)  per share was determined by dividing net income (loss) by the weighted average ordinary shares outstanding during the period.
Diluted net loss per share was determined by dividing net income (loss) by the diluted weighted average shares outstanding. Diluted weighted average shares reflect the dilutive effect, if any, of stock options, stock appreciation rights, and restricted share units based on the treasury stock method, in accordance with ASC, 260, "Earning Per Share".
	r.	Fair value of financial instruments:
The carrying amounts of financial instruments, including cash and cash equivalents, bank deposits, accounts receivable, short-term bank credit, accounts payable and accrued liabilities, approximate fair value because of their generally short maturities.
The Company applies ASC 820, "Fair Value and Disclosure" (ASC 820). Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	Level 1 -	Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;
	Level 2 -	Significant other observable inputs based on market data obtained from sources independent of the reporting entity;
	Level 3 -	Unobservable inputs which are supported by little or no market activity (for example cash flow modeling inputs based on assumptions).
The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.
Assets and liabilities measured at fair value on a recurring basis are comprised of marketable securities, investment in affiliated company, hedging contracts and contingent considerations (see Note 4). Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. Each reporting period, the Company revalues these contingent considerations and records increases or decreases in their fair value as an adjustment to contingent consideration expense within the consolidated statement of operations. Changes in the fair value of the contingent consideration can result from adjustments to the discount rates, the probability of achievement of any revenue milestones and due to discounting to present value each reporting date. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
The fair value of the Company's equity interest in Iluminage Beauty (see Note 1b1) was calculated by a third party appraisal firm using the discount cash flow and the OPM method, which uses significant unobservable inputs such as cash flows to be generated from the underlying investment and discounted at a weighted average cost of capital.
	s.	Income taxes:
The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reduces deferred tax assets by an allowance if, based on the weight of available positive and negative evidence, it is more likely than not that the Company will not realize some portion, or all, of the deferred tax asset.
Deferred tax liabilities and assets are classified as current or non-current based on the classification of the related asset or liability for financial reporting, or according to the expected reversal dates of the specific temporary differences if not related to an asset or liability for financial reporting.
The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).
	t.	Employee benefit plan:
Certain of the Company's U.S. employees are eligible to participate in a defined contribution pension plan (Plan).  Participants in the Plan may elect to defer a portion of their pre-tax earnings into the Plan, which is run by an independent party.  The Company makes pension contributions at rates varying up to 10% of the participant's pensionable salary. Contributions to the Plan are recorded as an expense in the consolidated statements of operations.
Candela's U.S. operations maintain a retirement plan (Candela U.S. Plan) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Participants in the Candela U.S. Plan may elect to defer a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. Candela matches 50% of each participant's contributions up to a maximum of 6% of the participant's elective deferral.  Each participant may contribute a percentage of their pay or a flat dollar amount.  Contributions to the Candela U.S. Plan are recorded during the year contributed as an expense in the consolidated statements of operations.
Total contributions for the years ended December 31, 2013, 2012 and 2011 were $327, $255 and $297, respectively.
Syneron's U.S. operations maintain a retirement plan (Syneron U.S. Plan) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code.  Participants in the Syneron U.S. Plan may elect to defer a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. The Company matches 100% of each participant's elective deferrals that do not exceed 3% of the participant's compensation, plus 50% of the portion of the participant's elective deferrals on the next 2% of compensation for the Plan year.  Each participant may contribute from 1% to 50% of compensation on a pretax basis up to the maximum permitted by the Internal Revenue Code.  Contributions to Syneron's U.S. Plan are recorded during the year contributed as an expense in the consolidated statements of operations.
Total contributions for the years ended December 31, 2013, 2012 and 2011 were $206, $196 and $166, respectively.
Severance pay:
The Company's liability for severance pay to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date. Employees are entitled to one month's salary for each year of employment or portion thereof. The Company's liability for all of its Israeli employees is covered by monthly deposits for insurance policies and by an accrual. The value of these policies is recorded as an asset on the Company's balance sheet.
The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Israeli Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits accumulated up to the balance sheet date.
The majority of the Company's agreements with its employees in Israel are in accordance with section 14 of the Israeli Severance Pay Law. Upon contribution of the full amount of the employee's monthly salary, and release of the policy to the employee, no additional legal obligation exists between the parties and no additional payments are made by the Company to the employee; therefore related assets and liabilities are not presented in the balance sheet.
Severance pay expenses for the years ended December 31, 2013, 2012 and 2011 amounted to approximately $933, $744 and $755, respectively.
	u.	Shipping and handling costs:
Shipping and handling costs, which amounted to $ 6,610, $ 6,475 and $ 4,408 for the years ended December 31, 2013, 2012 and 2011, respectively, are included in sales and marketing expenses in the consolidated statements of operations. Shipping and handling costs include all costs associated with the distribution of finished products, consumables and spare parts from the Company's point of manufacturing directly to customers, distributors and international subsidiaries.
	v.	Advertising expenses:
Advertising expenses are charged to the statements of operations, as incurred. Advertising expenses for the years ended December 31, 2013, 2012 and 2011 were $ 9,049, $ 6,334 and $ 5,723, respectively.
	w.	Legal expenses:
		Legal expenses are charged to the statement of operations as incurred.
	x.	Concentration of credit risk:
Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash and cash equivalents, bank deposits, derivative instruments, marketable securities, and trade receivables.
The majority of the Group's cash and cash equivalents and banks deposits are invested in dollar instruments of major banks in Israel and in the United States. Management believes that the financial institutions that hold the Company's investments are institutions with high credit standing and that, accordingly, low credit risk exists with respect to these investments.
The Company's marketable securities include investments in highly rated debentures of U.S. and Israeli, corporations and governmental bonds. Based on the above and the fact that the portfolio is well diversified, management believes that low credit risk exists with respect to these marketable securities. The Company has implemented additional measures with respect to its investment policy. Such measures include among others: reducing credit exposure to corporate sector securities and increasing the overall credit quality of the portfolio.
The Company and its subsidiaries have no material off-balance sheet concentration of financial instruments subject to credit risk such as foreign exchange contracts, option contracts or other hedging arrangements, except those mentioned in Note 14.
The Company's trade receivables are derived mainly from sales to large independent distributors and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection.
The following table provides details of the change in the Company's allowance for doubtful accounts:
		December 31,
		2013			2012			2011
Balance at the beginning of the year		$	6,792		$	5,478		$	7,704
Charged to expenses, net of recoveries			1,217			1,782			(847	)
Deconsolidation of subsidiary			(141	)		-			-
Write-off			(1,483	)		(523	)		(1,443	)
Exchange rate			112			55			64
Balance at the end of the year		$	6,497		$	6,792		$	5,478
	y.	Warranty:
The Company provides a one to three year standard warranty for its products, depending on the type of product and the country in which the Company does business. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company's warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
The following table provides details of the change in the Company's product warranty accrual:
		December 31,
		2013			2012			2011
Warranty provision at the beginning of the year		$	7,197		$	6,514		$	6,854
Warranty provision related to the acquisition of Ultrashape			-			44			-
Warranty provision related to the Deconsolidation of Syneron Beauty			(129	)		-			-
Charged to costs and expenses relating to new sales			9,122			9,058			7,856
Costs of product warranty claims			(9,209	)		(8,419	)		(8,196	)
Warranty provision at the end of the year		$	6,981		$	7,197		$	6,514
	z.	Comprehensive income (loss):
The Company reports comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This Statement establishes standards for the reporting and presentation of comprehensive income and its components in a full set of general purpose financial statements. Comprehensive income generally represents all changes in equity during the period except those resulting from investments by, or distributions to, stockholders. The Company determined that items of other comprehensive income relate to unrealized gains and losses on available-for-sale marketable securities, hedging contracts and currency translation adjustments.
	aa.	Treasury shares:
The Company repurchased its ordinary shares on the open market and holds such shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction in equity.
	ab.	Impact of recently issued accounting standards:
In July 2013, the Financial Accounting Standards Board ("FASB") issued new accounting guidance on the presentation of unrecognized tax benefits. This new guidance requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists, with limited exceptions. This new guidance is effective for the periods beginning after December 15, 2013, and should be applied prospectively with retroactive application permitted. The adoption of this guidance does not have a material impact on the Company's consolidated financial position, results of operations or cash flows.
In March 2013, the FASB issued guidance that requires a parent company to release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. This new guidance is effective beginning after December 15, 2013. The adoption of this guidance does not have a material impact on the Company's consolidated financial position, results of operations or cash flows.

AVAILABLEFORSALE_MARKETABLE_SE

AVAILABLE-FOR-SALE MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2013
AVAILABLE-FOR-SALE MARKETABLE SECURITIES [Abstract]	'
AVAILABLE-FOR-SALE MARKETABLE SECURITIES	'
	NOTE 3:-	AVAILABLE-FOR-SALE MARKETABLE SECURITIES
			31-Dec-13
			Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair
										value
	Money market funds		$	1,535	$	-	$	-		$	1,535
	Available-for-sale - matures within one year:
	Certificate of deposit			2,494		3		-			2,497
	Government debentures - fixed interest rate			1,516		13		-			1,529
	Government sponsored enterprises - fixed interest rate			455		-		(8	)		447
	Corporate debentures - fixed interest rate			5,274		35		-			5,309
				9,739		51		(8	)		9,782
	Available-for-sale - matures after one year through three years:
	Certificate of deposit			2,735		1		(6	)		2,730
	Government debentures - fixed interest rate			2,260		-		(6	)		2,254
	Government sponsored enterprises - fixed interest rate			3,236		-		(2	)		3,234
	Corporate debentures - fixed interest rate			29,398		126		(62	)		29,462
				37,629		127		(76	)		37,680
	Available-for-sale - matures after three years through five years:
	Corporate debentures - fixed interest rate			4,465		17		(36	)		4,446
	Available-for-sale - matures after five years:
	ARS			1,197		-		(136	)		1,061
			$	54,565	$	195	$	(256	)	$	54,504
	Reclassification of certain securities to long-term										25,571
										$	28,933
			31-Dec-12
			Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair
										value
	Money market funds		$	3,548	$	-	$	-		$	3,548
	Available-for-sale - matures within one year:
	Certificate of deposit			5,658		11		(1	)		5,668
	Government debentures - fixed interest rate			2,617		43		-			2,660
	Government sponsored enterprises - fixed interest rate			4,558		-		-			4,558
	Corporate debentures - fixed interest rate			2,609		2		(9	)		2,602
				15,442		56		(10	)		15,488
	Available-for-sale - matures after one year through three years:
	Certificate of deposit			3,260		16		-			3,276
	Government debentures - fixed interest rate			1,570		72		-			1,642
	Government sponsored enterprises - fixed interest rate			8,671		4		(2	)		8,673
	Corporate debentures - fixed interest rate			13,669		96		(34	)		13,731
				27,170		188		(36	)		27,322
	Available-for-sale - matures after three years through five years:
	Corporate debentures - fixed interest rate			1,531		-		(17	)		1,514
	Available-for-sale - matures after five years:
	ARS			1,387		-		(157	)		1,230
			$	49,078	$	244	$	(220	)		49,102
	Reclassification of certain securities to long-term										7,966
										$	41,136
	The table below presents the fair value of investments in available-for-sale securities that have been in an unrealized loss position as of December 31, 2013 and 2012 and the length of time that those investments have been in a continuous loss position:
			31-Dec-13
			Less than 12 months				12 months or longer					Total
			Fair		Unrealized losses		Fair			Unrealized losses		Fair		Unrealized losses
			value				value					value
	Government sponsored enterprises		$	2,780	$	10	$	-		$	-	$	2,780	$	10
	Government debentures			2,255		6		-			-		2,255		6
	Corporate debentures			13,523		76		4,127			22		17,650		98
	ARS			-		-		1,061			136		1,061		136
	Certificate of deposit			2,372		6		-			-		2,372		6
			$	20,930	$	98	$	5,188		$	158	$	26,118	$	256
			31-Dec-12
			Less than 12 months				12 months or longer					Total
			Fair		Unrealized losses		Fair			Unrealized losses		Fair		Unrealized losses
			value				value					value
	Government sponsored enterprises		$	500	$	2	$	1,002		$	*) -	$	1,502	$	2
Corporate debentures			7,061		60		-			-		7,061		60
ARS			-		-		1,230			157		1,230		157
Certificate of deposit			1,019		*) -		244			1		1,263		1
		$	8,580	$	62	$	2,476		$	158	$	11,056	$	220
	*)	Represents an amount lower than $1.
As of December 31, 2013 and 2012, there were 43 and 21 securities in a loss position, respectively.
For the years ended December 31, 2013, 2012 and 2011, the Company recognized gross realized gains of $120, $2 and $47, respectively, and gross realized losses of $3, $0 and $42, respectively. The Company determines realized gains or losses on the sale of marketable securities on a specific identification method, and reflects such gains and losses as a component of financial income, net, in the Company's consolidated statements of operations.

FAIR_VALUE_MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2013
FAIR VALUE MEASUREMENT [Abstract]	'
FAIR VALUE MEASUREMENT	'
	NOTE 4:-	FAIR VALUE MEASUREMENT
	The Company measures its marketable securities, foreign currency derivative contracts, investment in Iluminage Beauty Ltd and contingent considerations at fair value. Marketable securities are classified within Level 1 or Level 2 because they are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. Investments in ARS, investment in Iluminage Beauty Ltd and liabilities with respect to contingent considerations are classified within Level 3 because they are valued using valuation techniques. Some of the inputs to these models are unobservable in the market and are significant.
	The Company's financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of December 31, 2013 and 2012:
			31-Dec-13
			Level 1			Level 2			Level 3		Total
	Assets:
	Corporate debentures		$	-		$	39,216		$	-	$	39,216
	ARS			-			-			1,061		1,061
	Government debentures			-			3,783			-		3,783
	Government sponsored enterprises			-			3,682			-		3,682
	Money markets funds			6,762			-			-		6,762
	Investment in affiliated companies			-			-			24,720		24,720
	Total		$	6,762		$	46,681		$	25,781	$	79,224
	Liabilities:
	Foreign currency derivatives		$	-		$	16		$	-	$	16
	Contingent consideration		$	-		$	-		$	7,896	$	7,896
	Total		$	-		$	16		$	7,896	$	7,912
			31-Dec-12
			Level 1			Level 2			Level 3		Total
	Assets:
	Corporate debentures		$	-		$	17,847		$	-	$	17,847
	ARS			-			-			1,230		1,230
	Government debentures			-			4,302			-		4,302
	Government sponsored enterprises			-			13,231			-		13,231
	Money markets funds			12,492			-			-		12,492
	Foreign currency derivatives			-			152			-		152
	Total		$	12,492		$	35,532		$	1,230	$	49,254
	Liabilities:
	Contingent consideration		$	-		$	-		$	6,750	$	6,750
	Total		$	-		$	-		$	6,750	$	6,750
	The estimated fair value of the Company's ARS holdings and collateralized debt obligations investment as of December 31, 2013 and 2012 were $ 1,061 and $ 1,230, respectively, which reflects cumulative other than temporary impairment of $ 2,803 and $ 2,813, respectively, below their cost.
	The table below presents the changes in Level 3 investments measured on a recurring basis:
			December 31,
			2013			2012
	Balance at the beginning of the year		$	1,230		$	1,313
	Changes in realized gains included in earnings			31			5
	Sales (*)			(200	)		(100	)
	Changes in unrealized gains included in Other comprehensive income			-			12
	Balance at the end of the year		$	1,061		$	1,230
		(*)	During 2013, the Company sold ARS with carrying amount of $169 for a total consideration of $200, which reflects a gain of $31. During 2012, the Company sold ARS with carrying amount of $95 for a total consideration of $100, which reflects a gain of $5.
	The table below presents the changes in Level 3 contingent consideration obligations measured on a recurring basis and related to business combinations of THB in December 2010 and from RBT investment in May 2012:
			December 31,
			2013			2012
	Fair value at the beginning of the year		$	6,750		$	2,535
	Acquisition date fair value of contingent consideration related to additional investment in RBT (see Note 1b5)			-			6,125
	Changes in the fair value of contingent consideration, net			1,146			(1,910	)
	Fair value at the end of the year		$	7,896		$	6,750
	The fair value of the contingent consideration related to the acquisition of THB was $0 for the year ended December 31,  2012. The fair value was based on management's analysis, forecasts and estimates, regarding the probability that the revenues milestone will be achieved until May 31, 2013 and the Company will be required to pay the contingent consideration.   On May 31, 2013, the revenues milestone was not achieved and no payments to THB's shareholders were due. The Company recorded in 2012 and 2011, due to changes in fair value, an income in the amount of $2,535 and expenses of $126, respectively.
	The fair value of the contingent consideration related to the investment in RBT was $7,896 and $6,750 as of December 31, 2013 and 2012, respectively. . The fair value was based on management's analysis, forecasts and estimates, regarding the probability that the revenues milestone will be achieved until 2017 and the Company will be required to pay the contingent consideration. The Company recorded expenses of $1,146 and $625, respectively, in 2013 and 2012, due to changes in fair value as a result of the passage of time.
	Changes in the contingent consideration are recorded in the statements of operations under other expenses (income), net.
	The table below presents the changes in Level 3 investment in Iluminage Beauty measured on a recurring basis and related to deconsolidation of Syneron Beauty in December 9, 2013:
			December 31,
			2013			2012
	Fair value at the beginning of the year		$	-		$	-
	Fair value of investment in Iluminage Beauty (see Note 1b1)			24,720			-
	Changes in the fair value			-			-
	Fair value at the end of the year		$	24,720		$	-
	The fair value of the Company equity interest in Iluminage Beauty (see note 1b1) was calculated by a third party appraisal firm using the discount cash flow and the OPM method, which uses significant unobservable inputs such as cash flows to be generated from the underlying investment, discounted at a weighted average cost of capital.
	Assets measured at fair value on a nonrecurring basis:
	Level 3 assets measured on a nonrecurring basis at December 31, 2013 and 2012 consisted of intangible assets and investment in affiliated companies. As of December 31, 2013 and 2012, certain intangible assets were written down to their estimated fair values of $3,102 and $4,281, resulting in an impairment charge of $323 and $3,370, respectively The fair value for such assets were calculated by a third party appraisal firm using the discounted cash flow method, which uses significant unobservable inputs which require significant management judgment due to the absence of quoted market prices or observable inputs for assets of a similar nature (see also Note 16 and Note 7).
	During 2013, an investment in an affiliated company with a carrying amount of $1,000 was written down to its estimated fair values of $0, resulting in an impairment charge of $1,000. During 2012, an investment in affiliated company with a carrying amount of $200 was written down to its estimated fair values of $0, resulting in an impairment charge of $200.
	During 2011, an investment in another affiliated company with a carrying amount of $9,387 was written down to its estimated fair value of $0, resulting in an impairment charge of $9,387.
	All impairments mentioned above are recorded in the statements of Operations under other expenses (income), net (see also Note 17).

OTHER_ACCOUNTS_RECEIVABLE_AND_

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2013
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]	'
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES	'
	NOTE 5:-	OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES
			December 31,
			2013		2012
	Prepaid expenses and advanced payments		$	2,939	$	5,407
	Government authorities			903		919
	Deposits with escrow agent (see also 1b5)			1,760		1,760
	Derivative instruments			-		152
	Other receivables			1,721		1,059
			$	7,323	$	9,297

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2013
INVENTORIES [Abstract]	'
INVENTORIES	'
	NOTE 6:-	INVENTORIES
			December 31,
			2013		2012
	Raw materials		$	9,845	$	12,552
	Work in process			1,299		2,250
	Finished products			23,563		22,060
			$	34,707	$	36,862

INVESTMENTS_IN_AFFILIATED_COMP

INVESTMENTS IN AFFILIATED COMPANIES	12 Months Ended
	Dec. 31, 2013
INVESTMENTS IN AFFILIATED COMPANIES [Abstract]	'
INVESTMENTS IN AFFILIATED COMPANIES	'
	NOTE 7:-	INVESTMENTS IN AFFILIATED COMPANIES
			December 31,
			2013		2012
	Investment in Iluminage Beauty (1)		$	24,720	$	-
	Investment in Juvenis Ltd. (Juvenis) (2)			-		1,000
			$	24,720	$	1,000
		-1	On December 9, 2013, based on the fair value method, the Company recorded an investment in Iluminage Beauty of $24,720, which represents the fair value of Iluminage Beauty's common stock held by the Company on the deconsolidation date. Refer to Note 4 and 1b1 for further details.
		(2)	On March 15, 2012, Syneron invested in Juvenis, an Israel-based company. Under terms of the agreement, Syneron made an initial investment in Juvenis of $1,000 in cash.
			On November 11, 2013, Juvenis' board of directors resolved that, due to its financial situation, Juvenis should cease its operations due to lack of funds.

PROPERTY_AND_EQUIPMENT_NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT, NET [Abstract]	'
PROPERTY AND EQUIPMENT, NET	'
	NOTE 8:-       PROPERTY AND EQUIPMENT, NET
			December 31,
				2013(*)		2012
	Cost:
	Computers, software, manufacturing, laboratory equipment and demonstration equipment		$	13,560	$	11,681
	Leasehold improvements			3,140		2,082
	Office furniture and equipment			1,846		2,048
				18,546		15,811
	Accumulated depreciation:
	Computers, software, manufacturing, laboratory equipment and demonstration equipment			9,000		7,135
	Leasehold improvements			1,778		1,708
	Office furniture and equipment			1,165		820
				11,943		9,663
	Depreciated cost		$	6,603	$	6,148
	Depreciation expenses for the years ended December 31, 2013, 2012 and 2011 were $ 3,445, $ 3,104 and $ 1,990, respectively.
		(*)	As part of Syneron Beauty's deconsolidation, the Company deconsolidated Syneron Beauty's Property and Equipment, in the total net amount of $847.

INTANGIBLE_ASSETS_NET

INTANGIBLE ASSETS, NET	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS, NET [Abstract]	'
INTANGIBLE ASSETS, NET	'
	NOTE 9:-	INTANGIBLE ASSETS, NET
			Weighted average remaining useful life		December 31,
			(years)		2013		2012
	Original cost:
	Patent			-	$	1,899	$	1,899
	Distribution agreements (2)			-		163		1,600
	Brand name			-		295		295
	In process R&D (1,2)			-		-		263
	Developed technologies (1,2)			4.6		29,618		31,255
	Trade name			7		3,300		3,300
	Non-compete covenant			-		1,200		1,200
	Customer relationships			3.1		10,773		10,773
	Distribution exclusivity (1)			1		1,632		1,632
						48,880		52,217
	Accumulated amortization:
	Patent					1,899		1,899
	Distribution agreements (2)					163		506
	Brand name					295		251
	In process R&D (2)					-		63
	Developed technologies (2)					12,673		8,386
	Trade name					1,200		900
	Non-compete covenant					1,200		1,200
	Customer relationships					8,497		7,360
	Distribution exclusivity					1,514		1,219
						27,441		21,784
	Amortized cost				$	21,439	$	30,433
		-1	During the years ended December 31, 2013, 2012 and 2011, the Company recorded an impairment charge in the total amount of $ 323, $ 3,370 and $ 123, respectively. The impairment charge in 2013 was attributed to developed technology in the amount of $323. The impairment charge in 2012 was attributed to in-process R&D and developed technology in the amounts of $510 and $2,860, respectively. The impairment charge in 2011 was attributed to distribution exclusivity license in the amount of $123.
		-2	As part of Syneron Beauty's deconsolidation, the Company deconsolidated Distribution agreements, In Process R&D and Developed technologies in the total net amount of $856, $87 and $699, respectively.
	During 2013, 2012 and 2011, the Company recorded amortization expenses in the amount of $7,027, $7,877 and $8,058, respectively. The annual amortization expense relating to intangible assets as of December 31, 2013 is estimated to be as follows:
	2014		$	4,924
	2015			4,988
	2016			4,241
	2017			3,886
	2018			1,739
	Thereafter			1,661
	Total		$	21,439

GOODWILL

GOODWILL	12 Months Ended
	Dec. 31, 2013
GOODWILL [Abstract]	'
GOODWILL	'
	NOTE 10:-     GOODWILL
	Changes in goodwill for the years ended December 31, 2013 and 2012, by reporting units are as follows:
			Syneron (*)		LI		RBT		THB (**)			Total
	As of December 31, 2011		$	8,206	$	3,005	$	2,528	$	5,128		$	18,867
	Acquisitions and others			6,729		73		-		-			6,802
	Impairment (see Note 2m)			-		-		-		(450	)		(450	)
	As of December 31, 2012			14,935		3,078		2,528		4,678			25,219
	Acquisitions and others			386		49		-		-			435
	Deconsolidation of subsidiary			-		-		-		(4,678	)		(4,678	)
	As of December 31, 2013		$	15,321	$	3,127	$	2,528	$	-		$	20,976
		(*) Includes Ultrashape and TransPharma
		(**) Includes Fluorinex

ACCUMULATED_OTHER_COMPREHENSIV

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	12 Months Ended
	Dec. 31, 2013
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	NOTE 11:-      ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the year ended December 31, 2013:
		Unrealized			Unrealized gains (losses) on cash flow hedges (*)			Foreign Currency Translation Adjustments
		gains (losses) on available-for-sale marketable securities (*)
											Total
	Beginning balance	$	24		$	152		$	450		$	626
	Other comprehensive income (loss) before reclassifications		32			179			(1,844	)		(1,633	)
	Amounts reclassified from accumulated other comprehensive income		(117	)		(347	)		-			(464	)
	Net  current period other comprehensive income (loss)		(85	)		(168	)		(1,844	)		(2,097	)
	Ending balance	$	(61	)	$	(16	)	$	(1,394	)	$	(1,471	)
	(*) Refer to Note 3 and Note 12 for the affected line item in the statement of income.

DEFERRED_REVENUES

DEFERRED REVENUES	12 Months Ended
	Dec. 31, 2013
DEFERRED REVENUES [Abstract]	'
DEFERRED REVENUES	'
	NOTE 12:-     DEFERRED REVENUES
	The Company offers extended warranty contracts, generally for periods of one to three years that may be purchased after the standard warranty period has expired. The Company recognizes extended warranty contract revenue ratably over the life of the contract.
	The following table reflects changes in the Company's deferred revenue during the years ended December 31:
		December 31,
		2013			2012
	Balance at the beginning of the year	$	15,910		$	15,662
	Deferral of new sales		12,821			11,957
	Recognition of previously deferred revenue		(11,986	)		(11,550	)
	Foreign currency translation adjustments		(283	)		(159	)
	Balance at the end of the year	$	16,462		$	15,910
	The following table reflects the Company's current and long-term deferred revenues:
		December 31,
		2013			2012
	Total deferred revenues	$	16,462		$	15,910
	Less - current portion		13,001			11,986
	Long-term deferred revenues	$	3,461		$	3,924

OTHER_ACCOUNTS_PAYABLE_AND_ACC

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2013
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES	'
	NOTE 13:-	OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES
			December 31,
			2013		2012
	Warranty accruals		$	6,202	$	6,489
	Accrued expenses			8,632		15,749
	Voluntary field action			-		1,496
	Accrued commission			3,466		3,493
	Employees and related expenses			5,658		8,503
	Tax authorities			3,837		14,149
	Other payables			36		10
			$	27,831	$	49,889

DERIVATIVE_INSTRUMENTS

DERIVATIVE INSTRUMENTS	12 Months Ended
	Dec. 31, 2013
DERIVATIVE INSTRUMENTS [Abstract]	'
DERIVATIVE INSTRUMENTS	'
	NOTE 14:-	DERIVATIVE INSTRUMENTS
		The fair values of outstanding derivative instruments were as follows:
				Fair value of
				derivative instruments
				December 31,
		Balance sheet location		2013				2012
	Derivatives designated and qualified as cash flow hedging instruments:
	Foreign exchange contracts	Other accounts receivable and prepaid expenses		$	-			$	152
	Foreign exchange contracts	Other account payables and accrued expenses			(16	)			-
	Total derivatives designated as hedging instruments			$	(16	)		$	152
	The effect of derivative instruments in cash flow hedging relationships in the statement of operations and other comprehensive income (OCI) is summarized below:
			Amount of gain (loss) recognized in accumulated OCI (effective portion)
			Year ended December 31,
			2013				2012			2011
	Foreign exchange contracts		$	179			$	138		$	177
	Total		$	179			$	138		$	177
	Location		Amount of gain (loss) reclassified from accumulated OCI into income (effective portion)
			Year ended December 31,
			2013				2012			2011
	Revenues		$	(77	)		$	156		$	77
	Operating expenses			424				(95	)		25
	Total		$	347			$	61		$	102
		Gain (loss) recognized in income on derivatives
				December 31,
		Location		2013				2012			2011
	Derivatives not designated as hedging instruments:
	Foreign exchange contracts	Financial income, net		$	(3	)		$	89		$	65
	Total			$	(3	)		$	89		$	65

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	NOTE 15:-	COMMITMENTS AND CONTINGENCIES
		a.	Royalties:
		1.	In June 2004, the Company entered into an agreement effective from December 1, 2003 until December 1, 2021, for using the know-how of Tensor Technologies LLC ("Tensor"). For the usage of the know-how, the Company is obligated to pay royalties, at a rate of 4.5%, on sales of certain products to its distributors and subsidiaries.
	Royalty expenses amounted to $660, $1,163 and $525 for the years ended December 31, 2013, 2012 and 2011, respectively, were recorded as part of cost of revenues.
		2.	In August 2005, Candela entered into an agreement with the Regents of the University of California ("Regents") for exclusive license rights to the Dynamic Cooling Device ("DCD"), subject to certain limited license rights of CoolTouch, Inc. ("Cool Touch"), in the following fields of use: procedures that involve skin resurfacing and rejuvenation, vascular skin lesions, and laser hair removal. CoolTouch, a subsidiary of New Star Technology, Inc., obtained a license to the DCD on a co-exclusive basis with the Company, in certain narrower fields of use.
			Candela's agreement with the Regents called for an annual license fee, for calendar years up to 2015 of $300. The multi-year annual fee of $300 was paid to the Regents in a lump sum of $3,000 and is being amortized over the remaining life of the patent agreement, which as of December 31, 2013 was approximately one and a half years. As of December 31, 2013 and 2012, the unamortized portion of the license fee payment was reflected as follows: $ 300 is included in other receivables for both years and $150 and $450 are included in long-term assets, respectively.
			In addition, Candela's agreement with the Regents called for a minimum annual royalty obligation of $500. Candela's royalty obligation was 3% up to a certain level ("Net Sale Rate") of net sales and 2% above the Net Sale Rate. On June 30, 2011 Candela signed on an amendment to the license agreementeffective July 1, 2011, that increased the minimum annual royalty obligation to $750 beginning in the calendar year 2012. According to the amendment the Net Sale Rate was increased.
			Royalty expenses and license fees were amounted to $2,473, $2,683 and $2,529 for the years ended December 31, 2013, 2012 and 2011, respectively. The royalty and the amortization of the annual license fee payment are recorded as part of cost of revenues.
		3.	On September 16, 2011, Syneron Inc., Candela, and Syneron Medical Ltd. entered into a comprehensive settlement agreement with Palomar and Massachusetts General Hospital ending a patent disputes on mutually agreeable terms. According to the agreement, Palomar granted Syneron Inc. and its affiliates (including Syneron Medical Ltd. and Candela) a non-exclusive, royalty bearing license in the U.S. to Patents for consumer home-use lamp- based hair removal products. The Company will pay royalties to Palomar on sales of such products in the U.S. as follows: a 5% royalty up to a certain level of cumulative sales, then 6.5% up to another level of cumulative sales, and 7.5% on all cumulative sales thereafter. In addition, Palomar received a royalty-free license to certain Syneron Medical Ltd. and Candela patents.  As of December 31, 2013 the Company paid approximately $147 in regard to the Palomar royalties.
		b.	Leases:
	The Company leases several facilities and automobiles under non-cancelable lease agreements. The facility leases can be adjusted for increases in maintenance and insurance costs above specified levels. In addition, certain facility leases contain escalation provisions based on certain inflationary indices. These operating leases expire in various years through fiscal year 2018. These leases may be renewed for periods ranging from one to five years.
	The future minimum lease commitments of the Company under various non-cancelable operating lease agreements as of December 31, 2013, are as follows:
	Year ended December 31,
	2014			4,475
	2015			3,465
	2016			2,615
	2017			489
	2018			122
			$	11,166
	Rent expenses amounted to $3,611, $ 3,195 and $ 2,968 for the years ended December 31, 2013, 2012 and 2011, respectively.
		c.	Legal claims:
		1.	On December 23, 2008, the Company received a letter from Tensor Technologies LLC (Tensor) claiming that the Company was in breach of its royalty payment obligations to Tensor pursuant to a License Agreement between the Company and Tensor. On February 19, 2009, the Company sent a letter to Tensor denying Tensor's claims and denying any royalty payment obligations to Tensor whatsoever. The Company submitted the matter for arbitration and commenced the arbitration process. On May 5, 2011, the arbitrator issued a decision accepting most of Tensor's claims and denying most of the Company's counterclaims. The arbitrator appointed an expert accountant to examine the royalties to be paid to Tensor under the terms of the agreement. On April 8, 2012, the arbitrator ruled that the Company must pay Tensor a sum of $2.1 million plus interest. On September 13, 2012, the arbitrator's ruling was approved by the District Court of Haifa, and the Company subsequently paid Tensor.
		2.	An action against Syneron, Inc. was commenced in New York state court on October 25, 2010 by a plaintiff related to alleged injury received while undergoing a procedure performed in January 2009 with a Triniti E-Max machine. Plaintiff alleged negligent misrepresentation, negligence, and product liability with respect to Syneron, Inc. and the "Triniti E-Max-Laser/facial laser treatment" and sought $2 million in damages. In March 2014, the parties agreed to settle the matter in a the total amount of $430, of which $154 is to be paid in full by Syneron's insurer, and certain medical provider co-defendants are responsible for paying the remainder.
		3.	On August 15, 2010, a former sales representative sued the Company in Israel for breach of employment agreement with the Company and demanded $1.5 million (NIS 5.7 million). The Company filed its statement of defense rejecting the plaintiff's allegations in their entirety. After an initial preliminary hearing, the plaintiff subsequently filed an amended complaint pursuant to the court's order demanding $1.3 million (NIS 4.8 million). Following the second preliminary hearing, the plaintiff consented to limit the claim to NIS 3 million. An evidentiary hearing was held in May 27, 2013 at which the court rejected plaintiff's request to summon current and former employees of the Company.  Plaintiff appealed the court's decision to the National Labor Court. On July 18, 2013, the Company filed its response to the appeal and currently awaits the National Labor Court's decision with respect to the appeal.  The Company assessed that contingent losses related with this case are only reasonably possible and the amount cannot be reasonably estimated, pursuant to ASC 450, and an accrual has not been recorded for the loss contingencies.
		4.	On January 5, 2011, Mr. Avner Lior submitted an action for declaratory relief and a mandatory injunction in Haifa District Court to void a share purchase agreement between the plaintiff and the Company dated October 23, 2003 and to recover the shares he sold to the Company pursuant to that agreement. After various court proceedings and attempted mediation, the court dismissed all of the plaintiff's claims on July 8, 2013.
		5.	In November 2011, Estetitek S. de R.L. de C.V. (Estetitek), a Mexican distributor, filed a complaint with the arbitrator in Israel according to an arbitration clause in the distribution agreement entered into between the parties in 2006. Estetitek argues that Syneron breached the distribution agreement when it decided to cease selling products to Estetitek. Estetitek asks for compensation for the loss of profit caused to it by the failure to fulfill the distribution agreement in the amount of $1.7 million, and compensation for the damage to its reputation in the amount of $0.5 million. The case is currently in the post-discovery phase. The Company assessed that contingent losses related with this case are only reasonably possible and the amount cannot be reasonably estimated, pursuant to ASC 450, and an accrual has not been recorded for the loss contingencies.
		6.	On December 31, 2013, Syneron Medical Ltd. and its former subsidiary, Syneron Beauty Ltd.  (which following a joint venture with Unilever Ventures is now a subsidiary of Iluminage Beauty), received a copy of a petition filed with the Central District Court in Israel to approve the filing of a class action suit against Syneron Medical Ltd. and Syneron Beauty Ltd. (the "Respondents").  The Petitioner claims that the Respondents violated article 2 of the Consumer Protection Act resulting from misleading advertising regarding the Syneron Beauty mē hair removal device. The Petitioner claims that she suffered monetary damages as a result of relying on misleading representations by Respondents.  In addition, the Peititioner claims injury to bodily autonomy and integrity.  The Petitioner claims to represent the class of consumers that purchased the mē hair removal device and is seeking damages for the group in the amount of NIS 27.5 million.  The Company intends to vigorously defend itself in this matter. The Company assessed that contingent losses related with this case are only reasonably possible and the amount cannot be reasonably estimated, pursuant to ASC 450, and an accrual has not been recorded for the loss contingencies.
		7.	From time to time, the Company is party to various legal proceedings incidental to its business. The Company has accrued a total amount of $565 which it deems sufficient to cover probable losses from legal proceedings and threatened litigation.  The Company is unable to determine the likelihood of loss or range of loss for each matter described above. During the year ended December 31, 2013 the Company settled various legal claims and paid an amount of approximately $387.

EQUITY

EQUITY	12 Months Ended
	Dec. 31, 2013
EQUITY [Abstract]	'
EQUITY	'
	NOTE 16:-      EQUITY
		a.	Share capital:
		1.	Ordinary shares confer upon their holders voting rights, the right to receive dividends and the right to share in equity upon liquidation of the Company.
		2.	Certain of the Company's officers, directors and major shareholders that hold ordinary shares have the right to require the Company, on not more than one occasion, to file a registration statement on the appropriate form under the Securities Act in order to register the resale of their ordinary shares.
		b.	Syneron's option plan:
	In 2004, Syneron adopted the 2004 Israel Stock Option Plan (for Israeli residents) and the 2004 Incentive Stock Option Plan (for the United States, Canada and the rest of the world) (collectively the 2004 Plans). The number of options approved under the 2004 Plans was 2,000,000 options, increasing annually according to the evergreen provision included in each of the 2004 Plans. The evergreen provision calls for the annual increase by the lesser of 2,000,000 options or 3% of the share capital, provided however that the Board of Directors may at its sole discretion decrease, at any given year, the increase of the number of options to whatever number it sees fit.
	As of December 31, 2013, options to purchase 4,996,487 ordinary shares were available for grant under the 2004 Plans.
	Under the 2004 Plans, options are granted to employees, officers, directors and consultants at an exercise price equal to at least the fair market value at the date of grant and are granted for periods not to exceed seven years. Options granted under the 2004 Plans generally vest over a period of three to four years of employment. Any options that are cancelled or forfeited before expiration become available for future grants. In addition to granting stock options, the Company started to routinely grant Restricted Stock Units (RSUs) under the 2004 Plans. RSUs usually vest over a period of employment of up to four years. Upon vesting, the RSU beneficiary is entitled to receive a share per one RSU for no consideration ($0.01 per share). RSUs that are cancelled or forfeited become available for future grants.
		c.	Light Instruments Ltd. option plan:
	January 2, 2012, the Board of Directors of Light Instruments Ltd. adopted the 2011 Share Option Plan pursuant to which employees; officers, directors, and consultants may receive stock options exercisable into either shares of Light Instruments Ltd. or shares of the Company, if certain conditions are met.  The terms of the options granted under the plan, including the exercise price and vesting provisions, shall be determined by the administrator of the plan.  All options shall expire 10 years from the date of grant.   In addition, holders of Light Instruments options may elect to receive, upon exercise of the options, shares of the Company rather than shares of Light Instruments, subject to the approval of the administrator of the Plan, so long as there has been no initial public offering of Light Instruments and so long as Light Instruments remains wholly-owned by the Company (except for any underlying shares granted or to be issued upon exercise of options granted in accordance with the Plan).  The election may be made for all or a portion of the options which have vested and are exercisable on the date of the election.  Upon such election, the number of shares of the Company to be issued will be calculated based on the then-current fair market value of the underlying shares of Light Instruments subject to election (minus the applicable exercise price), as determined in good faith by the plan administrator, divided by the average of the closing price of the Company's shares during the 30 trading days immediately preceding the date of such election.  In addition, the administrator of the Plan shall not approve any election to receive shares of the Company unless the Company's shares are listed on an established stock exchange or national market system. As of December 31, 2013, there were 140,049 options granted under the plan and 270,648 shares available or reserved for future issuance under the plan.
		d.	The following is a summary of activities relating to the Company's stock options and SAR's (excluding Light Instruments options) granted to employees and directors among the Company's various plans during the year ended December 31, 2013:
											Aggregate
			Number				Weighted average				intrinsic Value (in
			of options				exercise price				thousands)
	Outstanding at beginning of year			4,366,897			$	12.65				-
	Granted			921,500			$	9.41				-
	Exercised			(867,106	)		$	8.47				-
	Forfeited			(954,997	)		$	15.81				-
	Outstanding at end of year			3,466,294			$	11.97			$	8,088
	Exercisable options at end of year			1,818,724			$	14.02			$	3,799
	Vested and expected to vest			3,333,107			$	11.86			$	8,418
	The intrinsic value of exercisable options (the difference between the Company's closing share price on the last trading day in fiscal 2013 and the average exercise price of in-the-money options, multiplied by the number of in-the-money options) included below represents the amount that would have been received by the option holders had all option holders exercised their options on December 31, 2013. This amounts changes based on the fair market value of the Company's ordinary shares.
	The following table summarizes the RSUs activity for the year ended December 31, 2013:
							Fair
			Number				value at
			of RSUs				grant date
	Non-vested at January 1, 2013			10,272			$	10.71
	Granted			65,862			$	7.12
	Vested			10,272			$	10.71
	Forfeited			-			$	-
	Non-vested at December 31			65,862			$	7.12
	The fair value of non-vested RSUs is determined based on the closing trading price of the Company's shares on the grant date. The weighted-average grant-date fair value of RSUs granted during the years 2013, 2012 and 2011, was $7.12, $11.15, and $9.16, respectively.
	The total fair value of RSU's vested during the year ended December 31, 2013 was $110.
	Aggregate intrinsic value, at the date of exercise, of options, SAR's and RSU's that were exercised during the years ended on December 31, 2013, 2012 and 2011 was $ 1,309, $ 901 and $ 4,001, respectively.
	The options and SAR's outstanding as of December 31, 2013, have been separated into ranges of exercise price, as follows:
					Outstanding										Exercisable
	Exercise price				Number of				Weighted average remaining contractual life (years)				Weighted		Number of		Weighted		Weighted average exercise price
					options								average		options (in		average
													exercise price		thousands)		remaining
																	contractual
																	life
																	(years)
	$	1.41				62,515				5.05			$	1.41		62,515		5.05	$	1.41
	$	4.81				41,897				5.62			$	4.81		41,897		5.62	$	4.81
	$	7.25-11.31				2,669,969				5.23			$	9.65		1,096,759		4.52	$	9.76
	$	12.09-14.74				458,952				3.39			$	13.25		384,592		3.13	$	13.43
	$	16.05-52.67				232,961				2.36			$	40.07		232,961		2.36	$	40.07
	$	1.41-52.67				3,466,294				4.8			$	11.97		1,818,724		3.99	$	14.02
	The weighted average fair values of options granted (including those granted to non-employees but excluding RSUs) during the years ended December 31, 2013, 2012 and 2011 were:
			Year ended December 31,
			2013				2012				2011
	Weighted average exercise prices		$	9.41			$	10.08			$	11.09
	Weighted average fair value on grant date		$	3.41			$	3.94			$	4.97
	The weighted average estimated fair value of employee stock options granted during the years ended December 31, 2013, 2012 and 2011 was calculated using the binomial model with the following weighted-average assumptions:
			Year ended December 31,
			2013				2012				2011
	Volatility			35	%			42	%			52	%
	Risk-free interest rate			1.05	%			0.75	%			2.07	%
	Dividend yield			0	%			0	%			0	%
	Post-vesting cancellation rate			6.8	%			9.5	%			7	%
	Suboptimal exercise factor			2				2				2.5
	Expected life (in years)			6.15				4.84				5.53
	Volatility is based on the historical volatility of the Company ordinary share, for a period equal to the stock options excepted life.
The risk-free interest rate assumption is based on observed interest rates appropriate for the term of the Company's employee stock options.
The Company is required to assume a dividend yield as an input in the binomial model. The dividend yield assumption is based on the Company's historical and expectation of future dividend payouts and may be subject to substantial change in the future.
The post-vest cancellation rate was calculated on a monthly basis and is presented on an annual basis.
The sub optimal exercise factor is based on the average ratio between the stock price and the exercise price.
The expected life of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is a derived output of the binomial model. The expected life of employee stock options is impacted by all of the underlying assumptions used in the Company's model.
The binomial model assumes that employees' exercise behavior is a function of the option's remaining contractual life and the extent to which the option is in-the-money (i.e., the average stock price during the period is above the strike price of the stock option). The binomial model estimates the probability of exercise as a function of these two variables based on the history of exercises and factors in also the post-vesting termination rate of employees, as termination triggers the truncation of employee awards shortly thereafter.
As equity-based compensation expense recognized in the consolidated statement of operations is based on awards ultimately expected to vest, it should be reduced for estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
The total equity-based compensation expense recognized for the years ended December 31, 2013, 2012 and 2011, was comprised as follows:
		Year ended December 31,
		2013				2012				2011
Cost of revenues		$	288			$	205			$	40
Research and development			766				616				726
Sales and marketing			1,258				1,257				1,058
General and administrative			2,177				2,656				1,576
Total equity-based compensation expense before taxes		$	4,489			$	4,734			$	3,400
As of December 31, 2013, there was $4,959 of total unrecognized stock-based compensation cost related to non-vested stock-based compensation granted under the Company's stock option plans. That cost is expected to be recognized over a weighted average period of 1.37 years.
	e.	Dividends:
The Company has never paid cash dividends to shareholders. The Company intends to retain future earnings for use in its business and does not anticipate paying cash dividends on its shares in the foreseeable future. Any future dividend policy will be determined by the Board of Directors and will be based upon conditions then existing, including results of operations, financial condition, current and anticipated cash needs, contractual restrictions, potential tax implication and other conditions as the Board of Directors may deem relevant. In the event that cash dividends are declared in the future, such dividends will be paid in U.S. dollars subject to any statutory limitations.

OTHER_EXPENSES_INCOME_NET

OTHER EXPENSES (INCOME), NET	12 Months Ended
	Dec. 31, 2013
OTHER EXPENSES (INCOME), NET [Abstract]	'
OTHER EXPENSES (INCOME), NET	'
	NOTE 17:-     OTHER EXPENSES (INCOME), NET
			Year ended December 31,
			2013			2012			2011
	Legal settlement (*)		$	-		$	-		$	31,000
	Impairment of intangibles assets (see also Note 9)			323			3,370			123
	Impairment of goodwill (see also Note 2m)			-			450			-
	Reevaluation of contingent consideration			1,209			(1,836	)		(8,830	)
	Impairment of investment in an affiliated company (**) (see also Note 7)			1,000			200			9,387
	Gain from loss of control (see also Note 7)			(7,273	)		-			-
	Other			118			105			528
	Total		$	(4,623	)	$	2,289		$	32,208
		(*)	On September 16, 2011, Syneron Inc., Candela, and Syneron Medical Ltd. entered into a comprehensive settlement agreement with Palomar and Massachusetts General Hospital ending the patent disputes on mutually agreeable terms. The comprehensive settlement agreement includes two Non-Exclusive Patent Licenses. Under the first agreement, Palomar granted Syneron Inc. and its Affiliates (including Syneron Medical Ltd. and Candela) a non-exclusive, worldwide, fully paid-up, and irrevocable license to the '568 and '844 Patents and foreign counterparts for their professional laser and lamp-based hair removal systems. Pursuant to this agreement, the Company paid Palomar $31,000, and Palomar received a royalty free license to certain Candela patents. Under the second agreement royalties will be paid according to certain levels of sales (refer to Note 15 a.3).
		(**)	On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012.  The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
INCOME TAXES [Abstract]	'
INCOME TAXES	'
	NOTE 18:-     INCOME TAXES
		a.	Israeli taxation:
		1.	Corporate tax rate:
			Israeli corporate tax rate in 2011, 2012 and 2013 was 24%, 25% and 25%, respectively. Commencing January 1, 2014, the Israeli corporate tax rate was increased to 26.5%.
		2.	Measurement of taxable income:
			On February 26, 2008, the Israeli Parliament enacted the Income Tax Law (Inflationary Adjustments) (Amendment 20) (Restriction of Effective Period), 2008 (Inflationary Adjustments Amendment). In accordance with the Inflationary Adjustments Amendment, the effective period of the Inflationary Adjustments Law will cease at the end of the 2007 tax year, and as of the 2008 tax year, the provisions of the Law shall no longer apply, other than the transitional provisions intended at preventing distortions in the tax calculations. In accordance with the Inflationary Adjustments Amendment, commencing with the 2008 tax year, income for tax purposes will no longer be adjusted to a real (net of inflation) measurement basis.  Furthermore, the depreciation of inflation immune assets and carried forward tax losses will no longer be linked to the Israeli Consumer Price Index.
			In accordance with ASC 740, the Company has not provided deferred income taxes on the above difference between the reporting currency and the tax basis of assets and liabilities.
		3	Tax benefits under Israel's Law for the Encouragement of Industry (Taxes), 1969:
			The Company is an "Industrial Company", as defined by the Law for the Encouragement of Industry (Taxes), 1969, and as such, the Company is entitled to certain tax benefits, mainly amortization of costs relating to know-how and patents over eight years, accelerated depreciation and the right to deduct public issuance expenses for tax purposes.
		4	Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (Law) (see Item10.E. "Taxation - Israeli Taxation" for more information):
			The Company has been granted the status of "Privileged Enterprise" according to the Amendment to the Law, for eligible investments ended in 2005, 2007,2009 and 2012 ("Programs"). Those mentioned years are considered to be the election years for tax benefits under the Law.
			In accordance with the Law the Company has chosen to enjoy an "alternative benefits track" status. Accordingly, Syneron Medical Ltd.'s income attributed to the Programs is exempt from taxes on income derived therefrom, the earlier of, a period of 10 years starting in the year in which the Company first generates taxable income or 12 years starting the election year.
	As a "Privileged Enterprise" under the Law in Israel, the Company is partly exempt from taxes on income derived from its ""Privileged Enterprise," and the Company is obligated to pay taxes on income from other sources, which are not integral to its "Privileged Enterprise".
	In addition, it should be noted that some Israeli subsidiaries have a "Privileged Enterprise" status and are exempt from taxes on income derived from their  "Privileged Enterprise" status. The tax consequences of such status are not significant to the Company.
	Out of the Company's retained earnings as of December 31, 2013, approximately $299,238 is tax-exempt earnings attributable to its Approved Enterprise and Privileged Enterprise program. The tax-exempt income attributable to the Approved and Privileged Enterprise cannot be distributed to shareholders without subjecting the Company to taxes. If dividends are distributed out of tax-exempt profits, the Company will then become liable for tax at the rate applicable to its profits from the approved enterprise in the year in which the income was earned, as if it was not under the "alternative benefits track". Under the Law, tax-exempt income generated under the Approved or Privileged Enterprise status will be taxed upon dividend distribution or complete liquidation, whereas in accordance with the Law, tax exempt income generated under the Approved Enterprise status will be taxed upon dividend distribution.
	On October 27, 2013, the Company agreed to pay approximately $4 million to the Israeli Tax Authority to free up "trapped profits" in accordance with the Trapped Profits Law.   This payment gives the Company flexibility to use profits derived from its "Approved Enterprise" or "Privileged Enterprise" programs to undertake future business transactions, such as dividends, share buyback, or mergers and acquisitions, up to a limit of approximately $63.7 million without incurring any additional Israeli taxes.
	As of December 31, 2013, if the income attributed to the Approved Enterprise and Privileged Enterprise is distributed as a dividend, the Company will incur a tax liability of approximately up to $33,981, excluding approximately $4 million that was paid in accordance to the Trapped Profit Low, as mentioned above. These amounts will be recorded as an income tax expense in the period in which the Company declares the dividend.
	The Company's board of directors has determined that it will not distribute any amounts of its undistributed tax-exempt income as a dividend. The Company intends to reinvest the amount of its tax-exempt income. Accordingly, no deferred income taxes have been provided on income attributable to the Company's Approved and Privileged Enterprise programs as the undistributed tax-exempt income is essentially permanent in duration.
	The entitlement to the above benefits is conditional upon the Company's fulfilling the conditions stipulated by the Law, regulations published thereunder and the certificates of approval for the specific investments in Approved Enterprises.
	Should the Company fail to meet such requirements in the future, income attributable to its Programs could be subject to the statutory Israeli corporate tax rate and the Company could be required to refund a portion of the tax benefits already received, with respect to such program. The Company's management believes that the Company is meeting the aforementioned conditions.
	Income from sources other than the "Approved Enterprise" and/or "Privileged Enterprise" is subject to tax at regular Israeli corporate tax rate of 25%.
		b.	Non-Israeli subsidiaries:
			Non-Israeli subsidiaries are taxed based on tax laws in their respective jurisdictions. The Corporate income tax rate of significant jurisdictions are as follows:
			Tax Rate
	Australia			30	%
	Canada (*)			15	%
	Germany			28	%
	Hong Kong			16.5	%
	Japan			39.6	%
	Spain			30	%
	United States (*)			35	%
		*)	Federal.
		c.	Deferred taxes:
	Significant components of the Company's deferred tax assets and liabilities are as follows:
			December 31,
			2013			2012
	Net operating loss carryforward		$	44,440		$	50,525
	Tax credits			6,079			3,080
	Share-based compensation costs			248			2,487
	Company's capital losses carryforward (1)			20,087			15,630
	Bad debt reserve			868			831
	Deferred revenues			2,278			1,907
	Obsolete inventory Reserve			821			639
	Intangible Assets - Patents			1,132			1,200
	Other temporary differences			3,186			2,474
	Total deferred tax asset before valuation allowance			79,139			78,773
	Valuation allowance			(51,561	)		(52,530	)
	Total deferred tax asset			27,578			26,243
	Intangible assets acquired			(5,142	)		(7,682	)
	Total deferred tax liability			(5,142	)		(7,682	)
	Net deferred tax asset (2)		$	22,436		$	18,561
		-1	The Company has capital loss carryforwards resulting mainly from the difference between the reporting currency and the tax basis of the investments in Marketable securities.
		-2	Net deferred tax asset (liability) is recorded in the following balance sheet line items:
			December 31,
			2013			2012
	Current Assets		$	6,939		$	3,266
	Deferred tax assets			17,927			18,390
	Deferred tax liability			(2,430	)		(3,095	)
	Net deferred tax asset		$	22,436		$	18,561
	At December 31, 2013, the Company's U.S. subsidiaries had cumulative net operating losses (NOL) for US federal and state income tax return purposes of $80,271 and $68,198 respectively. The federal NOL carryforwards expire between 2025 and 2031. The state NOL carryforwards begin to expire in 2014. The federal and state NOL carryforwards for tax return purposes are $38,170 greater than their NOL for financial reporting purposes due to unrecognized tax benefits and excess tax benefits. Excess tax benefits related to option exercises cannot be recognized until realized through a reduction of current taxes payable.
	Such losses are subject to limitations of Internal Revenue Code, Section 382, which in general provides that utilization of NOL's is subject to an annual limitation if an ownership change results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period.  The annual limitations may result in the expiration of losses before utilization.
	The Company has available Israeli carryforward capital tax losses of $63,691 and $42,396 in 2013 and 2012, respectively. The Company has Israeli available carryforward net operating tax losses of $98,919 and $71,650 in 2013 and 2012, respectively to offset against future tax profits for an indefinite period.
	Changes in tax laws and rates may affect recorded deferred tax assets and liabilities and the Company's effective tax rate in the future. The American Taxpayer Relief Act of 2012 (Act) was signed into law on January 2, 2013. Because a change in tax law is accounted for in the period of enactment, certain provisions of the Act benefiting the Company's 2012 U.S. federal taxes, including the research and experimentation credit, could not be recognized in the Company's 2012 financial results and instead have be reflected in the Company's 2013 financial results.
At December 31, 2013, the Company's U.S. subsidiaries had available federal research and development (R&D) tax credit carryforwards of approximately $2,387 expiring between 2026 and 2033, capital loss carryforwards of $9,169 expiring in 2017, and alternative minimum tax credits of approximately $655 with an unlimited carryforward period. The Company also had available state R&D tax credits of approximately $1,081. Federal and state R&D credit carryforwards for tax return purposes are $430 greater than their federal and state R&D credit carryforwards for financial reporting purposes due to unrecognized tax benefits.
ASC 740 requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluated the net deferred tax assets for each separate tax entity.  For certain entities, the Company concluded that it is not more likely than not that the net deferred tax assets will be realized and a valuation allowance has been recorded against these assets. Based on a consideration of these factors, the Company has established a valuation allowance of $51,561 and $52,530 at December 31, 2013 and 2012, respectively. The Company's U.S. subsidiary recorded in 2013 a valuation allowance release of $7,935 on the basis of management's reassessment of the amount of its deferred tax assets that are more likely than not to be realized.  The Company's estimate of future book-taxable income considers all available evidence, both positive and negative, about its operating businesses and investments, included an aggregation of individual projections for each significant operating business and investment, estimated apportionment factors for state and local taxing jurisdictions and included all future years that the Company estimated it would have available net operating loss carryforwards ("NOLs").
For other entities, the Company has determined that the positive evidence outweighs the negative evidence for other deferred tax assets and concluded that these deferred tax assets are realizable on a "more likely than not" basis. This determination was based on many factors, including the following:  (i) the net temporary differences resulting in the deferred tax assets and in the deferred tax liabilities are expected to reverse in similar time periods; (ii) the history of utilizing tax benefits, (iii) certain significant costs that are not expected to occur in future periods, and (iv) expected future results of operations.
No amount for income tax has been provided on undistributed earnings of the Company's foreign subsidiaries because the Company considers the approximate $7,557 of accumulated foreign earnings to be indefinitely reinvested. The Company expects existing domestic cash and short-term investments and cash flows from operations to continue to be sufficient to fund the operating activities and cash commitments for investing and financing activities, and capital expenditures, for at least the next 12 months and thereafter for the foreseeable future. Determination of the amount of income tax liability that would be incurred is not practicable.
	d.	Tax contingencies for unrecognized tax benefits:
The changes to unrecognized tax benefits from January 1, 2012 through December 31, 2013, were as follows:
Gross tax liabilities at January 1, 2012		$	8,862
Additions based on tax positions related to the current year			6,917
Additions for tax positions of prior years			-
Reductions due to settlements with tax authorities			-
Reductions for positions of prior years			(960	)
Gross tax liabilities at December 31, 2012			14,819
Additions based on tax positions related to the current year			5
Additions for tax positions of prior years			5
Reductions due to settlements with tax authorities			(12,552	)
Reductions for positions of prior years			(158	)
Gross tax liabilities at December 31, 2013		$	2,119
Included in the balance of tax contingencies for uncertain tax positions at December 31, 2013 was approximately $2,119 of unrecognized tax benefits that, if recognized, would affect the annual effective income tax rate. The unrecognized tax benefits and interest are recorded in net deferred taxes assets and long-term obligations on the balance sheet.
The liability for unrecognized tax benefits as of December 31, 2013 and 2012 included accrued interest of $ 213 and $ 158, respectively.
The Company operates in multiple jurisdictions throughout the world, and its tax returns are periodically audited or subject to review by both domestic and foreign authorities. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. The following describes the open tax years, by major tax jurisdiction, as of December 31, 2013:
Israel	-	2012 - present
United States	-	2010 - present
Australia	-	2009 - present
Germany	-	2009 - present
Canada	-	2009 - present
Japan	-	2010 - present
Spain	-	2009 - present
	e.	Loss before taxes on income:
		Year ended December 31,
		2013			2012			2011
Domestic		$	(14,289	)	$	(21,890	)	$	(24,353	)
Foreign			8,196			15,047			(23,453	)
		$	(6,093	)	$	(6,843	)	$	(47,806	)
	f.	Taxes on income:
		Year ended December 31,
		2013			2012			2011
Current taxes:
Domestic		$	(6,338	)	$	6,782		$	592
Foreign			2,084			780			3,531
			(4,254	)		7,562			4,123
Deferred taxes:
Domestic			(140	)		(207	)		(153	)
Foreign			(3,246	)		(11,857	)		(26	)
			(3,386	)		(12,064	)		(179	)
Taxes on income (tax benefit)		$	(7,640	)	$	(4,502	)	$	3,944
	g.	The reconciliation from the federal statutory tax rate to the effective tax rate is as follows:
		Year ended December 31,
		2013			2012			2011
Loss before taxes on income		$	(6,093	)	$	(6,843	)	$	(47,806	)
Statutory tax rate			25	%		25	%		24	%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate		$	(1,523	)	$	(1,711	)	$	(11,473	)
Increase in taxes resulting from "Privileged Enterprise" benefits			-			-			3,625
Difference in basis of measurement for tax purpose			1,288			2,984			(947	)
Change in valuation allowance, net			(969	)		(12,176	)		19,151
Non-deductible stock-based compensation			1,485			122			511
Non-deductible expenses			492			257			(1,759	)
State deferred taxes			2,363			(400	)		(492	)
Increase (decrease) in taxes resulting from tax settlement with tax authorities			(8,925	)		-			697
Difference in tax rates			(1,667	)		4,118			(3,161	)
Tax contingencies			(111	)		5,929			554
Return to provision			(16	)		(3,449	)		(2,915	)
Pre-paid taxes			-			-			1,001
Others			(57	)		(176	)		(848	)
Actual tax expense (benefit)		$	(7,640	)	$	(4,502	)	$	3,944

FINANCIAL_INCOME_NET

FINANCIAL INCOME, NET	12 Months Ended
	Dec. 31, 2013
FINANCIAL INCOME, NET [Abstract]	'
FINANCIAL INCOME, NET	'
	NOTE 19:-     FINANCIAL INCOME, NET
		Year ended December 31,
		2013			2012			2011
	Income:
	Interest on cash equivalents	$	90		$	48		$	82
	Gain and interest on available-for-sale marketable securities		557			758			1,607
	Interest on bank deposits		211			681			189
	Expenses:
	Interest on short-term credit and bank  commissions		(254	)		(272	)		(274	)
	Loss on available-for-sale marketable securities		(3	)		-			(42	)
	Foreign currency translation adjustments, net		(575	)		(290	)		(547	)
		$	26		$	925		$	1,015

SEGMENT_REPORTING

SEGMENT REPORTING	12 Months Ended
	Dec. 31, 2013
SEGMENT REPORTING [Abstract]	'
SEGMENT REPORTING	'
	NOTE 20:-     SEGMENT REPORTING
		a.	General:
	The Company's segment information has been prepared in accordance with ASC 280, "Segment Reporting." Operating segments are defined as components of an enterprise engaging in business activities about which separate financial information is available that is evaluated regularly by the Company's chief operating decision-maker (CODM) in deciding how to allocate resources and assess performance. The Company's CODM is a combination of both its Chief Executive Officer and its Chief Financial Officer, who evaluates the Company's performance and allocates resources based on segment revenues and operating loss.
		b.	The CODM evaluates the financial information under two reportable segments in accordance with ASC 280. The Company's operating segments are as follows:
		1.	Professional Aesthetic Devices (PAD), in which the Company engaged in research, development marketing and sales of aesthetic medical equipment for the treatment of body and face for dermatologists, plastic surgeons and other qualified practitioners worldwide (professional market).
		2.	Emerging Business Units (EBU), includes Syneron Beauty, RBT, Light Instruments and Fluorinex products. The Company provides these products in various countries throughout North America, Europe, Israel and Asia Pacific.
		Following the deconsolidation of Syneron Beauty, effective January 1, 2014 the Company has eliminated the Emerging Business Unit and intends to operate going forward with a single business unit.
		c.	Financial data relating to reportable operating segments:
	The following financial information is the information that management uses for analyzing its results. The Company presents the segment information based on its reporting business units.
	Segment operating loss is defined as loss from operations. Expenses included in segment operating loss consist principally of cost of revenues, selling and marketing costs, general and administrative costs and research and development costs.
	The tables below present financial information for the Company's two reportable segments:
			Year ended December 31, 2013
			PAD			EBU			Total
	Revenues from external customers			226,445			30,470			256,915
	Operating income (loss)			6,996			(13,115	)		(6,119	)
	Financial income (expenses), net			280			(254	)		26
	Income (loss) before taxes on income			7,276			(13,369	)		(6,093	)
	Segment goodwill			15,321			5,655			20,976
	Segment identifiable assets			277,871			6,630			284,501
			Year ended December 31, 2012
			PAD			EBU			Total
	Revenues from external customers			236,516			27,106			263,622
	Operating income (loss)			7,802			(15,570	)		(7,768	)
	Financial income (expenses), net			1,199			(274	)		925
	Income (loss) before taxes on income			9,001			(15,844	)		(6,843	)
	Segment goodwill			14,935			10,284			25,219
	Segment identifiable assets			270,420			23,459			293,879
			Year ended December 31, 2011
			PAD			EBU			Total
	Revenues from external customers		$	208,280		$	20,041		$	228,321
	Operating loss			(31,422	)		(17,434	)		(48,856	)
	Financial income (expenses), net			1,226			(211	)		1,015
	Other income			35			-			35
	Loss before taxes on income			(30,161	)		(17,645	)		(47,806	)
	Segment goodwill			8,206			10,661			18,867
	Segment identifiable assets		$	284,198		$	19,946		$	304,144
		d.	Financial data relating to geographic areas:
	The Company's total revenues are attributed to geographic areas based on the location of the end customer.
	The following table presents total revenues and long lived assets for the years ended December 31, 2013, 2012 and 2011. Other than as shown, no foreign country contributed materially to revenues or long-lived assets for these periods.
			2013						2012					2011
			Total revenue			Long-lived assets			Total revenue			Long-lived assets		Total revenue		Long-lived assets
	North America		$	90,618		$	2,917		$	93,247		$	3,467	$	78,525	$	1,924
	Europe  and Middle East (excluding Israel)			87,539			407			86,436			399		78,182		345
	Asia Pacific			39,744			76			41,423			95		30,489		122
	Japan			26,409			12			30,816			17		29,572		22
	Israel			4,620			3,191			3,924			2,170		5,050		1,742
	Others			7,985			-			7,776			-		6,503		-
			$	256,915		$	6,603		$	263,622		$	6,148	$	228,321	$	4,155
		e.	Significant customers:
	No major customer accounted for more than 10% of the Company's consolidated revenues for the years ended December 31, 2013, 2012 and 2011.

NET_INCOME_LOSS_PER_SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2013
NETINCOME(LOSS)PER SHARE [Abstract]	'
NETINCOME(LOSS)PER SHARE	'
	NOTE 21:-     NET INCOME (LOSS) PER SHARE
		The following table sets forth the computation of basic and diluted net income (loss) per share:
			Year ended December 31,
			2013		2012			2011
	Numerator:
	Net income (loss) attributable to Syneron's shareholders		$	1,647	$	(1,343	)	$	(50,795	)
	Denominator:
	Total weighted average number of shares outstanding used in computing:
	Basic net income (loss) per share			35,921,848		35,474,693			35,158,191
	Diluted net income (loss) per share			36,203,848		35,474,693			35,158,191
	Basic and diluted net income (loss) per share		$	0.04	$	(0.04	)	$	(1.44	)
	Anti-dilutive securities:
	The following numbers of shares were excluded from the computation of diluted net income (loss) per ordinary share for the periods presented because including them would have had an anti-dilutive effect:
			Year ended December 31,
			2013		2012			2011
	Ordinary shares			3,184,294		4,513,130			3,603,423

DISCLOSURE_ON_RELATED_PARTIES_

DISCLOSURE ON RELATED PARTIES TRANSACTION	12 Months Ended
	Dec. 31, 2013
Disclosure on related parties transactions [Abstract]	'
Disclosure on related parties transactions	'
	NOTE 22:-     DISCLOSURE ON RELATED PARTIES TRANSACTION
	The Company Chairman of the Board, Shimon Eckhouse, previously owned 9.85% of the issued and outstanding shares of RBT and, until February 29, 2012, served as chairman of the board of directors of RBT. Together with other RBT shareholders, Shimon Eckhouse sold his holdings in RBT to the Company on May 30, 2012 in consideration of his pro-rata share of: (i) an initial purchase price of $5,000, (ii) an additional $5,000 paid on May 30, 2013, (iii) certain milestone payments in the aggregate amount equal to $15,240, (iv) the repayment of certain loan amounts provided by RBT to certain of its shareholders,  and (v) the payment of 2.019% of annual net sales generated by RBT intellectual properties for an unlimited period.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
	NOTE 23:-	SUBSEQUENT EVENTS
	On March 5, 2014, we acquired New Star Lasers, Inc., which conducts business as CoolTouch, Inc. ("CoolTouch"), for approximately $11 million in cash and earn out based on certain milestones of up to $4 million to be achieved in 2014 and 2015, which earn-out shall be paid in 2015 and 2016, respectively.
	CoolTouch develops, manufactures and markets the CoolTouch family of aesthetic devices.

SIGNIFICANT_ACCOUNTING_POLICIE1

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Use of estimates:	'
		a.	Use of estimates:
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates, judgments and assumptions. The Company's management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.
Financial statements in U.S. dollars:	'
		b.	Financial statements in U.S. dollars:
	A major part of the Group's operations is carried out by the Company and its subsidiaries in the United States and Israel. The functional currency of these entities is the U.S. dollar (dollar or $) as the revenues and a substantial portion of the costs are incurred in dollars.
	Accordingly, monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with ASC 830, "Foreign Currency Matters" (ASC 830). All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.
	The functional currency of the remaining subsidiaries and associates in most instances is their relevant local currency. The financial statements of those companies are included in consolidation, based on translation into U.S. dollars. Assets and liabilities are translated at year-end exchange rates, while revenues and expenses are translated at monthly average exchange rates during the year in accordance with ASC 830. Differences resulting from translation are presented as a separate component, under accumulated other comprehensive income (loss) in changes in equity.
Principles of consolidation:	'
		c.	Principles of consolidation:
	The consolidated financial statements include the accounts of Syneron Medical Ltd. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated.
	Changes in the parent's ownership interest in a subsidiary with no change of control are treated as equity transactions, with any difference between the amount of consideration paid and the change in the carrying amount of the non-controlling interest, recognized in equity (APIC) which is based on ASC 810.
Cash and cash equivalents:	'
		d.	Cash and cash equivalents:
	Cash and cash equivalents are short-term highly liquid investments that are readily convertible into cash with original maturities of three months or less at the date acquired.
Short-term bank deposits:	'
		e.	Short-term bank deposits:
	Short term bank deposits are deposits with original maturities of more than three months but less than one year from the balance sheet date. Deposits are presented at their cost including accrued interest. Interest on deposits is recorded as financial income. As of December 31, 2013 and 2012, the Company held short-term interest bearing deposits in the amount of $16,453 and $20,520, respectively, with a weighted average interest of 1.35% and 1.59%, respectively.
Marketable securities:	'
		f.	Marketable securities:
	The Company classifies all of its marketable securities as available-for-sale securities in accordance with ASC 320, "Investment in Debt and Equity Securities". Such marketable securities consist primarily of U.S. government treasury bonds, U.S. agencies and government guaranteed debts and corporate bonds which are stated at fair value. Unrealized gains and losses are comprised of the difference between fair value and amortized costs of such securities and are reflected as "accumulated other comprehensive income (loss)" in changes in equity. Realized gains and losses on marketable securities are included in earnings, under financial income, net.
	The Company applied FASB ASC 320-10 which requires the Other-Than-Temporary Impairment (OTTI) for debt securities to be separated into (a) the amount representing the credit loss and (b) the amount related to all other factors. The Company typically invests in highly-rated securities, and its policy generally limits the amount of credit exposure to any one issuer. When evaluating the investments for OTTI, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, and the Company's intent to sell, or whether it is more likely than not that it will be required to sell, the investment before recovery of the investment's amortized cost basis.
	In regard to the Company's ARS, the Company used a discounted cash flow analysis to determine the portion of the impairment that relates to the credit loss. To the extent that the net present value of the estimate of the present value of cash flows expected to be collected from the debt security discounted at the effective interest rate implicit in the security at the date of acquisition is less than the amortized cost basis of the security, the difference is considered credit loss and is recorded through earnings.
	The Company did not recognize any other-than-temporary loss on outstanding securities during the three year period ended December 31, 2013. Refer to Note 3 for further details.
Derivatives and hedging activities:	'
		g.	Derivatives and hedging activities:
	The Company implemented the requirements of ASC No. 815, "Derivatives and Hedging" which requires companies to recognize all of their derivative instruments as either assets or liabilities in the balance sheet at fair value. The accounting for changes in fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualified as part of a hedging transaction and further, on the type of hedging transaction. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.  Due to the Company's global operations, it is exposed to foreign currency exchange rate fluctuations in the normal course of its business.
	The Company's policy allows it to offset the risks associated with the effects of certain foreign currency exposures through the purchase of foreign exchange forward or option contracts (Hedging Contracts).
	The policy prohibits the Company from speculating on such Hedging Contracts for profit. To protect against the increase in value of forecasted foreign currency cash flow resulting from salaries paid in New Israeli Shekels (NIS) during the year and for certain forecasted revenue transactions in currencies other than the U.S. dollar, the Company instituted a foreign currency cash flow hedging program. The Company hedges portions of the anticipated payroll of its Israeli employees denominated in NIS or revenues anticipated in currencies other than the U.S. dollar for a period of one to 12 months with Hedging Contracts. Accordingly, when the dollar strengthens against the NIS, the decline in present value of future foreign currency expenses is offset by losses in the fair value of the Hedging Contracts.  Conversely, when the dollar weakens, the increase in the present value of future foreign currency expenses is offset by gains in the fair value of the Hedging Contracts.  These Hedging Contracts are designated and qualify as cash flow hedges.
	For derivative instruments that are designated and qualify as a cash flow hedge (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk), the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings.  Any gain or loss on a derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item is recognized in current earnings during the period of change. As of December 31, 2013 and 2012, the Company had outstanding forward contracts with a notional amount of $4,295 and $3,419, respectively, and outstanding option contracts with a notional amount of $900 and $4,790, respectively.
	For derivative instruments that are not designated and qualify as hedging instruments (the ineffective portion), the gain or loss on those derivative instruments is recorded in to earning.
Inventories:	'
		h.	Inventories:
	Inventories are stated at the lower of cost or market value. Inventory reserve is provided for slow-moving items.
	Cost is determined as follows:
	Raw materials: based on standard cost.
	Work in process: on the basis of average costs, including materials, labor and other direct and indirect manufacturing costs.
	Finished products: based on standard cost (which approximates actual cost on a first-in, first-out basis) which includes materials, labor and manufacturing overhead. Standard costs are monitored and updated as necessary, to reflect the changes in raw material costs and labor and overhead rates.
	The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. Inventory of $34,707 and $36,862 as of December 31, 2013 and 2012, respectively, is stated net of inventory reserves of $6,033 and $5,402, respectively. If actual demand for the Company's products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required.
Property and equipment, net:	'
		i.	Property and equipment, net:
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:
			%
	Computers, software, manufacturing, laboratory equipment and demonstration equipment (*)		10 - 50 (mainly 33)
	Office furniture and equipment		6- 30 (mainly 15)
	Leasehold improvements		The shorter of the term of the lease or the useful life of the asset
		(*)	Demonstration equipment consists of systems for use in marketing and selling activities. Demonstration equipment is generally not held for sale and is recorded as property and equipment. The demonstration equipment is amortized on a straight-line method over their estimated economic life not to exceed two years.
Impairment of long-lived assets:	'
		j.	Impairment of long-lived assets:
	The Company's long-lived assets and identifiable intangibles subject to amortization are reviewed for impairment in accordance with ASC 360, "Property, Plant and Equipment", whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of the asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds its fair value. During 2013, 2012 and 2011 the Company recorded an impairment charge, related to intangible assets, in the amount of $323, $2,860 and $123, respectively.
Business combinations:	'
		k.	Business combinations:
	The Company accounts for business combinations in accordance with ASC No. 805, "Business Combinations". ASC 805 requires recognition of assets acquired, liabilities assumed, and any non-controlling interest at the acquisition date, measured at their fair values as of that date. It also requires the fair value of acquired in-process research and development (IPR&D) to be recorded as an indefinite life intangible asset (subject to impairment) until the research and developments efforts are either completed or abandoned, and restructuring and acquisition-related costs to be expensed as incurred. Any excess of the fair value of net assets acquired over the purchase price and any subsequent changes in estimated contingencies are to be recorded in earnings. In addition, changes in valuation allowance related to acquired deferred tax assets and acquired income tax positions are to be recognized in earnings.
	Contingent considerations to former owners agreed in a business combination, e.g, in the form of milestone payments upon the achievement of certain sales target, are recognized as liabilities at fair value as of the recognition date. Any subsequent changes in amounts recorded as liability are recognized in earnings under other expenses (income), net.
Investments in affiliated companies:	'
		1	Investments in affiliated companies:
	Part of the Company investments in affiliates are stated at cost since the Company does not have the ability to exercise significant influence over their operating and financial policies. The Company followed ASC 323, "Investments - Equity and Joint Ventures", to determine whether it should apply the equity method of accounting to investments in other-than-common stock, with regard to certain investments in preferred shares, and determined that they are not in substance common stock. The Company's investment in the affiliated companies is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an investment may not be recoverable, in accordance with ASC 325-20. During 2013 and 2012 and 2011, the Company recognized an impairment loss of $ 1,000, $ 200 and $ 9,387, respectively, relating to its investments.
	As of December 31, 2013, pursuant to the deconsolidation of Syneron Beauty and its subsidiaries from December 9, 2013, the Company elected to recognize the investments in Iluminage Beauty at fair value at each reporting date with changes in the fair value recognized in earnings under other expenses (income), net. Refer to Note 4 and 7 for further details.  .
Goodwill and intangible assets:	'
		m.	Goodwill and intangible assets:
	Goodwill and intangible assets have been recorded as a result of acquisitions. Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired.
	The Company applies ASC 350, "Intangibles - Goodwill and Other". Under ASC 350, goodwill is not amortized but instead tested for impairment at least annually (or more frequently if impairment indicators arise). The Company determined June 30 as the date of the annual impairment test for each of its reporting units. The Company operates in two operating segments: the Professional Aesthetic Devices (PAD) segment (which is comprised of two reporting units) and the Emerging Business Units (EBU) segment (which is comprised of three reporting units).
	ASC 350, as amended by ASU 2011-08, provides companies an option to first perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value before performing a two-step approach to testing goodwill for impairment for each reporting unit. The Company reporting units are determined by the components of the Company operating segments that constitute a business for which both: (1) discrete financial information is available and (2) segment management regularly reviews the operating results of that component.
	The first step measures for impairment by applying fair-value-based tests at the reporting unit level. The second step (if necessary) measures the amount of impairment by applying fair-value-based tests to the individual assets and liabilities within each reporting unit.
	Fair value is determined using discounted cash flows methodology. Significant estimates used in the fair value methodologies include estimates of future cash flows, future growth rates and the weighted average cost of capital of the reporting units. During 2013 and 2011 no impairment charges were recorded on Goodwill. During 2012 the Company recorded a goodwill impairment charge of $450 and impairment charge of $510 related to in-process research and development assets from the acquisition of Candela.
Revenue recognition:	'
		n.	Revenue recognition:
	Revenues are recognized in accordance with ASC 605, "Revenue Recognition" when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred.
	The timing for revenue recognition amongst the various products and customers is dependent upon satisfaction of such criteria and generally varies from shipment to delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer. Revenues from service contracts are recognized on a straight-line basis over the life of the related service contracts.
	Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers.
	The Company's products sold through agreements with distributors are generally non-exchangeable, non-refundable, non-returnable and without any rights of price protection or stock rotation. Accordingly, the Company considers all the distributors as end-users.
	In the PAD segment, in most cases, the Company does not grant a right of return for its products. In the EBU segment, customer returns are recorded on an actual basis throughout the year and also include an estimate at the end of each reporting period for future customer returns related to sales recorded prior to the end of the period.  The Company generally estimates customer returns based upon the time lag that historically occurs between the date of the sale and the date of the return, while also factoring other business conditions that might impact the historical analysis.  The Company believes that the amount of future returns is reasonably estimated. The provision for returns is recorded through a reduction of revenue.
	In respect of sale of systems with installation, the Company considers the elements in the arrangement to be a single unit of accounting. In accordance with ASC 605, the Company has concluded that its arrangements are generally consistent with the indicators suggesting that installation is not essential to the functionality of the Company's systems. Accordingly, installation is considered inconsequential and perfunctory relative to the system, and therefore the Company recognizes revenue for the system and installation upon delivery to the customer in accordance with the agreement delivery terms once all other revenue recognition criteria have been met, and provides an accrual for installation costs as appropriate.
	Part of the Company's revenue transaction with end-users includes multiple elements within a single contract and it is determined that multiple units of accounting exist.
	According to ASC 605-25, when a sales arrangement contains multiple deliverables, such as sales of products and related services, the multiple deliverables are evaluated to determine the units of accounting, and the entire fee from the arrangement is allocated to each unit of accounting based on the relative selling price. Under this approach, the selling price of a unit of accounting is determined by using a selling price hierarchy which requires the use of vendor-specific objective evidence (VSOE)  of fair value if available, third-party evidence (TPE) if VSOE is not available, or best estimate of selling price (BESP) if neither VSOE nor TPE is available. Revenue is recognized when the revenue recognition criteria for each unit of accounting are met. Accordingly, for such products and services the Company determined the selling price by reviewing historical transactions, and considering several other external and internal factors including, but not limited to, pricing practices including discounting and margin objectives.
	In certain cases, when product arrangements are bundled with extended warranty, the separation of the extended warranty falls under the scope of ASC 605- 20-25-1 through 25-6, and the separately price of the extended warranty stated in the agreement is deferred and recognized ratably over the extended warranty period.
	Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues.
Research and development costs:	'
		o.	Research and development costs:
			Research and development costs are expensed when incurred.
Share-based compensation:	'
		p.	Share-based compensation:
	The Company measures and recognizes the compensation expense for all equity-based payments to employees and directors based on their estimated fair values in accordance with ASC 718, "Compensation-Stock Compensation". The Company estimates the fair value of employee stock options at the date of grant using a binomial valuation model and values restricted stock units based on the market value of the underlying shares at the date of grant.
	The Company recognizes compensation expenses for the value of its awards based on the straight line method over the requisite service period of each of the awards, net of estimated forfeitures. Estimated forfeitures are based on actual historical pre-vesting forfeitures.
Basic and diluted net income (loss) per share:	'
		q.	Basic and diluted net income (loss) per share:
	Basic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each year. Basic net income (loss)  per share was determined by dividing net income (loss) by the weighted average ordinary shares outstanding during the period.
	Diluted net loss per share was determined by dividing net income (loss) by the diluted weighted average shares outstanding. Diluted weighted average shares reflect the dilutive effect, if any, of stock options, stock appreciation rights, and restricted share units based on the treasury stock method, in accordance with ASC, 260, "Earning Per Share".
Fair value of financial instruments:	'
		r.	Fair value of financial instruments:
	The carrying amounts of financial instruments, including cash and cash equivalents, bank deposits, accounts receivable, short-term bank credit, accounts payable and accrued liabilities, approximate fair value because of their generally short maturities.
	The Company applies ASC 820, "Fair Value and Disclosure" (ASC 820). Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
		Level 1 -	Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;
		Level 2 -	Significant other observable inputs based on market data obtained from sources independent of the reporting entity;
		Level 3 -	Unobservable inputs which are supported by little or no market activity (for example cash flow modeling inputs based on assumptions).
	The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.
	Assets and liabilities measured at fair value on a recurring basis are comprised of marketable securities, investment in affiliated company, hedging contracts and contingent considerations (see Note 4). Contingent consideration liabilities represent future amounts the Company may be required to pay in conjunction with various business combinations. Each reporting period, the Company revalues these contingent considerations and records increases or decreases in their fair value as an adjustment to contingent consideration expense within the consolidated statement of operations. Changes in the fair value of the contingent consideration can result from adjustments to the discount rates, the probability of achievement of any revenue milestones and due to discounting to present value each reporting date. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.
	The fair value of the Company's equity interest in Iluminage Beauty (see Note 1b1) was calculated by a third party appraisal firm using the discount cash flow and the OPM method, which uses significant unobservable inputs such as cash flows to be generated from the underlying investment and discounted at a weighted average cost of capital.
Income taxes:	'
		s.	Income taxes:
	The Company accounts for income taxes in accordance with ASC 740, "Income Taxes". ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company reduces deferred tax assets by an allowance if, based on the weight of available positive and negative evidence, it is more likely than not that the Company will not realize some portion, or all, of the deferred tax asset.
	Deferred tax liabilities and assets are classified as current or non-current based on the classification of the related asset or liability for financial reporting, or according to the expected reversal dates of the specific temporary differences if not related to an asset or liability for financial reporting.
	The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).
Employee benefit plan:	'
		t.	Employee benefit plan:
	Certain of the Company's U.S. employees are eligible to participate in a defined contribution pension plan (Plan).  Participants in the Plan may elect to defer a portion of their pre-tax earnings into the Plan, which is run by an independent party.  The Company makes pension contributions at rates varying up to 10% of the participant's pensionable salary. Contributions to the Plan are recorded as an expense in the consolidated statements of operations.
	Candela's U.S. operations maintain a retirement plan (Candela U.S. Plan) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Participants in the Candela U.S. Plan may elect to defer a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. Candela matches 50% of each participant's contributions up to a maximum of 6% of the participant's elective deferral.  Each participant may contribute a percentage of their pay or a flat dollar amount.  Contributions to the Candela U.S. Plan are recorded during the year contributed as an expense in the consolidated statements of operations.
	Total contributions for the years ended December 31, 2013, 2012 and 2011 were $327, $255 and $297, respectively.
	Syneron's U.S. operations maintain a retirement plan (Syneron U.S. Plan) that qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code.  Participants in the Syneron U.S. Plan may elect to defer a portion of their pre-tax earnings, up to the Internal Revenue Service annual contribution limit. The Company matches 100% of each participant's elective deferrals that do not exceed 3% of the participant's compensation, plus 50% of the portion of the participant's elective deferrals on the next 2% of compensation for the Plan year.  Each participant may contribute from 1% to 50% of compensation on a pretax basis up to the maximum permitted by the Internal Revenue Code.  Contributions to Syneron's U.S. Plan are recorded during the year contributed as an expense in the consolidated statements of operations.
	Total contributions for the years ended December 31, 2013, 2012 and 2011 were $206, $196 and $166, respectively.
	Severance pay:
	The Company's liability for severance pay to its Israeli employees is calculated pursuant to the Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date. Employees are entitled to one month's salary for each year of employment or portion thereof. The Company's liability for all of its Israeli employees is covered by monthly deposits for insurance policies and by an accrual. The value of these policies is recorded as an asset on the Company's balance sheet.
	The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to the Israeli Severance Pay Law or labor agreements. The value of the deposited funds is based on the cash surrender value of these policies, and includes immaterial profits accumulated up to the balance sheet date.
	The majority of the Company's agreements with its employees in Israel are in accordance with section 14 of the Israeli Severance Pay Law. Upon contribution of the full amount of the employee's monthly salary, and release of the policy to the employee, no additional legal obligation exists between the parties and no additional payments are made by the Company to the employee; therefore related assets and liabilities are not presented in the balance sheet.
	Severance pay expenses for the years ended December 31, 2013, 2012 and 2011 amounted to approximately $933, $744 and $755, respectively.
Shipping and handling costs:	'
		u.	Shipping and handling costs:
	Shipping and handling costs, which amounted to $ 6,610, $ 6,475 and $ 4,408 for the years ended December 31, 2013, 2012 and 2011, respectively, are included in sales and marketing expenses in the consolidated statements of operations. Shipping and handling costs include all costs associated with the distribution of finished products, consumables and spare parts from the Company's point of manufacturing directly to customers, distributors and international subsidiaries.
Advertising expenses:	'
		v.	Advertising expenses:
	Advertising expenses are charged to the statements of operations, as incurred. Advertising expenses for the years ended December 31, 2013, 2012 and 2011 were $ 9,049, $ 6,334 and $ 5,723, respectively.
Legal expenses:	'
		w.	Legal expenses:
			Legal expenses are charged to the statement of operations as incurred.
Concentration of credit risk:	'
		x.	Concentration of credit risk:
	Financial instruments that potentially subject the Group to concentrations of credit risk consist principally of cash and cash equivalents, bank deposits, derivative instruments, marketable securities, and trade receivables.
	The majority of the Group's cash and cash equivalents and banks deposits are invested in dollar instruments of major banks in Israel and in the United States. Management believes that the financial institutions that hold the Company's investments are institutions with high credit standing and that, accordingly, low credit risk exists with respect to these investments.
	The Company's marketable securities include investments in highly rated debentures of U.S. and Israeli, corporations and governmental bonds. Based on the above and the fact that the portfolio is well diversified, management believes that low credit risk exists with respect to these marketable securities. The Company has implemented additional measures with respect to its investment policy. Such measures include among others: reducing credit exposure to corporate sector securities and increasing the overall credit quality of the portfolio.
	The Company and its subsidiaries have no material off-balance sheet concentration of financial instruments subject to credit risk such as foreign exchange contracts, option contracts or other hedging arrangements, except those mentioned in Note 14.
	The Company's trade receivables are derived mainly from sales to large independent distributors and to end-users world-wide. The Company performs ongoing credit evaluations of its customers. An allowance for doubtful accounts is determined with respect to those specific amounts that the Company has determined to be doubtful of collection.
	The following table provides details of the change in the Company's allowance for doubtful accounts:
			December 31,
			2013			2012			2011
	Balance at the beginning of the year		$	6,792		$	5,478		$	7,704
	Charged to expenses, net of recoveries			1,217			1,782			(847	)
	Deconsolidation of subsidiary			(141	)		-			-
	Write-off			(1,483	)		(523	)		(1,443	)
	Exchange rate			112			55			64
	Balance at the end of the year		$	6,497		$	6,792		$	5,478
Warranty:	'
		y.	Warranty:
	The Company provides a one to three year standard warranty for its products, depending on the type of product and the country in which the Company does business. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company's warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.
	The following table provides details of the change in the Company's product warranty accrual:
			December 31,
			2013			2012			2011
	Warranty provision at the beginning of the year		$	7,197		$	6,514		$	6,854
	Warranty provision related to the acquisition of Ultrashape			-			44			-
	Warranty provision related to the Deconsolidation of Syneron Beauty			(129	)		-			-
	Charged to costs and expenses relating to new sales			9,122			9,058			7,856
	Costs of product warranty claims			(9,209	)		(8,419	)		(8,196	)
	Warranty provision at the end of the year		$	6,981		$	7,197		$	6,514
Comprehensive income (loss):	'
		z.	Comprehensive income (loss):
	The Company reports comprehensive income (loss) in accordance with ASC 220, "Comprehensive Income". This Statement establishes standards for the reporting and presentation of comprehensive income and its components in a full set of general purpose financial statements. Comprehensive income generally represents all changes in equity during the period except those resulting from investments by, or distributions to, stockholders. The Company determined that items of other comprehensive income relate to unrealized gains and losses on available-for-sale marketable securities, hedging contracts and currency translation adjustments.
Treasury shares:	'
		aa.	Treasury shares:
	The Company repurchased its ordinary shares on the open market and holds such shares as treasury stock. The Company presents the cost to repurchase treasury stock as a reduction in equity.
Impact of recently issued accounting standards:	'
		ab.	Impact of recently issued accounting standards:
	In July 2013, the Financial Accounting Standards Board ("FASB") issued new accounting guidance on the presentation of unrecognized tax benefits. This new guidance requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset when a net operating loss carryforward, a similar tax loss or a tax credit carryforward exists, with limited exceptions. This new guidance is effective for the periods beginning after December 15, 2013, and should be applied prospectively with retroactive application permitted. The adoption of this guidance does not have a material impact on the Company's consolidated financial position, results of operations or cash flows.
	In March 2013, the FASB issued guidance that requires a parent company to release any related cumulative translation adjustment into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. This new guidance is effective beginning after December 15, 2013. The adoption of this guidance does not have a material impact on the Company's consolidated financial position, results of operations or cash flows.

GENERAL_Tables

GENERAL (Tables)	12 Months Ended
	Dec. 31, 2013
TransPharma Medical Ltd. [Member]	'
Business Acquisition [Line Items]	'
Acquisition Date Fair Value Of Consideration Transferred	'
	The following table summarizes the estimated fair values of the assets acquired at the acquisition date:
			Fair value
	Property and equipment			59
	Technology			2,407
	Goodwill			1,185
	Assets acquired		$	3,651
Ultrashape Ltd. [Member]	'
Business Acquisition [Line Items]	'
Schedule Of Fair Value Of Assets Acquired And Liabilities Assumed	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date:
			Fair value
	Cash		$	837
	Current assets			1,241
	Property and equipment			710
	Developed technology (1)			5,617
	Customer relationship (2)			1,843
	Total identifiable assets acquired			10,248
	Current liabilities			(3,767	)
	Accrued severance pay			(26	)
	Total liabilities assumed			(3,793	)
	Net identifiable assets assumed			6,455
	Goodwill			5,545
	Net assets acquired		$	12,000
		-1	The developed technology will be amortized using the straight-line method over its useful life which is estimated at six years.
		-2	The Customer relationship will be amortized using a method that will reflect the consummation of such asset which is estimated at eight years.

SIGNIFICANT_ACCOUNTING_POLICIE2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]	'
Schedule Of Depreciation Rates [Table Text Block]	'
	Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets at the following annual rates:
			%
	Computers, software, manufacturing, laboratory equipment and demonstration equipment (*)		10 - 50 (mainly 33)
	Office furniture and equipment		6- 30 (mainly 15)
	Leasehold improvements		The shorter of the term of the lease or the useful life of the asset
		(*)	Demonstration equipment consists of systems for use in marketing and selling activities. Demonstration equipment is generally not held for sale and is recorded as property and equipment. The demonstration equipment is amortized on a straight-line method over their estimated economic life not to exceed two years.
Allowance for Doubtful Accounts [Member]	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'
Schedule Of Movement In Valuation Allowances And Reserves [Table Text Block]	'
	The following table provides details of the change in the Company's allowance for doubtful accounts:
			December 31,
			2013			2012			2011
	Balance at the beginning of the year		$	6,792		$	5,478		$	7,704
	Charged to expenses, net of recoveries			1,217			1,782			(847	)
	Deconsolidation of subsidiary			(141	)		-			-
	Write-off			(1,483	)		(523	)		(1,443	)
	Exchange rate			112			55			64
	Balance at the end of the year		$	6,497		$	6,792		$	5,478
Warranty Reserves [Member]	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'
Schedule Of Movement In Valuation Allowances And Reserves [Table Text Block]	'
	The following table provides details of the change in the Company's product warranty accrual:
			December 31,
			2013			2012			2011
	Warranty provision at the beginning of the year		$	7,197		$	6,514		$	6,854
	Warranty provision related to the acquisition of Ultrashape			-			44			-
	Warranty provision related to the Deconsolidation of Syneron Beauty			(129	)		-			-
	Charged to costs and expenses relating to new sales			9,122			9,058			7,856
	Costs of product warranty claims			(9,209	)		(8,419	)		(8,196	)
	Warranty provision at the end of the year		$	6,981		$	7,197		$	6,514

AVAILABLEFORSALE_MARKETABLE_SE1

AVAILABLE-FOR-SALE MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2013
AVAILABLE-FOR-SALE MARKETABLE SECURITIES [Abstract]	'
Schedule of Available-For-Sale Securities	'
			31-Dec-13
			Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair
										value
	Money market funds		$	1,535	$	-	$	-		$	1,535
	Available-for-sale - matures within one year:
	Certificate of deposit			2,494		3		-			2,497
	Government debentures - fixed interest rate			1,516		13		-			1,529
	Government sponsored enterprises - fixed interest rate			455		-		(8	)		447
	Corporate debentures - fixed interest rate			5,274		35		-			5,309
				9,739		51		(8	)		9,782
	Available-for-sale - matures after one year through three years:
	Certificate of deposit			2,735		1		(6	)		2,730
	Government debentures - fixed interest rate			2,260		-		(6	)		2,254
	Government sponsored enterprises - fixed interest rate			3,236		-		(2	)		3,234
	Corporate debentures - fixed interest rate			29,398		126		(62	)		29,462
				37,629		127		(76	)		37,680
	Available-for-sale - matures after three years through five years:
	Corporate debentures - fixed interest rate			4,465		17		(36	)		4,446
	Available-for-sale - matures after five years:
	ARS			1,197		-		(136	)		1,061
			$	54,565	$	195	$	(256	)	$	54,504
	Reclassification of certain securities to long-term										25,571
										$	28,933
			31-Dec-12
			Amortized cost		Gross unrealized gains		Gross unrealized losses			Fair
										value
	Money market funds		$	3,548	$	-	$	-		$	3,548
	Available-for-sale - matures within one year:
	Certificate of deposit			5,658		11		(1	)		5,668
	Government debentures - fixed interest rate			2,617		43		-			2,660
	Government sponsored enterprises - fixed interest rate			4,558		-		-			4,558
	Corporate debentures - fixed interest rate			2,609		2		(9	)		2,602
				15,442		56		(10	)		15,488
	Available-for-sale - matures after one year through three years:
	Certificate of deposit			3,260		16		-			3,276
	Government debentures - fixed interest rate			1,570		72		-			1,642
	Government sponsored enterprises - fixed interest rate			8,671		4		(2	)		8,673
	Corporate debentures - fixed interest rate			13,669		96		(34	)		13,731
				27,170		188		(36	)		27,322
	Available-for-sale - matures after three years through five years:
	Corporate debentures - fixed interest rate			1,531		-		(17	)		1,514
	Available-for-sale - matures after five years:
	ARS			1,387		-		(157	)		1,230
			$	49,078	$	244	$	(220	)		49,102
	Reclassification of certain securities to long-term										7,966
										$	41,136
Schedule Of Unrealized Loss On Investments	'
	The table below presents the fair value of investments in available-for-sale securities that have been in an unrealized loss position as of December 31, 2013 and 2012 and the length of time that those investments have been in a continuous loss position:
			31-Dec-13
			Less than 12 months				12 months or longer					Total
			Fair		Unrealized losses		Fair			Unrealized losses		Fair		Unrealized losses
			value				value					value
	Government sponsored enterprises		$	2,780	$	10	$	-		$	-	$	2,780	$	10
	Government debentures			2,255		6		-			-		2,255		6
	Corporate debentures			13,523		76		4,127			22		17,650		98
	ARS			-		-		1,061			136		1,061		136
	Certificate of deposit			2,372		6		-			-		2,372		6
			$	20,930	$	98	$	5,188		$	158	$	26,118	$	256
			31-Dec-12
			Less than 12 months				12 months or longer					Total
			Fair		Unrealized losses		Fair			Unrealized losses		Fair		Unrealized losses
			value				value					value
	Government sponsored enterprises		$	500	$	2	$	1,002		$	*) -	$	1,502	$	2
	Corporate debentures			7,061		60		-			-		7,061		60
	ARS			-		-		1,230			157		1,230		157
	Certificate of deposit			1,019		*) -		244			1		1,263		1
			$	8,580	$	62	$	2,476		$	158	$	11,056	$	220
		*)	Represents an amount lower than $1.

FAIR_VALUE_MEASUREMENT_Tables

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2013
FAIR VALUE MEASUREMENT [Abstract]	'
Schedule Of Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis	'
	The Company's financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of December 31, 2013 and 2012:
			31-Dec-13
			Level 1			Level 2			Level 3		Total
	Assets:
	Corporate debentures		$	-		$	39,216		$	-	$	39,216
	ARS			-			-			1,061		1,061
	Government debentures			-			3,783			-		3,783
	Government sponsored enterprises			-			3,682			-		3,682
	Money markets funds			6,762			-			-		6,762
	Investment in affiliated companies			-			-			24,720		24,720
	Total		$	6,762		$	46,681		$	25,781	$	79,224
	Liabilities:
	Foreign currency derivatives		$	-		$	16		$	-	$	16
	Contingent consideration		$	-		$	-		$	7,896	$	7,896
	Total		$	-		$	16		$	7,896	$	7,912
			31-Dec-12
			Level 1			Level 2			Level 3		Total
	Assets:
	Corporate debentures		$	-		$	17,847		$	-	$	17,847
	ARS			-			-			1,230		1,230
	Government debentures			-			4,302			-		4,302
	Government sponsored enterprises			-			13,231			-		13,231
	Money markets funds			12,492			-			-		12,492
	Foreign currency derivatives			-			152			-		152
	Total		$	12,492		$	35,532		$	1,230	$	49,254
	Liabilities:
	Contingent consideration		$	-		$	-		$	6,750	$	6,750
	Total		$	-		$	-		$	6,750	$	6,750
Schedule Of Changes In Level 3 Investments Measured On A Recurring Basis	'
	The table below presents the changes in Level 3 investments measured on a recurring basis:
			December 31,
			2013			2012
	Balance at the beginning of the year		$	1,230		$	1,313
	Changes in realized gains included in earnings			31			5
	Sales (*)			(200	)		(100	)
	Changes in unrealized gains included in Other comprehensive income			-			12
	Balance at the end of the year		$	1,061		$	1,230
		(*)	During 2013, the Company sold ARS with carrying amount of $169 for a total consideration of $200, which reflects a gain of $31. During 2012, the Company sold ARS with carrying amount of $95 for a total consideration of $100, which reflects a gain of $5.
Schedule Of Changes In Level 3 Contingent Consideration Obligations Measured On A Recurring Basis	'
	The table below presents the changes in Level 3 contingent consideration obligations measured on a recurring basis and related to business combinations of THB in December 2010 and from RBT investment in May 2012:
			December 31,
			2013			2012
	Fair value at the beginning of the year		$	6,750		$	2,535
	Acquisition date fair value of contingent consideration related to additional investment in RBT (see Note 1b5)			-			6,125
	Changes in the fair value of contingent consideration, net			1,146			(1,910	)
	Fair value at the end of the year		$	7,896		$	6,750
Schedule of Fair Value Liabilities Measured on Recurring Basis Related to Deconsolidation	'
	The table below presents the changes in Level 3 investment in Iluminage Beauty measured on a recurring basis and related to deconsolidation of Syneron Beauty in December 9, 2013:
			December 31,
			2013			2012
	Fair value at the beginning of the year		$	-		$	-
	Fair value of investment in Iluminage Beauty (see Note 1b1)			24,720			-
	Changes in the fair value			-			-
	Fair value at the end of the year		$	24,720		$	-

OTHER_ACCOUNTS_RECEIVABLE_AND_1

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]	'
Schedule of Other Accounts Receivable and Prepaid Expenses	'
		December 31,
		2013		2012
	Prepaid expenses and advanced payments	$	2,939	$	5,407
	Government authorities		903		919
	Deposits with escrow agent (see also 1b5)		1,760		1,760
	Derivative instruments		-		152
	Other receivables		1,721		1,059
		$	7,323	$	9,297

INVENTORIES_Tables

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2013
INVENTORIES [Abstract]	'
Schedule of Inventory	'
		December 31,
		2013		2012
	Raw materials	$	9,845	$	12,552
	Work in process		1,299		2,250
	Finished products		23,563		22,060
		$	34,707	$	36,862

INVESTMENTS_IN_AFFILIATED_COMP1

INVESTMENTS IN AFFILIATED COMPANIES (Tables)	12 Months Ended
	Dec. 31, 2013
INVESTMENTS IN AFFILIATED COMPANIES [Abstract]	'
Investments In Affiliated Companies	'
			December 31,
			2013		2012
	Investment in Iluminage Beauty (1)		$	24,720	$	-
	Investment in Juvenis Ltd. (Juvenis) (2)			-		1,000
			$	24,720	$	1,000
		-1	On December 9, 2013, based on the fair value method, the Company recorded an investment in Iluminage Beauty of $24,720, which represents the fair value of Iluminage Beauty's common stock held by the Company on the deconsolidation date. Refer to Note 4 and 1b1 for further details.
		(2)	On March 15, 2012, Syneron invested in Juvenis, an Israel-based company. Under terms of the agreement, Syneron made an initial investment in Juvenis of $1,000 in cash.

PROPERTY_AND_EQUIPMENT_NET_Tab

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2013
PROPERTY AND EQUIPMENT, NET [Abstract]	'
Schedule of Property and Equipment	'
			December 31,
				2013(*)		2012
	Cost:
	Computers, software, manufacturing, laboratory equipment and demonstration equipment		$	13,560	$	11,681
	Leasehold improvements			3,140		2,082
	Office furniture and equipment			1,846		2,048
				18,546		15,811
	Accumulated depreciation:
	Computers, software, manufacturing, laboratory equipment and demonstration equipment			9,000		7,135
	Leasehold improvements			1,778		1,708
	Office furniture and equipment			1,165		820
				11,943		9,663
	Depreciated cost		$	6,603	$	6,148
	Depreciation expenses for the years ended December 31, 2013, 2012 and 2011 were $ 3,445, $ 3,104 and $ 1,990, respectively.
		(*)	As part of Syneron Beauty's deconsolidation, the Company deconsolidated Syneron Beauty's Property and Equipment, in the total net amount of $847.

INTANGIBLE_ASSETS_NET_Tables

INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Dec. 31, 2013
INTANGIBLE ASSETS, NET [Abstract]	'
Schedule of Components of Intangible Assets	'
			Weighted average remaining useful life		December 31,
			(years)		2013		2012
	Original cost:
	Patent			-	$	1,899	$	1,899
	Distribution agreements (2)			-		163		1,600
	Brand name			-		295		295
	In process R&D (1,2)			-		-		263
	Developed technologies (1,2)			4.6		29,618		31,255
	Trade name			7		3,300		3,300
	Non-compete covenant			-		1,200		1,200
	Customer relationships			3.1		10,773		10,773
	Distribution exclusivity (1)			1		1,632		1,632
						48,880		52,217
	Accumulated amortization:
	Patent					1,899		1,899
	Distribution agreements (2)					163		506
	Brand name					295		251
	In process R&D (2)					-		63
	Developed technologies (2)					12,673		8,386
	Trade name					1,200		900
	Non-compete covenant					1,200		1,200
	Customer relationships					8,497		7,360
	Distribution exclusivity					1,514		1,219
						27,441		21,784
	Amortized cost				$	21,439	$	30,433
		-1	During the years ended December 31, 2013, 2012 and 2011, the Company recorded an impairment charge in the total amount of $ 323, $ 3,370 and $ 123, respectively. The impairment charge in 2013 was attributed to developed technology in the amount of $323. The impairment charge in 2012 was attributed to in-process R&D and developed technology in the amounts of $510 and $2,860, respectively. The impairment charge in 2011 was attributed to distribution exclusivity license in the amount of $123.
		-2	As part of Syneron Beauty's deconsolidation, the Company deconsolidated Distribution agreements, In Process R&D and Developed technologies in the total net amount of $856, $87 and $699, respectively.
Schedule of Estimated Annual Amortization Expense Related to Intangible Assets	'
	The annual amortization expense relating to intangible assets as of December 31, 2013 is estimated to be as follows:
	2014		$	4,924
	2015			4,988
	2016			4,241
	2017			3,886
	2018			1,739
	Thereafter			1,661
	Total		$	21,439

GOODWILL_Tables

GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2013
GOODWILL [Abstract]	'
Schedule of Goodwill Activity	'
	Changes in goodwill for the years ended December 31, 2013 and 2012, by reporting units are as follows:
			Syneron (*)		LI		RBT		THB (**)			Total
	As of December 31, 2011		$	8,206	$	3,005	$	2,528	$	5,128		$	18,867
	Acquisitions and others			6,729		73		-		-			6,802
	Impairment (see Note 2m)			-		-		-		(450	)		(450	)
	As of December 31, 2012			14,935		3,078		2,528		4,678			25,219
	Acquisitions and others			386		49		-		-			435
	Deconsolidation of subsidiary			-		-		-		(4,678	)		(4,678	)
	As of December 31, 2013		$	15,321	$	3,127	$	2,528	$	-		$	20,976
		(*) Includes Ultrashape and TransPharma
		(**) Includes Fluorinex

ACCUMULATED_OTHER_COMPREHENSIV1

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	12 Months Ended
	Dec. 31, 2013
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) [Abstract]	'
Reclassifications out of accumulated other comprehensive income (loss)	'
	The following table summarizes the changes in accumulated balances of other comprehensive income (loss) for the year ended December 31, 2013:
		Unrealized			Unrealized gains (losses) on cash flow hedges (*)			Foreign Currency Translation Adjustments
		gains (losses) on available-for-sale marketable securities (*)
											Total
	Beginning balance	$	24		$	152		$	450		$	626
	Other comprehensive income (loss) before reclassifications		32			179			(1,844	)		(1,633	)
	Amounts reclassified from accumulated other comprehensive income		(117	)		(347	)		-			(464	)
	Net  current period other comprehensive income (loss)		(85	)		(168	)		(1,844	)		(2,097	)
	Ending balance	$	(61	)	$	(16	)	$	(1,394	)	$	(1,471	)
	(*) Refer to Note 3 and Note 12 for the affected line item in the statement of income.

DEFERRED_REVENUES_Tables

DEFERRED REVENUES (Tables)	12 Months Ended
	Dec. 31, 2013
DEFERRED REVENUES [Abstract]	'
Reconciliation of Deferred Revenue	'
	The following table reflects changes in the Company's deferred revenue during the years ended December 31:
		December 31,
		2013			2012
	Balance at the beginning of the year	$	15,910		$	15,662
	Deferral of new sales		12,821			11,957
	Recognition of previously deferred revenue		(11,986	)		(11,550	)
	Foreign currency translation adjustments		(283	)		(159	)
	Balance at the end of the year	$	16,462		$	15,910
Schedule of Current and Long-Term Deferred Revenues	'
	The following table reflects the Company's current and long-term deferred revenues:
		December 31,
		2013			2012
	Total deferred revenues	$	16,462		$	15,910
	Less - current portion		13,001			11,986
	Long-term deferred revenues	$	3,461		$	3,924

OTHER_ACCOUNTS_PAYABLE_AND_ACC1

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2013
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'
Schedule of Other Accounts Payable and Accrued Expenses	'
		December 31,
		2013		2012
	Warranty accruals	$	6,202	$	6,489
	Accrued expenses		8,632		15,749
	Voluntary field action		-		1,496
	Accrued commission		3,466		3,493
	Employees and related expenses		5,658		8,503
	Tax authorities		3,837		14,149
	Other payables		36		10
		$	27,831	$	49,889

DERIVATIVE_INSTRUMENTS_Tables

DERIVATIVE INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Derivatives Not Designated As Hedging Instruments [Line Items]	'
Schedule of Derivative Instruments Recognized in Other Comprehensive Income	'
	The effect of derivative instruments in cash flow hedging relationships in the statement of operations and other comprehensive income (OCI) is summarized below:
			Amount of gain (loss) recognized in accumulated OCI (effective portion)
			Year ended December 31,
			2013				2012			2011
	Foreign exchange contracts		$	179			$	138		$	177
	Total		$	179			$	138		$	177
Schedule of Cash Flow Hedges Reclassified in Accumulated Other Comprehensive Income	'
	Location		Amount of gain (loss) reclassified from accumulated OCI into income (effective portion)
			Year ended December 31,
			2013				2012			2011
	Revenues		$	(77	)		$	156		$	77
	Operating expenses			424				(95	)		25
	Total		$	347			$	61		$	102
Financial Income Net [Member]	'
Derivatives Not Designated As Hedging Instruments [Line Items]	'
Schedule of Derivatives Not Designated As Hedging Instruments	'
		Gain (loss) recognized in income on derivatives
				December 31,
		Location		2013				2012			2011
	Derivatives not designated as hedging instruments:
	Foreign exchange contracts	Financial income, net		$	(3	)		$	89		$	65
	Total			$	(3	)		$	89		$	65
Other Accounts Receivable And Prepaid Expenses [Member]	'
Derivatives Not Designated As Hedging Instruments [Line Items]	'
Schedule of Derivatives Not Designated As Hedging Instruments	'
	The fair values of outstanding derivative instruments were as follows:
				Fair value of
				derivative instruments
				December 31,
		Balance sheet location		2013				2012
	Derivatives designated and qualified as cash flow hedging instruments:
	Foreign exchange contracts	Other accounts receivable and prepaid expenses		$	-			$	152
	Foreign exchange contracts	Other account payables and accrued expenses			(16	)			-
	Total derivatives designated as hedging instruments			$	(16	)		$	152

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
COMMITMENTS AND CONTINGENCIES [Abstract]	'
Future Minimum Lease Commitments Under Operating Leases	'
	The future minimum lease commitments of the Company under various non-cancelable operating lease agreements as of December 31, 2013, are as follows:
	Year ended December 31,
	2014		4,475
	2015		3,465
	2016		2,615
	2017		489
	2018		122
		$	11,166

EQUITY_Tables

EQUITY (Tables)	12 Months Ended
	Dec. 31, 2013
EQUITY [Abstract]	'
Schedule of Stock Options and Stock Appreciation Rights Award Activity	'
	The following is a summary of activities relating to the Company's stock options and SAR's (excluding Light Instruments options) granted to employees and directors among the Company's various plans during the year ended December 31, 2013:
											Aggregate
			Number				Weighted average				intrinsic Value (in
			of options				exercise price				thousands)
	Outstanding at beginning of year			4,366,897			$	12.65				-
	Granted			921,500			$	9.41				-
	Exercised			(867,106	)		$	8.47				-
	Forfeited			(954,997	)		$	15.81				-
	Outstanding at end of year			3,466,294			$	11.97			$	8,088
	Exercisable options at end of year			1,818,724			$	14.02			$	3,799
	Vested and expected to vest			3,333,107			$	11.86			$	8,418
Summary of Restricted Stock Activity	'
	The following table summarizes the RSUs activity for the year ended December 31, 2013:
							Fair
			Number				value at
			of RSUs				grant date
	Non-vested at January 1, 2013			10,272			$	10.71
	Granted			65,862			$	7.12
	Vested			10,272			$	10.71
	Forfeited			-			$	-
	Non-vested at December 31			65,862			$	7.12
Schedule of Stock Option Activity by Exercise Price	'
	The options and SAR's outstanding as of December 31, 2013, have been separated into ranges of exercise price, as follows:
					Outstanding										Exercisable
	Exercise price				Number of				Weighted average remaining contractual life (years)				Weighted		Number of		Weighted		Weighted average exercise price
					options								average		options (in		average
													exercise price		thousands)		remaining
																	contractual
																	life
																	(years)
	$	1.41				62,515				5.05			$	1.41		62,515		5.05	$	1.41
	$	4.81				41,897				5.62			$	4.81		41,897		5.62	$	4.81
	$	7.25-11.31				2,669,969				5.23			$	9.65		1,096,759		4.52	$	9.76
	$	12.09-14.74				458,952				3.39			$	13.25		384,592		3.13	$	13.43
	$	16.05-52.67				232,961				2.36			$	40.07		232,961		2.36	$	40.07
	$	1.41-52.67				3,466,294				4.8			$	11.97		1,818,724		3.99	$	14.02
Schedule of Weighted Average Fair Value of Options Granted	'
	The weighted average fair values of options granted (including those granted to non-employees but excluding RSUs) during the years ended December 31, 2013, 2012 and 2011 were:
			Year ended December 31,
			2013				2012				2011
	Weighted average exercise prices		$	9.41			$	10.08			$	11.09
	Weighted average fair value on grant date		$	3.41			$	3.94			$	4.97
Schedule of Assumptions Used to Estimate Fair Value	'
	The weighted average estimated fair value of employee stock options granted during the years ended December 31, 2013, 2012 and 2011 was calculated using the binomial model with the following weighted-average assumptions:
			Year ended December 31,
			2013				2012				2011
	Volatility			35	%			42	%			52	%
	Risk-free interest rate			1.05	%			0.75	%			2.07	%
	Dividend yield			0	%			0	%			0	%
	Post-vesting cancellation rate			6.8	%			9.5	%			7	%
	Suboptimal exercise factor			2				2				2.5
	Expected life (in years)			6.15				4.84				5.53
Schedule of Share-Based Compensation Expense	'
	The total equity-based compensation expense recognized for the years ended December 31, 2013, 2012 and 2011, was comprised as follows:
			Year ended December 31,
			2013				2012				2011
	Cost of revenues		$	288			$	205			$	40
	Research and development			766				616				726
	Sales and marketing			1,258				1,257				1,058
	General and administrative			2,177				2,656				1,576
	Total equity-based compensation expense before taxes		$	4,489			$	4,734			$	3,400

OTHER_EXPENSES_INCOME_NET_Tabl

OTHER EXPENSES (INCOME), NET (Tables)	12 Months Ended
	Dec. 31, 2013
OTHER EXPENSES (INCOME), NET [Abstract]	'
Schedule of Other Expenses (Income)	'
		Year ended December 31,
		2013			2012			2011
	Legal settlement (*)	$	-		$	-		$	31,000
	Impairment of intangibles assets (see also Note 9)		323			3,370			123
	Impairment of goodwill (see also Note 2m)		-			450			-
	Reevaluation of contingent consideration		1,209			(1,836	)		(8,830	)
	Impairment of investment in an affiliated company (**) (see also Note 7)		1,000			200			9,387
	Gain from loss of control (see also Note 7)		(7,273	)		-			-
	Other		118			105			528
	Total	$	(4,623	)	$	2,289		$	32,208

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
INCOME TAXES [Abstract]	'
Schedule Of Corporate Income Tax Rate By Jurisdiction	'
	The Corporate income tax rate of significant jurisdictions are as follows:
			Tax Rate
	Australia			30	%
	Canada (*)			15	%
	Germany			28	%
	Hong Kong			16.5	%
	Japan			39.6	%
	Spain			30	%
	United States (*)			35	%
		*)	Federal.
Schedule of Deferred Income Taxes	'
	Significant components of the Company's deferred tax assets and liabilities are as follows:
			December 31,
			2013			2012
	Net operating loss carryforward		$	44,440		$	50,525
	Tax credits			6,079			3,080
	Share-based compensation costs			248			2,487
	Company's capital losses carryforward (1)			20,087			15,630
	Bad debt reserve			868			831
	Deferred revenues			2,278			1,907
	Obsolete inventory Reserve			821			639
	Intangible Assets - Patents			1,132			1,200
	Other temporary differences			3,186			2,474
	Total deferred tax asset before valuation allowance			79,139			78,773
	Valuation allowance			(51,561	)		(52,530	)
	Total deferred tax asset			27,578			26,243
	Intangible assets acquired			(5,142	)		(7,682	)
	Total deferred tax liability			(5,142	)		(7,682	)
	Net deferred tax asset (2)		$	22,436		$	18,561
		-1	The Company has capital loss carryforwards resulting mainly from the difference between the reporting currency and the tax basis of the investments in Marketable securities.
		-2	Net deferred tax asset (liability) is recorded in the following balance sheet line items:
Schedule Of Deferred Taxes Recorded In Balance Sheet	'
	Net deferred tax asset (liability) is recorded in the following balance sheet line items:
			December 31,
			2013			2012
	Current Assets		$	6,939		$	3,266
	Deferred tax assets			17,927			18,390
	Deferred tax liability			(2,430	)		(3,095	)
	Net deferred tax asset		$	22,436		$	18,561
Changes To Unrecognized Tax Benefits	'
	The changes to unrecognized tax benefits from January 1, 2012 through December 31, 2013, were as follows:
	Gross tax liabilities at January 1, 2012		$	8,862
	Additions based on tax positions related to the current year			6,917
	Additions for tax positions of prior years			-
	Reductions due to settlements with tax authorities			-
	Reductions for positions of prior years			(960	)
	Gross tax liabilities at December 31, 2012			14,819
	Additions based on tax positions related to the current year			5
	Additions for tax positions of prior years			5
	Reductions due to settlements with tax authorities			(12,552	)
	Reductions for positions of prior years			(158	)
	Gross tax liabilities at December 31, 2013		$	2,119
Tax Filings Subject To Examination	'
	The following describes the open tax years, by major tax jurisdiction, as of December 31, 2013:
	Israel	-	2012 - present
	United States	-	2010 - present
	Australia	-	2009 - present
	Germany	-	2009 - present
	Canada	-	2009 - present
	Japan	-	2010 - present
	Spain	-	2009 - present
Schedule Of Loss Before Taxes On Income	'
	Loss before taxes on income:
			Year ended December 31,
			2013			2012			2011
	Domestic		$	(14,289	)	$	(21,890	)	$	(24,353	)
	Foreign			8,196			15,047			(23,453	)
			$	(6,093	)	$	(6,843	)	$	(47,806	)
Schedule Of Taxes On Income	'
	Taxes on income:
			Year ended December 31,
			2013			2012			2011
	Current taxes:
	Domestic		$	(6,338	)	$	6,782		$	592
	Foreign			2,084			780			3,531
				(4,254	)		7,562			4,123
	Deferred taxes:
	Domestic			(140	)		(207	)		(153	)
	Foreign			(3,246	)		(11,857	)		(26	)
				(3,386	)		(12,064	)		(179	)
	Taxes on income (tax benefit)		$	(7,640	)	$	(4,502	)	$	3,944
Reconciliation Of Statutory Tax Rate To Effective Tax Rate	'
	The reconciliation from the federal statutory tax rate to the effective tax rate is as follows:
			Year ended December 31,
			2013			2012			2011
	Loss before taxes on income		$	(6,093	)	$	(6,843	)	$	(47,806	)
	Statutory tax rate			25	%		25	%		24	%
	Theoretical tax benefits on the above amount at the Israeli statutory tax rate		$	(1,523	)	$	(1,711	)	$	(11,473	)
	Increase in taxes resulting from "Privileged Enterprise" benefits			-			-			3,625
	Difference in basis of measurement for tax purpose			1,288			2,984			(947	)
	Change in valuation allowance, net			(969	)		(12,176	)		19,151
	Non-deductible stock-based compensation			1,485			122			511
	Non-deductible expenses			492			257			(1,759	)
	State deferred taxes			2,363			(400	)		(492	)
	Increase (decrease) in taxes resulting from tax settlement with tax authorities			(8,925	)		-			697
	Difference in tax rates			(1,667	)		4,118			(3,161	)
	Tax contingencies			(111	)		5,929			554
	Return to provision			(16	)		(3,449	)		(2,915	)
	Pre-paid taxes			-			-			1,001
	Others			(57	)		(176	)		(848	)
	Actual tax expense (benefit)		$	(7,640	)	$	(4,502	)	$	3,944

FINANCIAL_INCOME_NET_Tables

FINANCIAL INCOME, NET (Tables)	12 Months Ended
	Dec. 31, 2013
FINANCIAL INCOME, NET [Abstract]	'
Schedule of Financial Income (Expense), Net	'
		Year ended December 31,
		2013			2012			2011
	Income:
	Interest on cash equivalents	$	90		$	48		$	82
	Gain and interest on available-for-sale marketable securities		557			758			1,607
	Interest on bank deposits		211			681			189
	Expenses:
	Interest on short-term credit and bank  commissions		(254	)		(272	)		(274	)
	Loss on available-for-sale marketable securities		(3	)		-			(42	)
	Foreign currency translation adjustments, net		(575	)		(290	)		(547	)
		$	26		$	925		$	1,015

SEGMENT_REPORTING_Tables

SEGMENT REPORTING (Tables)	12 Months Ended
	Dec. 31, 2013
SEGMENT REPORTING [Abstract]	'
Summary of Information by Segment	'
	The tables below present financial information for the Company's two reportable segments:
		Year ended December 31, 2013
		PAD			EBU			Total
	Revenues from external customers		226,445			30,470			256,915
	Operating income (loss)		6,996			(13,115	)		(6,119	)
	Financial income (expenses), net		280			(254	)		26
	Income (loss) before taxes on income		7,276			(13,369	)		(6,093	)
	Segment goodwill		15,321			5,655			20,976
	Segment identifiable assets		277,871			6,630			284,501
		Year ended December 31, 2012
		PAD			EBU			Total
	Revenues from external customers		236,516			27,106			263,622
	Operating income (loss)		7,802			(15,570	)		(7,768	)
	Financial income (expenses), net		1,199			(274	)		925
	Income (loss) before taxes on income		9,001			(15,844	)		(6,843	)
	Segment goodwill		14,935			10,284			25,219
	Segment identifiable assets		270,420			23,459			293,879
		Year ended December 31, 2011
		PAD			EBU			Total
	Revenues from external customers	$	208,280		$	20,041		$	228,321
	Operating loss		(31,422	)		(17,434	)		(48,856	)
	Financial income (expenses), net		1,226			(211	)		1,015
	Other income		35			-			35
	Loss before taxes on income		(30,161	)		(17,645	)		(47,806	)
	Segment goodwill		8,206			10,661			18,867
	Segment identifiable assets	$	284,198		$	19,946		$	304,144
Schedule of Revenue and Long-lived Assets by Geographic Regions	'
	The following table presents total revenues and long lived assets for the years ended December 31, 2013, 2012 and 2011. Other than as shown, no foreign country contributed materially to revenues or long-lived assets for these periods.
		2013						2012					2011
		Total revenue			Long-lived assets			Total revenue			Long-lived assets		Total revenue		Long-lived assets
	North America	$	90,618		$	2,917		$	93,247		$	3,467	$	78,525	$	1,924
	Europe  and Middle East (excluding Israel)		87,539			407			86,436			399		78,182		345
	Asia Pacific		39,744			76			41,423			95		30,489		122
	Japan		26,409			12			30,816			17		29,572		22
	Israel		4,620			3,191			3,924			2,170		5,050		1,742
	Others		7,985			-			7,776			-		6,503		-
		$	256,915		$	6,603		$	263,622		$	6,148	$	228,321	$	4,155

NET_INCOME_LOSS_PER_SHARE_Tabl

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
NETINCOME(LOSS)PER SHARE [Abstract]	'
Computation of Basic and Diluted Net Income (Loss) Per Share	'
	The following table sets forth the computation of basic and diluted net income (loss) per share:
		Year ended December 31,
		2013		2012			2011
	Numerator:
	Net income (loss) attributable to Syneron's shareholders	$	1,647	$	(1,343	)	$	(50,795	)
	Denominator:
	Total weighted average number of shares outstanding used in computing:
	Basic net income (loss) per share		35,921,848		35,474,693			35,158,191
	Diluted net income (loss) per share		36,203,848		35,474,693			35,158,191
	Basic and diluted net income (loss) per share	$	0.04	$	(0.04	)	$	(1.44	)
Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Income (Loss) Per Share	'
	The following numbers of shares were excluded from the computation of diluted net income (loss) per ordinary share for the periods presented because including them would have had an anti-dilutive effect:
		Year ended December 31,
		2013		2012			2011
	Ordinary shares		3,184,294		4,513,130			3,603,423

GENERAL_Narrative_Details

GENERAL (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2013

Nov. 30, 2008

Dec. 31, 2011

30-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2011

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 07, 2010

Feb. 13, 2012

Mar. 31, 2012

Nov. 30, 2013

Nov. 30, 2013

Nov. 11, 2013

Syneron China [Member]

Syneron China [Member]

Syneron China [Member]

Flourinex Active Ltd. (Flurinex) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Tanda Health and Beauty, Inc. (THB, formaly known as Pharos Life Corporation and Syneron Beauty Inc.) [Member]

Tanda Health and Beauty, Inc. (THB, formaly known as Pharos Life Corporation and Syneron Beauty Inc.) [Member]

Tanda Health and Beauty, Inc. (THB, formaly known as Pharos Life Corporation and Syneron Beauty Inc.) [Member]

Tanda Health and Beauty, Inc. (THB, formaly known as Pharos Life Corporation and Syneron Beauty Inc.) [Member]

Tanda Health and Beauty, Inc. (THB, formaly known as Pharos Life Corporation and Syneron Beauty Inc.) [Member]

Ultrashape Ltd. [Member]

TransPharma Medical Ltd. [Member]

Unilever Ventures [Member]

Syneron Medical [Member]

Unilever Ventures and Iluminage Beauty [Member]

Preferred A-1 [Shares]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consideration: Cash

'

$15,901

'

$2,200

'

'

$4,625

'

'

'

'

$309

'

'

'

'

'

$12,000

$3,651

'

'

'

Percentage interest acquired

'

'

'

'

4.00%

'

74.96%

'

'

'

'

2.55%

'

'

'

'

100.00%

100.00%

'

'

'

'

Contingent consideration as a percentage of net sales

'

'

'

'

'

'

'

2.02%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deposits with escrow agent (see also Note 1b5)

1,760

1,760

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percent of issued and outstanding shares owned

'

9.85%

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost method investment ownership percentage

'

'

'

'

100.00%

'

'

'

'

'

49.52%

'

'

'

'

'

'

'

'

'

'

'

Investments in affiliated companies

24,720

1,000

200

'

'

'

'

'

'

'

4,275

'

'

'

'

'

'

'

'

'

'

25,000

Gain from loss of control

7,273

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Joint venture, capital investment

'

'

'

'

156

510

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total purchase consideration

'

15,901

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional amount to be paid for acquisition of shares

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration

'

'

'

'

'

'

'

15,240

7,896

6,750

'

'

'

'

'

'

15,750

'

'

'

'

'

Cumulative percentage ownership

'

'

'

'

'

'

74.96%

'

'

'

'

'

'

'

'

'

'

'

'

51.00%

49.00%

'

Contingent consideration fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,535

$2,409

'

'

'

'

'

Contingent consideration measurement period end date

'

'

'

'

'

'

'

'

'

'

'

'

31-May-13

'

'

'

'

'

'

'

'

'

GENERAL_Schedule_Of_Fair_Value

GENERAL (Schedule Of Fair Value Of Assets Acquired And Liabilities Assumed) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Feb. 13, 2012		Mar. 14, 2012
In Thousands, unless otherwise specified				Ultrashape Ltd. [Member]		TransPharma Medical Ltd. [Member]
Business Acquisition [Line Items]	'	'	'	'		'
Cash	'	$837	'	$837		'
Current assets	'	1,491	'	1,241		'
Non-current assets	'	769	'	'		'
Property and equipment	'	'	'	710		59
Intangible assets	'	9,867	'	'		'
Developed technology	'	'	'	5,617	[1]	'
Customer relationship	'	'	'	1,843	[2]	'
Technology	'	'	'	'		2,407
Total indentifiable assets acquired	'	'	'	10,248		'
Current liabilities	'	'	'	-3,767		'
Accrued severance pay	'	'	'	-26		'
Total liabilities assumed	'	-3,793	'	-3,793		'
Total Identifiable assets acquired and liabilities assumed:	'	15,901	'	6,455		'
Goodwill	20,976	25,219	18,867	5,545		1,185
Net assets acquired	'	'	'	$12,000		$3,651
[1]	The developed technology will be amortized using the straight-line method over its useful life which is estimated at six years.
[2]	The Customer relationship will be amortized using a method that will reflect the consummation of such asset which is estimated at eight years.

GENERAL_Useful_Life_Of_Acquire

GENERAL (Useful Life Of Acquired Intangible Assets) (Details) (Ultrashape [Member])	1 Months Ended
	Feb. 13, 2012
Developed Technologies [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Useful life of acquired intangible assets	'6 years
Customer Relationship [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Useful life of acquired intangible assets	'8 years

SIGNIFICANT_ACCOUNTING_POLICIE3

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'	'	'
Short-term Interest bearing deposits	$16,453	$20,520	'
Weighted average interest	1.35%	1.59%	'
Inventories	34,707	36,862	'
Inventory reserves	6,033	5,402	'
Impairment of intangibles assets (see also Note 9)	323	3,370	123
Impairment of investment in affiliated company	1,000	200	9,387	[1]
Shipping and handling costs	6,610	6,475	4,408
Advertising expenses	$9,049	$6,334	$5,723
[1]	On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012. The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

SIGNIFICANT_ACCOUNTING_POLICIE4

SIGNIFICANT ACCOUNTING POLICIES (Derivatives And Hedging Activities) (Narrative) (Details) (Cash Flow Hedging [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Forward Contracts [Member]	'	'
Derivative [Line Items]	'	'
Notional amount	$4,295	$3,419
Option Contracts [Member]	'	'
Derivative [Line Items]	'	'
Notional amount	$900	$4,790

SIGNIFICANT_ACCOUNTING_POLICIE5

SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Depreciation Rates) (Details)	12 Months Ended
	Dec. 31, 2013
Computers, software, manufacturing, laboratory equipment and demonstration equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	10.00%	[1]
Computers, software, manufacturing, laboratory equipment and demonstration equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	50.00%	[1]
Computers, software, manufacturing, laboratory equipment and demonstration equipment [Member] | Mainly [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	33.00%
Office furniture and equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	6.00%
Office furniture and equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	30.00%
Office furniture and equipment [Member] | Mainly [Member]	'
Property, Plant and Equipment [Line Items]	'
Annual depreciation rates	15.00%
Leasehold Improvements [Member]	'
Property, Plant and Equipment [Line Items]	'
Estimated useful life	'The shorter of the term of the lease or the useful life of the asset
[1]	Demonstration equipment consists of systems for use in marketing and selling activities. Demonstration equipment is generally not held for sale and is recorded as property and equipment. The demonstration equipment is amortized on a straight-line method over their estimated economic life not to exceed two years.

SIGNIFICANT_ACCOUNTING_POLICIE6

SIGNIFICANT ACCOUNTING POLICIES (Goodwill And Intangible Assets) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Impairment of intangible assests	'	$450	'
Candela Corporation [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Impairment of intangible assests	'	$510	'
Professional Aesthetic Devices And Emerging Business Units [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Number of operating segments	2	'	'
Professional Aesthetic Devices [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Number of reporting units	2	'	'
Emerging Business Units [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Number of reporting units	3	'	'

SIGNIFICANT_ACCOUNTING_POLICIE7

SIGNIFICANT ACCOUNTING POLICIES (Employee Benefit Plan) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Severance pay expenses	$933	$744	$755
Candela U. S. Plan [Member]	'	'	'
Employer contribution	327	255	297
Syneron U. S. Plan [Member]	'	'	'
Employer contribution	$206	$196	$166
Minimum [Member] | Syneron U. S. Plan [Member]	'	'	'
Annual contribution per employee, percentage	1.00%	'	'
Maximum [Member] | Defined Contribution Pension [Member]	'	'	'
Annual contribution per employee, percentage	10.00%	'	'
Maximum [Member] | Syneron U. S. Plan [Member]	'	'	'
Annual contribution per employee, percentage	50.00%	'	'
100% Percent Employer Match [Member] | Syneron U. S. Plan [Member]	'	'	'
Employer matching contribution percentage	3.00%	'	'
50% Employer Match [Member] | Candela U. S. Plan [Member]	'	'	'
Employer matching contribution percentage	6.00%	'	'
50% Employer Match [Member] | Syneron U. S. Plan [Member]	'	'	'
Employer matching contribution percentage	2.00%	'	'

SIGNIFICANT_ACCOUNTING_POLICIE8

SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Change In Allowance For Doubtful Accounts) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Deconsolidation of subsidiary	($4,678)	'	'
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at the beginning of the year	6,792	5,478	7,704
Charged to expenses, net of recoveries	1,217	1,782	-847
Deconsolidation of subsidiary	-141	'	'
Write-off	-1,483	-523	-1,443
Exchange rate	112	55	64
Balance at the end of the year	$6,497	$6,792	$5,478

SIGNIFICANT_ACCOUNTING_POLICIE9

SIGNIFICANT ACCOUNTING POLICIES (Warranty) (Details) (Warranty Provision [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at the beginning of the year	$7,197	$6,514	$6,854
Charged to costs and expenses relating to new sales	9,122	9,058	7,856
Costs of product warranty claims	-9,209	-8,419	-8,196
Balance at the end of the year	6,981	7,197	6,514
Ultrashape [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Warranty provision related to acquisitions	'	44	'
Syneron Beauty Inc [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Warranty provision related to acquisitions	($129)	'	'

AVAILABLEFORSALE_MARKETABLE_SE2

AVAILABLE-FOR-SALE MARKETABLE SECURITIES (Schedule Of Available-For-Sale Securities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	$54,565	$49,078
Gross unrealized gains	195	244
Gross unrealized losses	-256	-220
Fair value	54,504	49,102
Reclassification of certain securities to long-term	25,571	7,966
Short-term marketable securities	28,933	41,136
Matures Within One Year [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	9,739	15,442
Gross unrealized gains	51	56
Gross unrealized losses	-8	-10
Fair value	9,782	15,488
Matures After One Year Through Three Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	37,629	27,170
Gross unrealized gains	127	188
Gross unrealized losses	-76	-36
Fair value	37,680	27,322
Money Market Funds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,535	3,548
Gross unrealized gains	'	'
Gross unrealized losses	'	'
Fair value	1,535	3,548
Certificate of deposit [Member] | Matures Within One Year [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	2,494	5,658
Gross unrealized gains	3	11
Gross unrealized losses	'	-1
Fair value	2,497	5,668
Certificate of deposit [Member] | Matures After One Year Through Three Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	2,735	3,260
Gross unrealized gains	1	16
Gross unrealized losses	-6	'
Fair value	2,730	3,276
Government Debentures - Fixed Interest Rate [Member] | Matures Within One Year [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,516	2,617
Gross unrealized gains	13	43
Gross unrealized losses	'	'
Fair value	1,529	2,660
Government Debentures - Fixed Interest Rate [Member] | Matures After One Year Through Three Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	2,260	1,570
Gross unrealized gains	'	72
Gross unrealized losses	-6	'
Fair value	2,254	1,642
Government Sponsored Enterprises - Fixed Interest Rate [Member] | Matures Within One Year [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	455	4,558
Gross unrealized gains	'	'
Gross unrealized losses	-8	'
Fair value	447	4,558
Government Sponsored Enterprises - Fixed Interest Rate [Member] | Matures After One Year Through Three Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	3,236	8,671
Gross unrealized gains	'	4
Gross unrealized losses	-2	-2
Fair value	3,234	8,673
Corporate Debentures - Fixed Interest Rate [Member] | Matures Within One Year [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	5,274	2,609
Gross unrealized gains	35	2
Gross unrealized losses	'	-9
Fair value	5,309	2,602
Corporate Debentures - Fixed Interest Rate [Member] | Matures After One Year Through Three Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	29,398	13,669
Gross unrealized gains	126	96
Gross unrealized losses	-62	-34
Fair value	29,462	13,731
Corporate Debentures - Fixed Interest Rate [Member] | Matures After Three Years Through Five Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	4,465	1,531
Gross unrealized gains	17	'
Gross unrealized losses	-36	-17
Fair value	4,446	1,514
ARS [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair value	1,061	1,230
ARS [Member] | Matures After Five Years [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized cost	1,197	1,387
Gross unrealized gains	'	'
Gross unrealized losses	-136	-157
Fair value	$1,061	$1,230

AVAILABLEFORSALE_MARKETABLE_SE3

AVAILABLE-FOR-SALE MARKETABLE SECURITIES (Schedule Of Unrealized Loss On Investments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	$20,930	$8,580
Available-for-sale securities, Unrealized losses, Less than 12 months	98	62
Available-for-sale securities, Fair Value, 12 months or longer	5,188	2,476
Available-for-sale securities, Unrealized losses, 12 months or longer	158	158
Available-for-sale securities, Fair Value Total	26,118	11,056
Available-for-sale securities, Unrealized losses, Total	256	220
Number of securities in a loss position	43	21
Government Sponsored Enterprises [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	2,780	500
Available-for-sale securities, Unrealized losses, Less than 12 months	10	2
Available-for-sale securities, Fair Value, 12 months or longer	'	1,002
Available-for-sale securities, Unrealized losses, 12 months or longer	'	'	[1]
Available-for-sale securities, Fair Value Total	2,780	1,502
Available-for-sale securities, Unrealized losses, Total	10	2
Government Debentures [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	2,255	'
Available-for-sale securities, Unrealized losses, Less than 12 months	6	'
Available-for-sale securities, Fair Value, 12 months or longer	'	'
Available-for-sale securities, Unrealized losses, 12 months or longer	'	'
Available-for-sale securities, Fair Value Total	2,255	'
Available-for-sale securities, Unrealized losses, Total	6	'
Corporate Debentures [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	13,523	7,061
Available-for-sale securities, Unrealized losses, Less than 12 months	76	60
Available-for-sale securities, Fair Value, 12 months or longer	4,127	'
Available-for-sale securities, Unrealized losses, 12 months or longer	22	'
Available-for-sale securities, Fair Value Total	17,650	7,061
Available-for-sale securities, Unrealized losses, Total	98	60
ARS [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	'	'
Available-for-sale securities, Unrealized losses, Less than 12 months	'	'
Available-for-sale securities, Fair Value, 12 months or longer	1,061	1,230
Available-for-sale securities, Unrealized losses, 12 months or longer	136	157
Available-for-sale securities, Fair Value Total	1,061	1,230
Available-for-sale securities, Unrealized losses, Total	136	157
Certificate of deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, Fair Value, Less than 12 months	2,372	1,019
Available-for-sale securities, Unrealized losses, Less than 12 months	6	'	[1]
Available-for-sale securities, Fair Value, 12 months or longer	'	244
Available-for-sale securities, Unrealized losses, 12 months or longer	'	1
Available-for-sale securities, Fair Value Total	2,372	1,263
Available-for-sale securities, Unrealized losses, Total	$6	$1
[1]	Represents an amount lower than $1.

AVAILABLEFORSALE_MARKETABLE_SE4

AVAILABLE-FOR-SALE MARKETABLE SECURITIES (Realized Gains And Losses) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
AVAILABLE-FOR-SALE MARKETABLE SECURITIES [Abstract]	'	'	'
Realized gain	$120	$2	$47
Gross realized losses	$3	'	$42

FAIR_VALUE_MEASUREMENT_Narrati

FAIR VALUE MEASUREMENT (Narrative) (Details) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

30-May-12

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Primaeva [Member]

Primaeva [Member]

Syneron Beauty Inc [Member]

Syneron Beauty Inc [Member]

Syneron Beauty Inc [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Rakuto Bio Technologies Ltd. (RBT) [Member]

Auction Rate Securities [Member]

Auction Rate Securities [Member]

Investment In Affliate [Member]

Investment In Affliate [Member]

Investment In Affliate [Member]

Schedule of Cost-method Investments [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment's, fair value

'

'

'

'

'

'

'

'

'

'

'

'

$1,061

$1,230

'

$1,000

'

Impairment charge for cost method investment

1,000

200

9,387

[1]

'

'

'

'

'

'

'

'

'

2,803

2,813

'

200

'

Contingent consideration

'

'

'

'

'

'

'

'

7,896

6,750

15,240

'

'

'

'

'

'

Acquisition income (expense)

'

'

'

'

'

2,535

126

'

1,146

625

'

'

'

'

'

'

-9,387

Intangible asset, fair value

3,102

4,281

530

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of intangible assets

323

3,370

123

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investments in affiliated companies

$24,720

$1,000

$200

'

'

'

'

'

'

'

'

$4,275

'

'

'

'

'

[1]

On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012. The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

FAIR_VALUE_MEASUREMENT_Schedul

FAIR VALUE MEASUREMENT (Schedule Of Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	$54,504	$49,102
ARS [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	1,061	1,230
Cumulative other than temporary impairment	2,803	2,813
Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	1,535	3,548
Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in affiliated companies	24,720	'
Total	79,224	49,254
Forward currency derivatives	16	152
Contingent consideration	7,896	6,750
Total	7,912	6,750
Recurring Basis [Member] | Corporate Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	39,216	17,847
Recurring Basis [Member] | ARS [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	1,061	1,230
Recurring Basis [Member] | Government Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	3,783	4,302
Recurring Basis [Member] | Government Sponsored Enterprises [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	3,682	13,231
Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	6,762	12,492
Level 1 [Member] | Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in affiliated companies	'	'
Total	6,762	12,492
Forward currency derivatives	'	'
Contingent consideration	'	'
Total	'	'
Level 1 [Member] | Recurring Basis [Member] | Corporate Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 1 [Member] | Recurring Basis [Member] | ARS [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 1 [Member] | Recurring Basis [Member] | Government Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 1 [Member] | Recurring Basis [Member] | Government Sponsored Enterprises [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 1 [Member] | Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	6,762	12,492
Level 2 [Member] | Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in affiliated companies	'	'
Total	46,681	35,532
Forward currency derivatives	16	152
Contingent consideration	'	'
Total	16	'
Level 2 [Member] | Recurring Basis [Member] | Corporate Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	39,216	17,847
Level 2 [Member] | Recurring Basis [Member] | ARS [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 2 [Member] | Recurring Basis [Member] | Government Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	3,783	4,302
Level 2 [Member] | Recurring Basis [Member] | Government Sponsored Enterprises [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	3,682	13,231
Level 2 [Member] | Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 3 [Member] | Recurring Basis [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Investment in affiliated companies	24,720	'
Total	25,781	1,230
Forward currency derivatives	'	'
Contingent consideration	7,896	6,750
Total	7,896	6,750
Level 3 [Member] | Recurring Basis [Member] | Corporate Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 3 [Member] | Recurring Basis [Member] | ARS [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	1,061	1,230
Level 3 [Member] | Recurring Basis [Member] | Government Debentures [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 3 [Member] | Recurring Basis [Member] | Government Sponsored Enterprises [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'
Level 3 [Member] | Recurring Basis [Member] | Money Market Funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities	'	'

FAIR_VALUE_MEASUREMENT_Schedul1

FAIR VALUE MEASUREMENT (Schedule Of Changes In Level 3 Investments Measured On A Recurring Basis) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'
Realized gain	$120		$2		$47
Auction Rate Securities [Member]	'		'		'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'		'
Balance at the beginning of the year	1,230		1,313		'
Changes in realized gains included in earnings	31		5		'
Sales	-200	[1]	-100	[1]	'
Changes in unrealized gains included in Other comprehensive income	'		12		'
Balance at the end of the year	1,061		1,230		'
Par value	169		95		'
Sale proceeds	200		100		'
Realized gain	$31		$5		'
[1]	During 2013, the Company sold ARS with carrying amountof $169 for a total consideration of $200,which reflects a gain of $31.During 2012, the Company sold ARS with carrying amount of $95 for a total consideration of $100, which reflects a gain of $5.

FAIR_VALUE_MEASUREMENT_Changes

FAIR VALUE MEASUREMENT (Changes In Level 3 Contingent Consideration Obligations Measured On A Recurring Basis) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Contingent Consideration Obligations [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Fair value at the beginning of the year	$6,750	$2,535
Fair value of investment in Iluminage Beauty (see Note 1b1)	'	6,125
Changes in the fair value of contingent consideration, net	1,146	-1,910
Fair value at the end of the year	7,896	6,750
Deconsolidation Of Syneron Beauty [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Fair value at the beginning of the year	'	'
Fair value of investment in Iluminage Beauty (see Note 1b1)	24,720	'
Changes in the fair value of contingent consideration, net	'	'
Fair value at the end of the year	$24,720	'

OTHER_ACCOUNTS_RECEIVABLE_AND_2

OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES [Abstract]	'	'
Prepaid expenses and advanced payments	$2,939	$5,407
Government authorities	903	919
Deposits with escrow agent (see also Note 1b5)	1,760	1,760
Derivative instruments	'	152
Other receivables	1,721	1,059
Other accounts receivable and prepaid expenses, total	$7,323	$9,297

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
INVENTORIES [Abstract]	'	'
Raw materials	$9,845	$12,552
Work in process	1,299	2,250
Finished products	23,563	22,060
Inventories	$34,707	$36,862

INVESTMENTS_IN_AFFILIATED_COMP2

INVESTMENTS IN AFFILIATED COMPANIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012		Mar. 15, 2012	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified				Investment in Iluminage Beauty [Member]		Investment in Iluminage Beauty [Member]		Investment in Existing Customer [Member]	Investment in Juvenis Ltd. (Juvenis) [Member]	Investment in Juvenis Ltd. (Juvenis) [Member]
Schedule of Cost-method Investments [Line Items]	'	'	'	'		'		'	'	'
Investments in affiliated companies	$24,720	$1,000	$200	$24,720	[1]	'	[1]	$1,000	'	$1,000
[1]	On December 9, 2013, based on the fair value method, the Company recorded an investment in Iluminage Beauty of $24,720, which represents the fair value of Iluminage Beauty's common stock held by the Company on the deconsolidation date. Refer to Note 4 and 1b1 for further details.

PROPERTY_AND_EQUIPMENT_NET_Det

PROPERTY AND EQUIPMENT, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'		'	'
Cost	$18,546	[1]	$15,811	'
Accumulated depreciation	11,943	[1]	9,663	'
Depreciated cost	6,603		6,148	'
Depreciation expenses	3,445		3,104	1,990
Deconsolidation Of Syneron Beauty [Member]	'		'	'
Property, Plant and Equipment [Line Items]	'		'	'
Depreciated cost	847		'	'
Computers, software, manufacturing, laboratory equipment and demonstration equipment [Member]	'		'	'
Property, Plant and Equipment [Line Items]	'		'	'
Cost	13,560	[1]	11,681	'
Accumulated depreciation	9,000	[1]	7,135	'
Leasehold improvements [Member]	'		'	'
Property, Plant and Equipment [Line Items]	'		'	'
Cost	3,140	[1]	2,082	'
Accumulated depreciation	1,778	[1]	1,708	'
Office furniture and equipment [Member]	'		'	'
Property, Plant and Equipment [Line Items]	'		'	'
Cost	1,846	[1]	2,048	'
Accumulated depreciation	$1,165	[1]	$820	'
[1]	As part of Syneron Beauty's deconsolidation, the Company deconsolidated Syneron Beauty's Property and Equipment, in the total net amount of $847.

INTANGIBLE_ASSETS_NET_Schedule

INTANGIBLE ASSETS, NET (Schedule of Components of Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	$48,880		$52,217		'
Accumulated amortization	27,441		21,784		'
Total	21,439		30,433		'
Impairment charge	323		3,370		123
Deconsolidation of subsidiary	-4,678		'		'
Patent [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	1,899		1,899		'
Accumulated amortization	1,899		1,899		'
Distribution agreements [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	163	[1]	1,600	[1]	'
Accumulated amortization	163	[1]	506	[1]	'
Deconsolidation of subsidiary	856		'		'
Brand name [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	295		295		'
Accumulated amortization	295		251		'
In-process research and development asset [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	'	[1],[2]	263	[1],[2]	'
Accumulated amortization	'	[1]	63	[1]	'
Impairment charge	'		510		'
Deconsolidation of subsidiary	87		'		'
Developed Technologies [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Intangible assets useful life	'4 years 7 months 6 days		'		'
Cost of intangible asset	29,618	[1],[2]	31,255	[1],[2]	'
Accumulated amortization	12,673	[1]	8,386	[1]	'
Impairment charge	'		2,860		'
Deconsolidation of subsidiary	699		'		'
Trade Name [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Intangible assets useful life	'7 years		'		'
Cost of intangible asset	3,300		3,300		'
Accumulated amortization	1,200		900		'
Non-Compete Covenant [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Cost of intangible asset	1,200		1,200		'
Accumulated amortization	1,200		1,200		'
Customer Relationship [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Intangible assets useful life	'3 years 1 month 6 days		'		'
Cost of intangible asset	10,773		10,773		'
Accumulated amortization	8,497		7,360		'
Distribution exclusivity [Member]	'		'		'
Finite-Lived Intangible Assets [Line Items]	'		'		'
Intangible assets useful life	'1 year		'		'
Cost of intangible asset	1,632	[2]	1,632	[2]	'
Accumulated amortization	1,514		1,219		'
Impairment charge	'		'		$123
[1]	As part of Syneron Beauty's deconsolidation, the Companydeconsolidated Distribution agreements, In ProcessR&D and Developed technologies in the total net amount of $856, $87 and $699, respectively.
[2]	During the years ended December 31, 2013, 2012 and 2011, the Company recorded an impairment charge in the total amount of $ 323, $ 3,370 and $ 123, respectively. The impairment charge in 2013 was attributed to developed technologyin the amount of $323. The impairment charge in 2012 was attributed to in-process R&D and developed technology in the amounts of $510 and $2,860, respectively. The impairment charge in 2011 was attributed to distribution exclusivity license in the amount of $123.

INTANGIBLE_ASSETS_NET_Schedule1

INTANGIBLE ASSETS, NET (Schedule of Estimated Annual Amortization Expense Related to Intangible Assets) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INTANGIBLE ASSETS, NET [Abstract]	'	'	'
Amortization expenses	$7,027	$7,877	$8,058
2014	4,924	'	'
2015	4,988	'	'
2016	4,241	'	'
2017	3,886	'	'
2018	1,739	'	'
Thereafter	1,661	'	'
Total	$21,439	$30,433	'

GOODWILL_Details

GOODWILL (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Goodwill [Line Items]	'		'		'
Goodwill, Beginning Balance	$25,219		$18,867		'
Acquisitions and others	435		6,802		'
Impairment (see Note 2m)	'		-450		'
Deconsolidation of subsidiary	-4,678		'		'
Goodwill, Ending Balance	20,976		25,219		18,867
Syneron [Member]	'		'		'
Goodwill [Line Items]	'		'		'
Goodwill, Beginning Balance	14,935	[1]	8,206	[1]	'
Acquisitions and others	386	[1]	6,729	[1]	'
Impairment (see Note 2m)	'	[1]	'	[1]	'
Goodwill, Ending Balance	15,321	[1]	14,935	[1]	'
LI [Member]	'		'		'
Goodwill [Line Items]	'		'		'
Goodwill, Beginning Balance	3,078		3,005		'
Acquisitions and others	49		73		'
Impairment (see Note 2m)	'		'		'
Goodwill, Ending Balance	3,127		3,078		'
RBT [Member]	'		'		'
Goodwill [Line Items]	'		'		'
Goodwill, Beginning Balance	2,528		2,528		'
Acquisitions and others	'		'		'
Impairment (see Note 2m)	'		'		'
Goodwill, Ending Balance	2,528		2,528		'
THB [Member]	'		'		'
Goodwill [Line Items]	'		'		'
Goodwill, Beginning Balance	4,678	[2]	5,128	[2]	'
Acquisitions and others	'	[2]	'	[2]	'
Impairment (see Note 2m)	'	[2]	-450	[2]	'
Deconsolidation of subsidiary	-4,678	[2]	'		'
Goodwill, Ending Balance	'	[2]	$4,678	[2]	'
[1]	Includes Ultrashape and TransPharma
[2]	Includes Fluorinex

ACCUMULATED_OTHER_COMPREHENSIV2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Reclassifications out of accumulated other comprehensive income (loss)) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning balance	$626
Other comprehensive income (loss) before reclassifications	-1,633
Amounts reclassified from accumulated other comprehensive income	-464
Net current period other comprehensive income (loss)	-2,097
Ending balance	-1,471
Unrealized gains (losses) on available-for-sale marketable securities [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning balance	24
Other comprehensive income (loss) before reclassifications	32	[1]
Amounts reclassified from accumulated other comprehensive income	-117	[1]
Net current period other comprehensive income (loss)	-85	[1]
Ending balance	-61	[1]
Unrealized gains (losses) on cash flow hedges [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning balance	152
Other comprehensive income (loss) before reclassifications	179	[1]
Amounts reclassified from accumulated other comprehensive income	-347	[1]
Net current period other comprehensive income (loss)	-168	[1]
Ending balance	-16	[1]
Foreign Currency Translation Adjustments [Member]	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'
Beginning balance	450
Other comprehensive income (loss) before reclassifications	-1,844
Amounts reclassified from accumulated other comprehensive income	'
Net current period other comprehensive income (loss)	-1,844
Ending balance	($1,394)
[1]	Refer to Note 3 and Note 12 for the affected line item in the statement of income.

DEFERRED_REVENUES_Reconciliati

DEFERRED REVENUES (Reconciliation of Deferred Revenue) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
DEFERRED REVENUES [Abstract]	'	'
Deferred revenue at the beginning of the year	$15,910	$15,662
Deferral of new sales	12,821	11,957
Recognition of previously deferred revenue	-11,986	-11,550
Foreign currency translation adjustments	-283	-159
Deferred revenue at the end of the year	$16,462	$15,910
Service contract minimum period	'1 year	'
Service contract maximum period	'3 years	'

DEFERRED_REVENUES_Schedule_of_

DEFERRED REVENUES (Schedule of Current and Long-Term Deferred Revenues) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
DEFERRED REVENUES [Abstract]	'	'	'
Total deferred revenues	$16,462	$15,910	$15,662
Less - current portion	13,001	11,986	'
Long-term deferred revenues	$3,461	$3,924	'

OTHER_ACCOUNTS_PAYABLE_AND_ACC2

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]	'	'
Warranty accruals	$6,202	$6,489
Accrued expenses	8,632	15,749
Voluntary field action	'	1,496
Accrued commission	3,466	3,493
Employees and related expenses	5,658	8,503
Tax authorities	3,837	14,149
Derivative instruments	'	'
Other payables	36	10
Other payables and accrued expenses	$27,831	$49,889

DERIVATIVE_INSTRUMENTS_Fair_Va

DERIVATIVE INSTRUMENTS (Fair Value of Outstanding Derivative Instruments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Derivatives designated as hedging instruments [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value of derivative instruments	($16)	$152
Foreign exchange contracts [Member] | Derivatives designated and qualified as cash flow hedging instruments [Member] | Other accounts receivable and prepaid expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value of derivative instruments	'	152
Foreign exchange contracts [Member] | Derivatives designated and qualified as cash flow hedging instruments [Member] | Other account payables and accrued expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair value of derivative instruments	($16)	'

DERIVATIVE_INSTRUMENTS_Schedul

DERIVATIVE INSTRUMENTS (Schedule of Derivative Instruments Recognized in Other Comprehensive Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount of gain (loss) recognized in accumulated OCI (effective portion)	$179	$138	$177
Foreign exchange contracts [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amount of gain (loss) recognized in accumulated OCI (effective portion)	$179	$138	$177

DERIVATIVE_INSTRUMENTS_Schedul1

DERIVATIVE INSTRUMENTS (Schedule of Cash Flow Hedges Reclassified in Accumulated Other Comprehensive Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amounts reclassified from accumulated other comprehensive income	$347	$61	$102
Revenues [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amounts reclassified from accumulated other comprehensive income	-77	156	77
Operating expenses [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Amounts reclassified from accumulated other comprehensive income	$424	($95)	$25

DERIVATIVE_INSTRUMENTS_Schedul2

DERIVATIVE INSTRUMENTS (Schedule of Derivatives Not Designated as Hedging Instruments) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in income on derivatives	($3)	$89	$65
Derivatives not designated as hedging instruments [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in income on derivatives	-3	89	65
Foreign exchange contracts [Member] | Derivatives not designated as hedging instruments [Member] | Financial income, net [Member]	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'
Gain (loss) recognized in income on derivatives	($3)	$89	$65

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Royalties) (Details) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 05, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 05, 2010

Jun. 30, 2011

Jun. 30, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Tensor [Member]

Tensor [Member]

Tensor [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Dynamic Cooling Device [Member]

Palomar And Massachusetts General Hospital [Member]

Palomar And Massachusetts General Hospital [Member]

Palomar And Massachusetts General Hospital [Member]

Palomar And Massachusetts General Hospital [Member]

Other Receivables [Member]

Other Receivables [Member]

Long-Term Assets [Member]

Long-Term Assets [Member]

Minimum [Member]

Minimum [Member]

Level One Net Sales [Member]

Level Two Net Sales [Member]

Level One Net Sales [Member]

Level Two Net Sales [Member]

Royalty Agreement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty rate

'

'

4.50%

4.50%

4.50%

'

'

'

'

'

'

'

'

'

'

3.00%

2.00%

'

5.00%

6.50%

7.50%

Royalty expense included in cost of revenues

'

'

$660

$1,163

$525

$2,473

$2,683

$2,529

'

'

'

'

'

'

'

'

'

$147

'

'

'

Annual license fee

'

'

'

'

'

300

300

300

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum annual royalty obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

750

500

'

'

'

'

'

'

Lump sum payment

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

Amortization period

'

'

'

'

'

'1 year 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets

21,439

30,433

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized license fee

'

'

'

'

'

'

'

'

'

300

300

150

450

'

'

'

'

'

'

'

'

Amount paid related to arbitration

$387

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Leases) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Future minimum payments, operating leases:	'	'	'
2014	$4,475	'	'
2015	3,465	'	'
2016	2,615	'	'
2017	489	'	'
2018	122	'	'
Future minimum lease commitments	11,166	'	'
Renewal option, minimum	'1 year	'	'
Renewal option, maximum	'5 years	'	'
Rent expenses	$3,611	$3,195	$2,968

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Legal Claims) (Details)	1 Months Ended	12 Months Ended		1 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Apr. 29, 2012	Oct. 25, 2010	Aug. 31, 2010	Aug. 31, 2010	Aug. 31, 2010	Aug. 31, 2010	Aug. 31, 2010	Nov. 30, 2011
	USD ($)	USD ($)	Syneron [Member]	Tensor [Member]	Product Liability [Member]	Employment Agreement Breach [Member]	Employment Agreement Breach [Member]	Employment Agreement Breach [Member]	Employment Agreement Breach [Member]	Employment Agreement Breach [Member]	Estetitek [Member]
			ILS	USD ($)	Syneron, Inc. [Member]	USD ($)	ILS	Initial Preliminary Hearing [Member]	Initial Preliminary Hearing [Member]	Second Preliminary Hearing [Member]	USD ($)
					USD ($)			USD ($)	ILS	ILS
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Litigation settlement amount	$430,000	'	'	'	'	'	'	'	'	'	'
Obligation to litigation settlement	154,000	'	'	'	'	'	'	'	'	3,000,000	'
Damages sought	'	'	27,500,000	'	'	1,500,000	5,700,000	1,300,000	4,800,000	'	'
Damages sought, loss of profit	'	'	'	'	'	'	'	'	'	'	1,700,000
Damages sought, reputation	'	'	'	'	2,000,000	'	'	'	'	'	500,000
Damages paid	'	387,000	'	2,100,000	'	'	'	'	'	'	'
Accrual for litigation	'	$565,000	'	'	'	'	'	'	'	'	'

EQUITY_Option_Plans_and_Stock_

EQUITY (Option Plans and Stock Appreciation Rights) (Narrative) (Details)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

In Thousands, except Share data, unless otherwise specified

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2004

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2004

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

ILS

ILS

2004 Plans [Member]

2004 Plans [Member]

2004 Plans [Member]

2004 Plans [Member]

2004 Plans [Member]

Candela Awards [Member]

Light Instruments Ltd [Member]

Minimum [Member]

Maximum [Member]

Annual Increase Lesser Of Two Options [Member]

1998 Plan [Member]

2011 Plan [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Total number of shares authorized

'

'

'

'

'

'

2,000,000

'

'

'

'

'

Annual increase option one, number of shares

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Annual increase option two, percentage of share capital

'

'

'

'

'

'

'

'

'

3.00%

'

'

Shares available for grant

'

'

'

'

'

4,996,487

'

'

'

'

'

270,648

Vesting period

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

Period before expiration

'

'

'

'

'

'7 years

'

'

'

'

'

'10 years

Ordinary shares, par value per share

'

'

'

0.01

0.01

'

'

'

'

'

'

'

Options and SARs outstanding

'

'

'

'

'

'

'

'

'

'

'

'

Granted

921,500

'

'

'

'

'

'

'

'

'

'

140,049

Fair value at grant date, RSU Granted

$7.12

$11.15

$9.16

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value, exercised

$1,309

$901

$4,001

'

'

'

'

'

'

'

'

'

EQUITY_Schedule_of_Stock_Optio

EQUITY (Schedule of Stock Options and Stock Appreciation Rights Award Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EQUITY [Abstract]	'	'	'
Number of options, Outstanding at beginning of year	4,366,897	'	'
Number of options, Granted	921,500	'	'
Number of options, Exercised	-867,106	'	'
Number of options, Forfeited	-954,997	'	'
Number of options, Outstanding at end of year	3,466,294	4,366,897	'
Number of options, Exercisable options at end of year	1,818,724	'	'
Number of options, Vested and expected to vest	3,333,107	'	'
Weighted average Exercise price, Outstanding at beginning of year	$12.65	'	'
Weighted average Exercise price, Granted	$9.41	$10.08	$11.09
Weighted average Exercise price, Exercised	$8.47	'	'
Weighted average Exercise price, Forfeited	$15.81	'	'
Weighted average Exercise price, Outstanding at end of year	$11.97	$12.65	'
Weighted average Exercise price, Exercisable options at end of year	$14.02	'	'
Weighted average Exercise price, Vested and expected to vest	$11.86	'	'
Aggregate intrinsic value, Outstanding at end of year	$8,088	'	'
Aggregate intrinsic value, Exercisable options at end of year	3,799	'	'
Aggregate intrinsic value, Vested and expected to vest	$8,418	'	'

EQUITY_Summary_of_Restricted_S

EQUITY (Summary of Restricted Stock Activity) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EQUITY [Abstract]	'	'	'
Number of RSUs, Non-vested at January 1, 2013	10,272	'	'
Number of RSUs, Granted	65,862	'	'
Number of RSUs, Vested	10,272	'	'
Number of RSUs, Forfeited	'	'	'
Number of RSUs, Non-vested at December 31	65,862	10,272	'
Fair value at grant date, Non-vested at January 1, 2013	$10.71	'	'
Fair value at grant date, RSU Granted	$7.12	$11.15	$9.16
Fair value at grant date, Vested	$10.71	'	'
Fair value at grant date, Forfeited	'	'	'
Fair value at grant date, Non-vested at December 31	$7.12	$10.71	'
Total fair value RSU vested	$110	'	'

EQUITY_Schedule_of_Stock_Optio1

EQUITY (Schedule of Stock Option Activity by Exercise Price) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
$1.41 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of options, Outstanding	62,515
Weighted average remaining contractual life, Outstanding	'5 years 18 days
Weighted average exercise price, Outstanding	$1.41
Number of options, Exercisable	62,515
Weighted average remaining contractual life, Exercisable	'5 years 18 days
Weighted average exercise price, Exercisable	$1.41
$4.81 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number of options, Outstanding	41,897
Weighted average remaining contractual life, Outstanding	'5 years 7 months 13 days
Weighted average exercise price, Outstanding	$4.81
Number of options, Exercisable	41,897
Weighted average remaining contractual life, Exercisable	'5 years 7 months 13 days
Weighted average exercise price, Exercisable	$4.81
$7.25-11.31 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, lower limit	$7.25
Range of exercise price, upper limit	$11.31
Number of options, Outstanding	2,669,969
Weighted average remaining contractual life, Outstanding	'5 years 2 months 23 days
Weighted average exercise price, Outstanding	$9.65
Number of options, Exercisable	1,096,759
Weighted average remaining contractual life, Exercisable	'4 years 6 months 7 days
Weighted average exercise price, Exercisable	$9.76
$12.09-14.74 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, lower limit	$12.09
Range of exercise price, upper limit	$14.74
Number of options, Outstanding	458,952
Weighted average remaining contractual life, Outstanding	'3 years 4 months 20 days
Weighted average exercise price, Outstanding	$13.25
Number of options, Exercisable	384,592
Weighted average remaining contractual life, Exercisable	'3 years 1 month 17 days
Weighted average exercise price, Exercisable	$13.43
$16.05-52.67 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, lower limit	$16.05
Range of exercise price, upper limit	$52.67
Number of options, Outstanding	232,961
Weighted average remaining contractual life, Outstanding	'2 years 4 months 10 days
Weighted average exercise price, Outstanding	$40.07
Number of options, Exercisable	232,961
Weighted average remaining contractual life, Exercisable	'2 years 4 months 10 days
Weighted average exercise price, Exercisable	$40.07
$1.41-52.67 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise price, lower limit	$1.41
Range of exercise price, upper limit	$52.67
Number of options, Outstanding	3,466,294
Weighted average remaining contractual life, Outstanding	'4 years 9 months 18 days
Weighted average exercise price, Outstanding	$11.97
Number of options, Exercisable	1,818,724
Weighted average remaining contractual life, Exercisable	'3 years 11 months 26 days
Weighted average exercise price, Exercisable	$14.71

EQUITY_Schedule_of_Weighted_Av

EQUITY (Schedule of Weighted Average Fair Value of Options Granted) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
EQUITY [Abstract]	'	'	'
Weighted average exercise prices	$9.41	$10.08	$11.09
Weighted average fair value on grant date	$3.41	$3.94	$4.97

EQUITY_Schedule_of_Assumptions

EQUITY (Schedule of Assumptions Used to Estimate Fair Value) (Details)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
EQUITY [Abstract]	'		'	'
Volatility	35.00%		42.00%	52.00%
Risk-free interest rate	1.05%		0.75%	2.07%
Dividend yield	0.00%		0.00%	0.00%
Post-vesting cancellation rate	6.80%	[1]	9.50%	7.00%
Suboptimal exercise factor	2		2	2.5
Expected life (in years)	'6 years 1 month 24 days		'4 years 10 months 2 days	'5 years 6 months 11 days
[1]

EQUITY_Schedule_of_ShareBased_

EQUITY (Schedule of Share-Based Compensation Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	$4,489	$4,734	$3,400
Period over which unrecognized compensation cost will be recognized	'1 year 4 months 13 days	'	'
Unrecognized share-based compensation expense	4,959	7,109	'
Cost of revenues [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	288	205	40
Research and development [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	766	616	726
Sales and marketing [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	1,258	1,257	1,058
General and administrative [Member]	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Share-based compensation	$2,177	$2,656	$1,576

OTHER_EXPENSES_INCOME_NET_Deta

OTHER EXPENSES (INCOME), NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Other Income And Expenses [Line Items]	'		'		'
Legal settlement	'	[1]	'	[1]	$31,000	[1]
Impairment of intangibles assets (see also Note 9)	323		3,370		123
Impairment of goodwill (see also Note 2m)	'		450		'
Reevaluation of contingent consideration	1,209		-1,836		-8,830
Impairment of investment in affiliated company	1,000		200		9,387	[2]
Gain from loss of control (b)	-7,273		'		'
Other	118		105		528
Total	($4,623)		$2,289		$32,208
[1]	On September 16, 2011,Syneron Inc., Candela, and Syneron Medical Ltd. entered into a comprehensive settlement agreement with Palomar and Massachusetts General Hospital ending the patent disputes on mutually agreeable terms. The comprehensive settlement agreement includes two Non-Exclusive Patent Licenses. Under the first agreement, Palomar granted Syneron Inc. and its Affiliates (including Syneron Medical Ltd. and Candela) a non-exclusive, worldwide, fully paid-up, and irrevocable license to the '568 and '844 Patents and foreign counterparts for their professional laser and lamp-based hair removal systems. Pursuant to this agreement, the Company paid Palomar $31,000, and Palomar received a royalty free license to certain Candela patents. Under the second agreement royalties will be paid according to certain levels of sales (refer to Note 15 a.3).
[2]	On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012. The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

OTHER_EXPENSES_INCOME_NET_Narr

OTHER EXPENSES (INCOME), NET (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011		Oct. 05, 2011	Nov. 22, 2010
					Exclusive Supply Agreement [Member]	Exclusive Supply Agreement [Member]
Other Income And Expenses [Line Items]	'	'	'		'	'
Cost of revenue	'	'	'		$3,200	$9,169
Fair value	'	'	'		'	1,400
Impairment of investment in affiliated company	$1,000	$200	$9,387	[1]	'	'
[1]	On November 22, 2010, the Company entered into an exclusive supply agreement ("the agreement") with an existing customer of the Company ("the customer"). In connection with such agreement, the Company invested $9,169 in exchange for preferred units which constitute an immaterial percentage of the customer's equity. The Company recorded the fair value of the preferred units received as part of the investments in affiliated companies and the fair value of the exclusive supply right in the amount of $1,400 was recorded as part of the intangible assets based on its fair value as was calculated by a third party appraisal. On October 5, 2011, the Company invested in this customer an additional $3,200 in exchange for additional preferred units. In December 2011, this customer filed for bankruptcy under protection of Chapter 11 of the U.S. Bankruptcy Code from which it emerged at the end of January 2012. The Company expects to continue doing business under a new exclusive supply agreement concluded with this customer under its new ownership. During 2011, the Company wrote off $9,387, reflecting losses related to the Company's investment in this customer.

INCOME_TAXES_Corporate_Tax_Rat

INCOME TAXES (Corporate Tax Rate) (Narrative) (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Applicable Tax Rates [Line Items]	'	'	'	'
Tax rate for Israeli corporate	26.50%	25.00%	25.00%	24.00%

INCOME_TAXES_Encouragement_Of_

INCOME TAXES (Encouragement Of Industry And Capital Investments) (Narrative) (Details) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Oct. 27, 2013
Encouragement Of Capital Investments Law [Line Items]	'	'	'	'	'
Tax exempt period	'	'10 years	'	'	'
Tax rate for Israeli corporate	26.50%	25.00%	25.00%	24.00%	'
Amount paid in accordance with the Trapped Profits Law	'	'	'	'	$4,000,000
Approved Enterprise Programs [Member]	'	'	'	'	'
Encouragement Of Capital Investments Law [Line Items]	'	'	'	'	'
Tax exempt earnings	'	299,238,000	'	'	'
Tax liability resulting from distribution of earnings	'	33,981,000	'	'	'
Know-How And Patents [Member]	'	'	'	'	'
Encouragement Of Capital Investments Law [Line Items]	'	'	'	'	'
Tax benefit amortization period	'	'8 years	'	'	'
Maximum [Member]	'	'	'	'	'
Encouragement Of Capital Investments Law [Line Items]	'	'	'	'	'
Amount paid in accordance with the Trapped Profits Law	'	'	'	'	$63,700,000

INCOME_TAXES_Schedule_Of_Corpo

INCOME TAXES (Schedule Of Corporate Income Tax Rate By Jurisdiction) (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2011
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	26.50%	25.00%		25.00%	24.00%
Israel [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	26.50%	25.00%		25.00%	24.00%
Australia [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	30.00%		'	'
Canada [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	15.00%	[1]	'	'
Germany [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	28.00%		'	'
Hong Kong [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	16.50%		'	'
Japan [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	39.60%		'	'
Spain [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	30.00%		'	'
Unites States [Member]	'	'		'	'
Income Tax Applicable Tax Rates [Line Items]	'	'		'	'
Corporate income tax rate	'	35.00%	[1]	'	'
[1]	Federal.

INCOME_TAXES_Schedule_Of_Defer

INCOME TAXES (Schedule Of Deferred Income Taxes) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Net operating loss carryforward	$44,440		$50,525
Tax credits	6,079		3,080
Share-based compensation costs	248		2,487
Company's capital losses carryforward	20,087	[1]	15,630	[1]
Bad debt reserve	868		831
Deferred revenues	2,278		1,907
Obsolete inventory Reserve	821		639
Intangible Assets - Patents	1,132		1,200
Other temporary differences	3,186		2,474
Total deferred tax assets before valuation allowance	79,139		78,773
Valuation allowance	-51,561		-52,530
Total deferred tax asset	27,578		26,243
Intangible assets acquired	-5,142		-7,682
Total deferred tax liability	-5,142		-7,682
Net deferred tax asset	$22,436	[2]	$18,561	[2]
[1]	The Company has capital loss carryforwards resulting mainly from the difference between the reporting currency and the tax basis of the investments in Marketable securities.
[2]	Net deferred tax asset (liability) is recorded in the following balance sheet line items:

INCOME_TAXES_Schedule_Of_Defer1

INCOME TAXES (Schedule Of Deferred Taxes Recorded In Balance Sheet) (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
INCOME TAXES [Abstract]	'		'
Current assets	$6,939		$3,266
Deferred tax assets	17,927		18,390
Deferred tax liability	-2,430		-3,095
Net deferred tax asset	$22,436	[1]	$18,561	[1]
[1]	Net deferred tax asset (liability) is recorded in the following balance sheet line items:

INCOME_TAXES_Deferred_Taxes_Na

INCOME TAXES (Deferred Taxes) (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-17		'		'
Company's capital losses carryforward	$20,087	[1]	$15,630	[1]	'
Excess operating loss carryforwards for tax return over financial reporting amount	38,170		'		'
Tax credit carryforwards	9,169		'		'
Change in valuation allowance on deferred tax assets	-969		-12,176		19,151
Excess research and development credit carryforwards for tax return over financial reporting amount	430		'		'
Deferred tax assets, valuation allowance	51,561		52,530		'
Undistributed earnings of the Company's foreign subsidiaries	7,557		'		'
Israel [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Company's capital losses carryforward	63,691		42,396		'
Prior year net operating loss limitations	'Such losses are subject to limitations of Internal Revenue Code, Section 382, which in general provides that utilization of NOL's is subject to an annual limitation if an ownership change results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The annual limitations may result in the expiration of losses before utilization.		'		'
Israel [Member] | Unlimited Carryforward Period [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Net operating loss carryforward	98,919		71,650		'
United States [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Net operating loss carryforward	80,271		'		'
United States [Member] | Research Tax Credit Carryforward [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Tax credit carryforwards	2,387		'		'
United States [Member] | Subsidiaries [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Change in valuation allowance on deferred tax assets	7,935		'		'
United States [Member] | Minimum [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-25		'		'
United States [Member] | Minimum [Member] | Research Tax Credit Carryforward [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-26		'		'
United States [Member] | Maximum [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-31		'		'
United States [Member] | Maximum [Member] | Research Tax Credit Carryforward [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-33		'		'
United States [Member] | Unlimited Carryforward Period [Member] | Capital Loss Carryforward [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Tax credit carryforwards	655		'		'
State [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Net operating loss carryforward	68,198		'		'
State [Member] | Research Tax Credit Carryforward [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Tax credit carryforwards	$1,081		'		'
State [Member] | Minimum [Member]	'		'		'
Operating Loss Carryforwards [Line Items]	'		'		'
Operating loss carryforwards, expiration dates	31-Dec-14		'		'
[1]	The Company has capital loss carryforwards resulting mainly from the difference between the reporting currency and the tax basis of the investments in Marketable securities.

INCOME_TAXES_Changes_To_Unreco

INCOME TAXES (Changes To Unrecognized Tax Benefits) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
INCOME TAXES [Abstract]	'	'
Gross tax liabilities at beginning of year	$14,819	$8,862
Additions based on tax positions related to the current year	5	6,917
Additions for tax positions of prior years	5	'
Reductions due to settlements with tax authorities	-12,552	'
Reductions for positions of prior years	-158	-960
Gross tax liabilities at end of year	2,119	14,819
Unrecognized tax benefits that would impact effective tax rate, if recognized	2,119	'
Accrued interest	$213	$158

INCOME_TAXES_Tax_Filings_Subje

INCOME TAXES (Tax Filings Subject To Examination) (Details)	12 Months Ended
	Dec. 31, 2013
Israel [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2012
Unites States [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2010
Australia [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2009
Germany [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2009
Canada [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2009
Japan [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2010
Spain [Member]	'
Income Tax Contingency [Line Items]	'
Open tax years	'2009

INCOME_TAXES_Schedule_Of_Loss_

INCOME TAXES (Schedule Of Loss Before Taxes On Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INCOME TAXES [Abstract]	'	'	'
Domestic	($14,289)	($21,890)	($24,353)
Foreign	8,196	15,047	-23,453
Loss before taxes on income	($6,093)	($6,843)	($47,806)

INCOME_TAXES_Schedule_Of_Taxes

INCOME TAXES (Schedule Of Taxes On Income) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INCOME TAXES [Abstract]	'	'	'
Domestic	($6,338)	$6,782	$592
Foreign	2,084	780	3,531
Current taxes	-4,254	7,562	4,123
Domestic	-140	-207	-153
Foreign	-3,246	-11,857	-26
Deferred taxes	-3,386	-12,064	-179
Taxes on income (tax benefit)	($7,640)	($4,502)	$3,944

INCOME_TAXES_Reconciliation_Of

INCOME TAXES (Reconciliation Of Statutory Tax Rate To Effective Tax Rate) (Details) (USD $)	1 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jan. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
INCOME TAXES [Abstract]	'	'	'	'
Income (loss) before taxes on income	'	($6,093)	($6,843)	($47,806)
Statutory tax rate	26.50%	25.00%	25.00%	24.00%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate	'	-1,523	-1,711	-11,473
Increase in taxes resulting from "Privileged Enterprise" benefits	'	'	'	3,625
Difference in basis of measurement for tax purpose	'	1,288	2,984	-947
Change in valuation allowance, net	'	-969	-12,176	19,151
Non-deductible stock-based compensation	'	1,485	122	511
Non-deductible expenses	'	492	257	-1,759
State deferred taxes	'	2,363	-400	-492
Increase (decrease) in taxes resulting from tax settlement with tax authorities	'	-8,925	'	697
Dffference in tax rates	'	-1,667	4,118	-3,161
Tax contingencies	'	-111	5,929	554
Return to provision	'	-16	-3,449	-2,915
Pre-paid taxes	'	'	'	1,001
Others	'	-57	-176	-848
Taxes on income (tax benefit)	'	($7,640)	($4,502)	$3,944

FINANCIAL_INCOME_NET_Details

FINANCIAL INCOME, NET (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
FINANCIAL INCOME, NET [Abstract]	'	'	'
Interest on cash equivalents	$90	$48	$82
Gain and interest on available-for-sale marketable securities	557	758	1,607
Interest on bank deposits	211	681	189
Interest on short-term credit and bank commissions	-254	-272	-274
Loss on available-for-sale marketable securities	-3	'	-42
Foreign currency translation adjustments, net	-575	-290	-547
Financial income, net	$26	$925	$1,015

SEGMENT_REPORTING_Summary_of_I

SEGMENT REPORTING (Summary of Information by Segment) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	$256,915	$263,622	$228,321
Operating income (loss)	-6,119	-7,768	-48,856
Financial income (expenses), net	26	925	1,015
Other income	'	'	35
Income (loss) before taxes on income	-6,093	-6,843	-47,806
Segment goodwill	20,976	25,219	18,867
Segment identifiable assets	305,477	319,098	304,144
PAD [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	226,445	236,516	208,280
Operating income (loss)	6,996	7,802	-31,422
Financial income (expenses), net	280	1,199	1,226
Other income	'	'	35
Income (loss) before taxes on income	7,276	9,001	-30,161
Segment goodwill	15,321	14,935	8,206
Segment identifiable assets	277,871	270,420	284,198
EBU [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenues from external customers	30,470	27,106	20,041
Operating income (loss)	-13,115	-15,570	-17,434
Financial income (expenses), net	-254	-274	-211
Other income	'	'	'
Income (loss) before taxes on income	-13,369	-15,844	-17,645
Segment goodwill	5,655	10,284	10,661
Segment identifiable assets	$6,630	$23,459	$19,946

SEGMENT_REPORTING_Schedule_of_

SEGMENT REPORTING (Schedule of Revenue and Long-lived Assets by Geographic Regions) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	$256,915	$263,622	$228,321
Long-Lived Assets	6,603	6,148	4,155
North America [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	90,618	93,247	78,525
Long-Lived Assets	2,917	3,467	1,924
Europe and Middle East (excluding Israel) [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	87,539	86,436	78,182
Long-Lived Assets	407	399	345
Asia Pacific [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	39,744	41,423	30,489
Long-Lived Assets	76	95	122
Japan [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	26,409	30,816	29,572
Long-Lived Assets	12	17	22
Israel [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	4,620	3,924	5,050
Long-Lived Assets	3,191	2,170	1,742
Others [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues from external customers	7,985	7,776	6,503
Long-Lived Assets	'	'	'

NET_INCOME_LOSS_PER_SHARE_Comp

NET INCOME (LOSS) PER SHARE (Computation of Basic and Diluted Net Loss Per Share) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
NETINCOME(LOSS)PER SHARE [Abstract]	'	'	'
Net income (loss) attributable to Syneron's shareholders	$1,647	($1,343)	($50,795)
Total weighted average number of shares outstanding used in computing:	'	'	'
Basic net income (loss) per share	35,921,848	35,474,693	35,158,191
Diluted net income (loss) per share	36,203,848	35,474,693	35,158,191
Basic and diluted net income (loss) per share	$0.04	($0.04)	($1.44)

NET_INCOME_LOSS_PER_SHARE_Sche

NET INCOME (LOSS) PER SHARE (Schedule of Anti-dilutive Securities Excluded from Computation of Diluted Net Loss Per Share) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
NETINCOME(LOSS)PER SHARE [Abstract]	'	'	'
Ordinary shares	3,184,294	4,513,130	3,603,423

DISCLOSURE_ON_RELATED_PARTIES_1

DISCLOSURE ON RELATED PARTIES TRANSACTION (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Disclosure on related parties transactions [Abstract]	'
Percent of issued and outstanding shares owned	9.85%
Consideration of the pro-rata initail purchase price	$5,000
Additional amounts paid to Shimon Eckhouse and other RBT shareholders	5,000
Certain milestone payments owed to Shimon Eckhouse and other RBT shareholders	$15,240
Percent of annual sales due to Shimon Eckhouse and other RBT shareholders	2.02%

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Feb. 28, 2014
				Subsequent Event [Member]
				New Star Lasers Inc [Member]
Subsequent Event [Line Items]	'	'	'	'
Cash paid for business acquisition	'	$15,901,000	'	$11,000,000
Earn out amount	'	'	'	$4,000,000